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Abstract 
Coronary heart disease is still the leading cause of death in the UK, despite significant 
advances in clinical treatments. Stem cell transplantation has the potential to improve 
cardiac function and patient outcome, but optimal cell types, cell preparation methods 
and cell delivery routes are yet to be established. 
The heart contains a small population of progenitor cells that, in culture, contribute to 
spontaneously formed spheroids known as cardiospheres (Csphs). Following further 
culture, Csphs give rise to cardiosphere derived cells (CDCs). Both Csphs and CDCs 
show paracrine benefit including neovascularisation in myocardial ischaemia, leading to 
improvement in heart function. The aims of this project were to use mouse models to (i) 
investigate the effect of hypoxic preconditioning on the pro-angiogenic potential of 
CDCs and (ii) characterise the contribution of cardiac fibroblasts (CFs) to CDCs.  
I used Col1a2-CreERT;Rosa26-STOP-YFP mice to track YFP-expressing CFs in 
myocardial tissue and in CDC culture. Co-staining experiments showed only partial 
overlap of YFP with other CF markers (vimentin and Fsp1) in heart tissue, which may 
be due to the heterogeneity of CFs and/or incomplete activation of YFP in CFs. I 
showed that CF-derived cells exist in all stages of CDC culture, and a small subset of 
these cells also expressed the stem cell markers Sca-1 or cKit, suggesting CF derived 
cells may contribute to the progenitor cell population.  
My results showed that preconditioning CDCs with 3%O2 enhances cell outgrowth from 
heart explants and promotes expression of stem cell and pro-angiogenic markers. I then 
assessed the pro-angiogenic potential of CDCs in vivo using a sub-dermal matrigel plug 
assay and showed that CDCs alone have limited pro-angiogenic potential. However, 
3%O2 preconditioning of CDCs significantly enhances this process.   
Further research will increase our understanding of CDC-mediated angiogenesis and 
improve clinical therapies for MI patients.   
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 The heart 1.1 
The mammalian heart is composed of four chambers, two atria and two ventricles. The 
role of the right atrium is to collect blood from the body and pump it to the right 
ventricle then the right ventricle pumps the blood to the lungs. When the blood is 
oxygenated in the lungs it returns to the left atrium. From there the blood goes into the 
left ventricle, and is pumped through the aorta to all the body. In order to generate the 
proper blood flow within the heart, cardiac valves including  tricuspid valve (between 
the right atrium and ventricle), mitral valve (between the left atrium and ventricle), 
pulmonary valve (between the right ventricle and the pulmonary artery) and finally the 
aortic valve are present[1]. 
The cardiac skeleton is a very dense connective tissue, mainly composed of collagen, 
and has three main roles: (i) to maintain the atrial and ventricular structure; (ii) to 
anchor the four valves of the heart and (iii); to electrically insulate the ventricles from 
the atria. Each heart beat is an electrical impulse which is generated from specialised 
myocardial cells located in the sinoatrial (SA) node located in the groove where the 
superior vena cava meets the right atrium. Cells in this region are smaller than ordinary 
cardiac muscle cells and have the ability to spontaneously depolarise and conduct the 
electric impulses through the other cardiac regions[1]. 
 
 Vascularity of the heart 1.1.1 
Anatomically, human heart has two main coronary arteries, originating from the aorta. 
The left main coronary artery (LM) originates from the left coronary sinus of the aorta 
and forms the left anterior descending coronary artery (LAD) and left circumflex 
coronary artery (LCX). The right coronary artery (RCA) originates from the right 
coronary sinus of aorta and gives three branches; proximal, mid, and distal. The 
coronary venous system is variable, but generally in humans there are two cardiac 
veins; the great cardiac vein (GCV) and the middle cardiac (MCV) vein. The GCV runs 
in parallel with the LAD and then courses superiorly, crossing the LCX and posteriorly 
draining into the coronary sinus. This vascular system is responsible for circulating 
blood to the heart muscle [1]. Figure 1-1 depicts schematically the coronary arteries and 
their branches.  
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Figure ‎1-1. The cellular composition of the heart and the coronary arteries. A) shows a 
cross section through the myocardium. The heart contains three layers: (i) the epicardium, (ii) 
the myocardium composed of cardiomyocytes, connective tissue, blood vessels and non-
cardiomyocyte cells; (iii) the inner endocardium. Note that non-cardiomyocyte cellular fraction 
of the heart contains: cardiac fibroblast, endothelial cells, vascular smooth muscle cells, immune 
cells and stem cells. The communication between all cell types within the heart is an important 
aspect in order to maintain cardiac homeostasis and its electrophysiological actions. B) shows 
the vascular supply to the heart with left and right coronary arteries and their branches. The 
image is adapted from [1]. 
 
 
 Cellular composition of the heart 1.1.2 
In a normal healthy heart, its cellular components interact in a fashion to respond to 
developmental, homeostatic, and pathological stimuli. The main cellular components 
that make up the heart include cardiomyocytes, cardiac fibroblasts (CFs), endothelial 
cells (ECs), and vascular smooth muscle cells (VSMCs), with the majority being CFs 
and cardiomyocytes. Transient cell populations of the heart include; lymphocytes, mast 
cells, and macrophages, which can interact with permanent cell types to affect cardiac 
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function. The adult heart also contains a limited number of cardiac stem cells which 
express stem cell markers such as; cKit and Sca-1 and are able to differentiate into 
different cell types. It has also been observed that there are significant differences in the 
makeup of the cardiac cell populations between the species, this could be important 
when examining myocardial remodelling. Current dogma claims that fibroblasts makes 
up the largest cell population of the heart; however, this appears to vary for different 
species, for example in mice and rats. However the cell composition of the heart 
maintains the electrical and biomechanical responsive reactions of the organ as well as 
the three-dimensional structure through autocrine, paracrine, and cell-cell interactions 
reviewed in [7]. Interruption of these interactions via cardiac remodelling can cause 
interference in this system leading to pathological conditions.  
 
 Coronary heart disease and myocardial infarction 1.2 
Acute myocardial infarction (MI) is a persistent public health issue and coronary heart 
disease (CHD) is the main cause of death in the UK (British Heart Foundation, 2012 
statistics). MI is the most common and clinically significant form of acute cardiac 
injury, which results in significant cardiomyocyte death. The underlying cause of MI is 
coronary atherosclerosis, and MI frequently happens as a result of an acute rupture of an 
atherosclerotic plaque. Following infarction a complex cascade of myocardial responses 
happen which are reviewed by Frangogiannis [8] (2008), but  will be briefly discussed 
here. Infarct healing consists of three phases: (i) inflammatory phase, (ii) proliferative 
phase and (iii) maturation phase (Figure 1-2). In the inflammatory phase, the injured 
tissue secretes chemokine and cytokine cascades that result in recruitment of neutrophils 
and macrophages to clear the necrotic debris. Activated macrophages release some 
cytokines and growth factors which then increase vascularization of the infarct region. 
Then at the proliferative stage the expression of pro-inflammatory mediators is reduced, 
and fibroblasts and endothelial cells (ECs) proliferate. Inflammatory leukocytes secrete 
a variety of cytokines which activate fibroblasts to form extracellular matrix (ECM). 
After myocardial infarction, the environment of the scar region draws further 
development of fibroblasts into myofibroblasts. For instance, Willems et al. (1994) 
showed that some interstitial cells within the human myocardial infarct regions express 
alpha-smooth muscle actin (αSMA), and vimentin. The authors used electron 
microscopy and showed that these cells have features of myofibroblasts [9]. 
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Desmoulière et al. (1993) showed that the subcutaneous administration of transforming 
growth factor-beta 1 (TGF-β1) to rats results in enhanced α-SMA expression in the 
granulation tissue. Furthermore administration of TGF-β1 also increases α-SMA 
expression at mRNA and protein level in the in-vitro fibroblast culture [10]. As the 
human heart has negligible cardiac regenerative potential, the fibrotic scar is permanent 
and significantly reduces the cardiac output. Therefore, to understand myocardial 
remodelling post-MI, it is valuable to address cardiac fibrosis and the cellular content of 
this event.  
There is some evidence which show that following MI, different cytokines and growth 
factors are produced, which cause different structural and functional changes. For 
instance, interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α) result in 
decreased expression of collagen and enhance matrix metalloproteinase (MMP) 
expression in the in vitro culture of rat-derived cardiac fibroblasts [11]. It has been 
shown TGF)-β/Smad3 signaling is activated in healing infarcts and induces fibrotic 
remodeling of the infarcted hearts. For instance Dobaczewski et al. (2010) showed that 
Smad3 Null murine infarcts had higher number of proliferating myofibroblast (α-SMA+ 
/ Ki67
+
) than wild type infarcts after 72 hours of reperfusion[12]. Angiogenic factors 
such as vascular endothelial growth factor (Vegf) and basic fibroblast growth factor 
(bFGF) are enhanced significantly and initiate neo-vessel formation. In this respect, 
Fukuda et al. (2004) showed a marked increase in arteriolar density of the hearts of rat 
MI models (+ischemic preconditioning with 4 repetitive coronary artery banding)  at 7, 
14 and 21 days after MI when compared to the control groups; further investigations 
showed that the level of Vegf protein was significantly higher in MI + ischemic 
preconditioning models versus the control groups [13]. Hif-1α overexpression in the 
murine heart resulted in attenuated infarct size and improved cardiac function 4 weeks 
post MI; furthermore, over expression of Hif-1α increased Vegf expression and 
capillary density in peri-infarct and infarct regions in the hearts of constitutive Hif-1α 
expressing animals versus control mice [14].  
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Figure ‎1-2 Three different phases of infarct healing in a mouse cardiac reperfusion model. 
Top panel is depicting fibrosis and ventricular atrophy of the infarct region during three phases 
of infarct healing. (A) During the inflammatory phase, chemokines and cytokines are induced in 
the infarct and marked leukocyte infiltration is noted (highlighted in the box). In this phase dead 
cells and matrix debris are cleared by neutrophils and macrophages. (B) Activated macrophages 
release angiogenic cytokines and growth factors and the number of fibroblasts, endothelial cells 
and extra cellular matrix (ECM) increases dramatically. (C) During the maturation phase 
macrophages and fibroblasts apoptose and the collagen scar stabilises. The image is adapted 
from [8].    
 
 CF morphology and functions 1.3 
The characteristic of cardiac fibroblasts (CFs) is a challenging topic and several articles 
have reviewed CFs in detail [15-18]. Here some important facts about CFs are 
discussed. CFs are defined as mesenchymal derived cells which produce collagen I, III 
and VI and associate directly with ECM. Morphologically, they all lack a basement 
membrane with spindle-shaped and multiple cytoplasmic processes emanating from the 
main cell with a speckled nucleus that typically has 1 or 2 nucleoli, reviewed in [15,16]. 
In general, fibroblasts are believed to be phenotypically heterogeneous based on 
morphology, collagen production, glycogen reservoirs and expressing fibroblast 
markers. For instance, gene array analysis has shown extreme diversity in the pattern of 
gene expression in 50 fibroblast cell cultures [19].  
Resident CFs are quiescent, and become active and proliferative by signalling 
molecules that are produced due to a cardiac injury. CFs are involved in different 
cardiac functions such as the production of cytokines and growth factors, cell 
proliferation, apoptosis, cardiomyocyte hypertrophy, ECM homeostasis, cell-to-cell 
   
7 
 
junctions with cardiomyocytes, conduction of electrical features of heart, cardiac 
remodelling, and angiogenesis reviewed in [18]. Figure 1-3 shows the different 
functions in which CFs are involved. 
 
Figure ‎1-3 Schematic representation of CF function. CFs produce different growth factors 
and cytokines in order to produce or degrade ECM components such as collagen I and III, and 
fibronectin. They may also promote cardiomyocyte proliferation, angiogenesis and cardiac 
electrophysiology. The image is adapted from [17]. 
 
 Origin and heterogeneity of CFs  1.3.1 
During embryonic life, interstitial CFs are derived from different origins. For instance, 
fibroblasts within the cardiac interstitium and the annulus are derived from 
mesenchymal cells of the embryonic pro-epicardium [20], which migrate over the 
embryonic heart and make the epicardium. Epicardial cells under the influence of 
growth factors, including platelet-derived growth factor (PDGF), FGF and TGF-β, 
undergo epithelial-mesenchymal transition (EMT) to form epicardium-derived cells 
(EPDC). These cells then further differentiate into fibroblasts and other cardiac cell 
types [21]. In addition to interstitial CFs, valvular fibroblasts are derived from the 
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cardiac endocardium during embryonic life, through a process called endothelial-
mesenchymal transition (End-MT) [22].  
 
 CF markers 1.3.2 
The limitation and the specificity of different fibroblast markers have been extensively 
discussed in the following reviews [15,23,24]. For instance, the discoidin domain 
receptor (DDR2), which is expressed in the majority of CFs, is a collagen receptor and 
mediates a wide range of cellular functions, such as migration, growth and 
differentiation. In fact, 26% of the cellular content of murine hearts are DDR2-
expressing cells [25]. Fibroblast specific protein 1 (FSP1), also known as S100A4, is 
also proposed to be a discriminative marker for fibroblasts. However, the validity of this 
marker has been questioned as FSP1 expression has been reported in a variety of other 
cell types such as leukocytes and cancer cells. In addition, not all CFs express FSP1. 
Vimentin also has been used widely to detect CFs but this marker is also expressed in 
endothelial cells and mesenchymal cells. Other markers such as periostin, fibronectin 
and connexin 40 (expressed in fibroblast-to-fibroblast boundaries) or connexin 45 
(expressed in fibroblast-to-myocyte boundaries) have also been shown to be CF 
markers, and are reviewed in [15,23,24]. Therefore, it seems that the identification of 
CFs may be more accurate by using a combination of several fibroblast markers in the 
context of their location and the physiological or pathological stages of the heart. 
Further identification of definitive fibroblast-specific markers will be necessary to better 
understand this heterogeneous cell type of the heart. 
 
 Origins of CFs in cardiopathy 1.3.3 
As mentioned above the lack of a robust CF specific marker makes CF studies difficult 
and, due to the variability among lineage-tracking tools, it is believed that there are 
multiple sources of CF. Specially, following cardiac injury several mechanisms and 
origins have been shown to be involved in CF composition in the heart.  
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 Endothelial-mesenchymal transition (End-MT) 1.3.3.1 
As discussed above End-MT happens during cardiac development, however Zeisberg et 
al. (2007) used an aortic banding model to determine the role of  End-MT in cardiac 
fibrosis [26]. The authors performed aortic banding in Tie1Cre;R26R-stop-lacZ adult 
mice and showed the expression of LacZ positive staining throughout the fibrotic 
region, whereas in the normal hearts LacZ expression was detected in blood vessels 
associated with endothelial cells [26]. Transition of endothelial cells into fibroblasts 
happens when endothelial cells are targeted by specific stimuli such as TGF-β ligands. 
TGF-β ligands mediate End-MT through the activation of the Snail family of 
transcription repressors which depends on Smad, MEK, PI3K and p38 MAPK 
activation, reviewed in [27]. Widyantoro et al. (2010), showed that diabetes mellitus–
induced cardiac fibrosis is associated with the emergence of fibroblasts from EC due to 
End-MT process, triggered by endothelin-1 (ET-1) [28]. These data suggest the distinct 
origins of CFs in physiological and pathological conditions. Figure 1-4 represents the 
schematic process of End-MT in tissue fibrosis. 
 
Figure ‎1-4 A schematic illustration of End-MT process in tissue fibrosis. TGF-β secretion 
by tissue-infiltrating inflammatory cells, such as lymphocytes and macrophages, triggers the 
transition of endothelial cells into myofibroblasts and then leads to the accumulation of 
myofibroblasts within the fibrotic tissue. The image is adapted from [29]. 
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 Bone-marrow-derived CFs 1.3.3.2 
Van Amerongen et al. (2008) studied the quantitative and functional aspects of bone 
marrow-derived  (BMD) myofibroblasts in myocardial scar formation and showed that 
following the transplantation of GFP-labelled or mismatched bone marrow (BM) cells, 
significant numbers of donor BM cells were observed in the fibrotic scar of the recipient 
hearts post-MI [30]. An interesting study compared the autopsy samples from male 
patients who had received a female donor heart with samples from such patients who 
developed MI after transplantation. They showed that in the fibrotic areas of MI about 
24.1±6.5% of cells carried the Y chromosome, compared to 5.3±1.1% of transplanted 
control patients without infarction [31]. When female mice were transplanted with male 
donor mice BM, the Y chromosome was detected in 13% of FSP1 and 21% of α-SMA 
fibroblasts in aortic-banded heart models, indicating that these CFs are derived from 
BM [26]. Van Amerongen et al. (2008) showed in the recipient mice which had 
undergone GFP
+
 BM transplantation, after myocardial injury, that GFP
+
 cells were 
observed in the fibrotic cardiac region and on average 21% of BMD cells were 
myofibroblasts which was 15% of the myofibroblast population in the infarct area [30]. 
However, there is a lot of controversy concerning the role of bone-marrow-derived 
(BMD) cells in the fibrotic reaction following cardiac injury, whether they are really 
fibroblasts or really inflammatory cells that are expressing fibroblast markers. In one 
study of mouse models of fibrotic ischemia/reperfusion cardiomyopathy a population of 
fibroblasts were identified that were highly proliferative and expressed collagen I and 
αSMA, CD34, and CD45 (a hematopoietic marker). These cells represented 3% of all 
non-myocyte cells [32]. More importantly, van Amerongen et al. (2007) used a murine 
cryo-injury model to induce left ventricular damage and showed that following 
infiltrating macrophage depletion, the CF population diminished in the infarct region 
and impaired the wound-healing process and subsequently reduce the heart failure rate 
[33], which suggest a key role of monocytes in fibrosis following MI. In general, these 
findings support the idea that hematopoietic stem cells and epicardium-derived cells are 
important sources of CF turnover in different regions of the adult heart and CFs are 
likely to have distinct sources in physiological and pathological states of the heart. 
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Figure ‎1-5 Origin of CFs in physiological and pathological heart tissue. EMT and End-MT 
are believed to be the two main sources of CFs during embryonic development. Proepicardial 
cells form interstitial fibroblasts through EMT, and End-MT is responsible for valvular 
fibroblast differentiation from endothelial cells. However, following cardiac injury CF 
recruitment occurs due to cell plasticity and pro-fibroblasts are mainly derived from endothelial 
or epithelial cells through EMT and End-MT. Other cell types such as monocytes, circulating-
BM progenitors, pericytes and fibrocytes are also proposed to be a source of CFs. Image is 
adapted from [18]. 
 
 CFs and myocardial remodelling 1.3.4 
One of the most significant responses of the injured heart after MI is enhanced 
angiogenesis of the peri-infarct zone which happens in response to the release of 
cytokines and growth factors from the infarcted heart. In order to understand the role of 
angiogenesis in myocardial remodelling, a brief review of vasculogenesis and 
angiogenesis will be helpful.  
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 Vasculogenesis and angiogenesis 1.4 
In vertebrates, blood vessel formation is through two distinct processes: 1) 
vasculogenesis and 2) angiogenesis. In embryonic development the heart and primitive 
vascular plexus formation is through vasculogenesis which is defined as de novo 
differentiation of mesoderm-derived precursor cells (angioblasts) to endothelial cells. 
However, vasculogenesis can also happen in adult life when circulating BMD or 
endothelial progenitor cells (EPCs) contribute to new vessels following injury, reviewed 
in [34]. Angiogenesis occurs in both development and in adult life. In the embryo, it is 
the process that remodels a pre-exiting primary plexus formed by vasculogenesis into a 
complex vessel network that supports growth and development of the vertebrate 
organism reviewed in [34]. Angiogenesis refers to two processes (i) endothelial 
sprouting and (ii) intussusceptive microvascular growth (IMG) (figure 1-6). The 
sprouting process involves the degradation of the basement membrane, endothelial cell 
migration, proliferation and tube formation, in response to a growth factor stimulus such 
as Vegf. IMG refers to the splitting and growing of vessels by folding of the interstitial 
tissue pillars into the lumen of the vessel. New vessel formation is supported by 
pericytes, vascular smooth muscle cells and the extra-cellular matrix. Neighbouring 
mesenchymal cells migrate towards the neo-vessel in response to cytokines such as 
PDGF and then differentiate into vascular SMCs (vSMCs) in response to TGF-β 
signalling, reviewed in [35]. These supporting mechanisms provide a stable 
environment for new vessels to develop.  
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Figure ‎1-6 Schematic representations of vasculogenesis and two types of angiogenesis. 
Vasculogenesis starts with the differentiation of angioblasts to form a primary capillary plexus, 
which then expands by angiogenesis. In sprouting angiogenesis, ECs proliferate behind the tip 
cells and form a lumen. Intussusceptive angiogenesis involves the folding of vascular interstitial 
tissue into the lumen of the vessel. In both mechanisms smooth muscles are required for 
stabilisation of the nascent vessels: resident mesenchymal cells migrate towards the new vessel 
in response to platelet-derived growth factor (PDGF) and then differentiate into vascular smooth 
muscle cells following intimate associations with endothelial cells and the activation of TGF-β. 
The image is modified from [35]. 
 
 Angiogenesis and its role in cardiac remodelling 1.5 
During adulthood the majority of blood vessels remain quiescent and angiogenesis is 
limited to the female reproductive cycle in the placenta during pregnancy. However, 
ECs retain their angiogenic response to different stimuli, reviewed  in [34]. For 
instance, angiogenesis is reactivated during wound-healing in order to repair tissue 
damage. But in some disorders angiogenesis changes from a balanced to either an 
insufficient or an enhanced state. Tumours and related malignancies are examples when 
angiogenesis has been enhanced. In this respect, new vessels feed the tumours and allow 
tumour cells to metastasise. On the other hand, insufficient angiogenesis happens when 
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the level of angiogenesis cannot respond sufficiently well to meet the metabolic 
demands of the tissue [34].  
Arteriogenesis, the process of enlargement and muscularisation of small arterioles, can 
happen following stenosis or occlusion of a major artery, and leads to enhanced 
reperfusion capacity of the injured tissue by acting as an alternative blood perfusion 
route. Scholz et al. (2000) investigated the structural and molecular histology of 
growing collateral arteries that develop after femoral artery occlusion in rabbits between 
2 hours to 240 days. They showed that arteriogenesis starts with arteriolar thinning, 
followed by the proliferation of ECs and smooth muscle cells (SMCs). Interestingly, 
these cellular modifications happen quickly as EC and SMC division start 24 hours after 
artery occlusion. Expression of the adhesion molecules such as intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) is enhanced 
after 12 hours [36]. Physical stimuli such as increasing blood pressure or fluid shear 
stress (FSS) have been shown to be a possible stimulator for arteriogenesis through the 
activation of ECs. In this respect, Scholz et al. (2000) showed the effect of in vitro FSS 
in cultured ECs which increased the expression of ICAM-1 and VCAM-1 between 2 h 
and 6 h after shear onset [36]. However, the healing processes with consequent 
angiogenic and arteriogenic responses are frequently insufficient to protect the 
myocardium from ischemic disease, which results in cardiomyocyte apoptosis and 
tissue necrosis. Hence therapeutic angiogenic strategies have the potential to improve 
myocardial function following MI.  
 
 Therapeutic angiogenic therapies in myocardial infarction 1.5.1 
The urgent treatment for the infarcted myocardium is to restore the blood flow via 
angioplasty combined with medical treatment to stabilise the patient. This method is 
able to overcome the cause of the infarction which is coronary artery occlusion and has 
led to a major improvement in patient survival. However angioplasty can lead to 
ischemia/reperfusion injury that is associated with EC apoptosis and loss of the local 
microcirculation. Therefore, much research has focussed on promoting angiogenesis in 
order to improve current treatments and decrease the level of cardiac injury in MI 
patients. Three main therapeutic routes, namely gene, protein and cell therapies, have 
been introduced. However, pro-angiogenic strategies with genes and proteins such as 
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Vegf and FGF resulted in limited and unstable success, probably due to their short half-
lives. Using angiogenic cytokines, although they activated rapid neo-vessel formation in 
MI models, the newly formed vessels were fragile and failed to anastomose with the 
coronary circulation properly [37]. Therefore, therapeutic angiogenesis with cells such 
as relevant progenitor cells could potentially provide a prolonged effect, because 
progenitor cells have been shown to be able to differentiate into vascular and 
cardiomyocytes. Furthermore, the transplanted cells are able to secrete growth factors 
which could activate paracrine mechanisms and help to stimulate host angiogenic cells 
to form new vessels. Several stem/progenitor cells have been used in order to assess 
their pro-angiogenic potential following cell transfer. BMDs, embryonic stem cells 
(ESCs), induced pluripotent stem cells (iPSCs), skeletal cells and adipose-derived stem 
cells (ADSCs) have been used in myocardial infarct models; although some 
improvements have been reported, the optimal cell therapy is remains uncertain. BMD 
cells are the most widely used cells in clinical trials for myocardial repair. They are 
autologous, so no need for immunosuppression. However, in a clinical trial study with 
200 patients which received BM cells after acute MI, the results showed very limited 
improvement of the left ventricular ejection fraction (LVEF) and did not have any 
obvious long term benefit [38]. It has been shown that the efficiency of BMC 
transplantation in old patients, diabetics and advanced cardiovascular disease is 
considerably reduced [39,40].  
 
 Cardiac stem cells (CSCs) 1.6 
Recent studies have shown that the mammalian adult heart has regeneration potential 
[41-44] so the heart is in principle capable of regeneration. CSCs have been isolated 
from adult human and different animals and are classified based on expression of stem 
cell markers such as Sca-1
+
 (stem cell antigen), cKit
+
 (CD117, the receptor of stem cell 
factor) Abcg2
+
 or a side population (a population of progenitors which are able to efflux 
Hoechst dye) and Isl1
+
 (an embryonic cardiac progenitor). Bearzi et al. (2007) isolated 
cKit
+
 hCSCs from samples of human myocardium and showed that these cells have the 
ability to form functionally competent human myocardium after delivery to the 
infarcted heart of immunocompromised mice and rats. These stem cells were self-
renewing, clonogenic, and multipotent. They also were able to differentiate into 
cardiomyocytes and occasionally into SMCs and ECs [45]. However, it has been shown 
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that the number of CSCs in the myocardium is relatively low which could explain that 
why the heart is unable to repair itself sufficiently following ischemic disease. The 
quantitative data have shown that on average there is 1 CSC per 18,000 myocytes in 
dog hearts [46]. Urbanek et al. (2005) studied the hearts from patients who died due to 
infarction, and hearts from patients who underwent cardiac transplantation after MI. The 
quantification of CSC showed that there were 40,000 CSCs per cm
3
 of tissue in the 
border zone region and less than 20,000 per cm
3
 in the remote region [47]. The true 
origin of CSCs is an interesting topic. For instance, it is possible that cKit
+
 expressing 
CSCs might have originated from extra cardiac tissue, as HSCs including cKit
+ 
cells are 
shown to leave BM to the other extra myeloid organs [48]. Lineage tracing of 
cardiomyocytes from heart transplant patients showed that endothelial and 
cardiomyocytes derived from the recipient have been reported within the donor heart 
which suggests the possibility of the recipient cells’ synchronisation with the donor 
heart [49].  
As discussed above, CSCs are classified based on their superficial stem cell markers. In 
this thesis I used Sca-1 and cKit to characterise cardiosphere derived cells (CDCs), so it 
is useful to consider Sca-1, cKit and Abcg2 in more detail. 
 
 Stem cell antigen-1 (Sca-1)  1.6.1 
Sca-1 is a common marker for murine hematopoietic stem cells (HSCs), and is used to 
isolate pure populations of HSCs. Sca-1 is a member of Ly-6 gene superfamily with 
diverse functions. Its expression in HSCs seems to be a subject to strain bias. For 
example, all HSCs in Ly6.2 strains such as C57BL/6 are Sca-1 positive [50], whereas 
25% of HSCs in Ly6.1 strains such as BALB/c express Sca-1 [51]. Sca-1 positive cells 
have been shown to be involved in the derivation of stem/progenitor cells from different 
tissues such as the heart, liver, mammary gland, dermis and skeletal muscle. However it 
is not yet clear if tissue Sca-1 progenitors are truly tissue specific or are derived from 
BM. Sca-1 is involved in different pathways such as lymphocyte maturation, stem cell 
maintenance, cell adhesion, haematopoiesis and tumorigenesis, reviewed in [52]. Batts 
et al. (2011) showed that silencing Sca-1 expression in mammary cell lines decreases 
cell migration and the silenced Sca-1 cells showed higher adhesion to ECM molecules. 
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The results from this study suggested that the delayed migration exhibited by Sca-1-
silenced cells could be due to increased cell-matrix interaction[53].   
In the heart, majority of adult-side population cells are Sca-1
+
, CD45
-
, CD34
-
 and 
expressing telomerase activity similar to the neonatal myocardium [54]. One hypothesis 
is that the Sca-1 population of CSCs may have a regenerative function after MI, as the 
number of Sca-1
+
 and CD31
-
 cells increase after 7 days post-MI as did the expression of 
the Sca-1 protein [55]. Transplantation of Sca-1 cells into the border zone of murine MI 
model, which attenuated post-MI ventricular remodelling, increased LVEF and 
angiogenesis [55]. It is already shown that Sca-1
+
/CD45
-
 CSCs are clonogenic (5.6%) 
and are able to reduce infarct scar size, and promote angio/cardiogeneis post-
transplantation into the MI heart [56]. 
 
 cKit  1.6.2 
cKit, also known as CD117, is a type III receptor tyrosine kinase (RTK) and another 
cardiac stem cell marker. It plays important roles in the amplification and tissue 
recruitment of mesenchymal stem cells. The gene encodes a ligand that maps to the 
steel locus and was hence named steel factor or stem cell factor (SF), and is reviewed in 
[57]. In the heart, cKit-expressing cells were the first cardiac stem cell population 
isolated. Although these cells are originally mesenchymal stem cells, they are negative 
for some blood lineage markers such as CD34 and CD45. cKit cells have been isolated 
successfully from human atrial biopsies and almost 1% of the cells derived from tissue 
samples were cKit
+
 [58]. Furthermore, cKit
+
-expressing cells have been shown to be 
clonogenic, self-renewing and multipotent, and have been shown to differentiate into 
smooth muscle, endothelial and cardiomyocyte cell types. Transplantation of human 
cKit
+
 cells into nude rat MI models significantly increased LVEF 3 weeks after cell 
delivery (LVEF ≈ 48% treated vs. LVEF ≈ 36% untreated) and enhanced angiogenesis 
in rat MI models [45]. 
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 Cardiac side population, Abcg2+ progenitors 1.6.3 
The adult heart contains a group of progenitor cells termed cardiac side populations 
(SPs), which are able to efflux metabolic markers such as Hoechst dye which 
represented 1% of total cardiac cells of adult heart[59]. These cells express a type of 
membrane pump encoded by a group of multidrug resistance genes. Martin et al. (2004) 
first attributed cardiac SP cells to ATP binding cassette transporter gene (Abcg2) and 
showed that the adult mouse heart has SP cells. Further characterisation of murine SP 
cells showed that 42.3% of SPs express Sca-1 and 2.1% cKit [60]. Interestingly, SPs 
were predominantly distinguished from myeloid lineages by the low expression of 
CD45 (1.5%). In another study, Pfister et al. (2010) showed that 84% of murine SPs are 
Sca-1
+
 and 75% are CD31
+
, although the cardiogenic potential of the Sca-1
+
/CD31
-
 
fraction of SPs is shown to be the highest, and this fraction corresponds only to 10% of 
SP cells [61]. In another study, Oyama et al. (2007) showed that after the intravenous 
injection of cardiac GFP-SP cells into adult cardiac cryo-injured models, GFP-SP cells 
migrated towards to site of injury (12 fold more than normal controls) and formed 
cardiomyocytes, endothelial cells, smooth muscle cells and fibroblasts [62]. Human 
endothelial cells also express Abcg2 [63], suggesting the possible endothelial fate of 
these cells.  
 
 Characterisation of EDCs, Csphs and CDCs 1.6.4 
In 2004, a group in Italy first showed that ex vivo culturing of human cardiac biopsies 
(explant) could yield cardiospheres (Csphs). Messina et al. (2004) showed that explant-
derived cells (EDCs) were able to form Csphs spontaneously and that Csphs expressed 
cardiac stem cell markers such as cKit and Sca-1 [42]. Although spheroid formation of 
progenitor cells is a controversial characteristic, Khaitan et al. (2006) showed that 
glucose consumption of spheroids from human Glioma cells is 2-3 times more than the 
monolayer cell culture [64]. This could be due to the hypoxic environment of the core 
of the spheroids and the expression of Hif-1α which activates glycolysis pathways to 
generate energy and decreased mitochondrial activity [64]. These findings suggest that 
spheroids are likely to provide a more beneficial niche for stem cells within the Csph 
3D structure as hypoxic conditions cause less oxidative damage. 
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Figure ‎1-7 Schematic representation of three stages of CDC culture. Heart biopsies from 
humans or whole hearts from mice cultured as cardiac explant after a brief enzymatic digestion. 
After several days when the explant-derived cells are confluent, they are then transferred into a 
high growth factor medium and cultured till the Csphs are fully formed. Finally, at the CDC 
stage Csphs are passaged twice and used for experiments. Figure is adapted from [65]. 
 
Using electron microscopy Barile et al. (2013) showed that Csphs have a unique 
microenvironment which contains secretory granules and intercellular contacts (figure 
1-8) [66]. Li et al. (2010) studied the effect of the 3D structure of Csphs on the stem cell 
niche and showed that the internal cells of the spheroids express cKit, shielded by 
Endoglin (Eng) and collagen IV expressing cells. Interestingly the authors showed that 
the proportion of cKit expression was significantly higher in Csphs in comparison with 
monolayers (16.9% vs. 9.1%) [67]. This finding marries with those of Smith et al. 
(2007), who proposed that mesenchymal cells could provide physical and secretory 
benefit to cKit-expressing cells [68]. In addition, Li et al. (2010) showed that Csphs 
show increased gene expression of: (i) some genes involved in ECM (such as MMPs), 
and collagen IV); (ii) stem cell markers such as Sox2, Nanog; and (iii) stem cell growth-
related factors such as HDAC2, Tert and IGF-1 in comparison to the monolayer culture 
[67]. Although this study indicated the importance of the Csph culture stage and its 
benefits for the subsequent derivative cells; there are some reports that even some 
terminally differentiated cells such as fibroblasts can make spheroids when cultured in 
the Csph culture medium [69]. Another point about Csph culture is that it needs 
expensive growth factors and it is time consuming. Therefore, Davis et al. (2010) 
characterised EDCs from rat atrial and ventricular samples. The authors repeatedly 
harvested rat cardiac explants and analysed the expression of cKit and its co-expression 
with two other stem cell markers: either Abcg2 or SSEA-1. Although the expression of 
cKit reached its peak at harvest 3, Abcg2 expression increased following extended 
culture. And SSEA-1 had negligible expression even at the highest peak in harvest 1 
(approximately 1%). However, this study was also important in showing the ability of 
rat-derived EDCs and CDCs to form tubes in a 2D matrigel assay and both cell groups 
were able to form cellular grafts following cell transplantation leading to improved 
cardiac contractility and angiogenesis mainly through paracrine activities [70].   
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Smith et al. (2007) modified the Csph culturing method and added a monolayer cell 
expansion post-cardiosphere stage to acquire cardiosphere-derived cells. This 
modification could be used to increase the yield of therapeutic cells for further 
investigations or clinical uses [68]. Davis et al. (2009) showed that CDCs had 
clonogenic properties (9 out of 65 single cells generated colonies) [71] and Messina et 
al. (2004) reported that the clonogenicity efficiency of GFP
+
 cardiosphere cells were 
1%-10%[42]. Following CDC expansion and characterisations, the heterogeneous 
expression of range markers was observed by Smith et al. (2007). Their CDCs at 
passage 2 express markers including gap junction protein (connexin 43), cKit (20%), 
CD90 (40%), Eng (>90%), CD34 (5%), CD31 (10%). The majority of CDCs at passage 
2 were negative for CD45 and lineage markers [68], indicating that the majority of 
CDCs are distinct from BMD haematopoietic progenitor cells.  
 
Figure ‎1-8 Electron microscopic analysis of human Csph showing secretory granules (red 
arrows) and primary lysosomes (yellow arrows). Image is modified from [66].  
 
Validation of Csphs and CDCs to culture cardiac progenitor cells have been reported in 
several species including the Rhesus monkey [44], pig [43], mouse [42,72,73], rat 
[70,74], dog [75,76] and humans [77]. However, not all scientists consider that Csph 
culture is an accepted method of propagating cardiac stem cells. For instance, Andersen 
et al. (2009) claimed that Csphs are not clonogenic and they do not represent CSC 
populations, but rather they expresses CD45 or Collagen 1 which suggests they are 
BMD cells or fibroblasts [78]. Subsequently Davis et al. (2009) confirmed that EDCs, 
Csphs and CDCs contain cKit-expressing cells and do not express haematopoietic 
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lineage markers. Finally, they concluded that Andersen’s group’s  findings could be due 
to technical differences in the Csph-culturing method that could significantly change 
their yield and phenotype[71]. However, CDCs share some immunophenotypic 
characteristics with fibroblasts such as CD90 expression. Although Mishra et al. (2011) 
showed by immunofluorescent staining that human CDCs are negative for Collagen 1 
expression [79], Carr et al. (2011) showed that 10% of rat-derived CDCs express DDR2 
(collagen receptor) [80], indicating the contribution of CFs in the CDC population.  
 
 The origin of Csphs and CDCs 1.6.5 
Massberg et al. (2007) showed that cKit
+
 cells occasionally leave the BM in order to 
provide local immune response in peripheral tissues such as the heart in response to 
pathogen invasions [48]. In human heart transplants, recipient cardiomyocyte and ECs 
have been observed in the donor hearts, suggesting that circulating stem cells could 
come into the donor heart and differentiate into different cell lineages [49]. 
Furthermore, it has been shown that almost 5% of cardiomyocytes of allogeneic BM-
recipient patients are chimeric [81], suggesting that the possible recruitment of 
cardiogenic progenitors from the circulating system could reach the heart. However, 
another study showed only 18.4±4.5% of cells in murine Csphs were derived from BM. 
Csphs were cultured from hearts at 2 weeks post-MI and from no surgery controls in 
chimeric mice (transplanted BM cells from GFP transgenic mice into the lethally 
irradiated C57BL/6 mice,) and cells that co-expressed GFP and CD45 were used to 
indicate their BM origin. However, in this study, all Sca-1
+ 
CD45
- 
cells (a proportion of 
cardiac progenitors in CDC culture) were GFP negative, suggesting their distinct origin 
from BM [56]. White et al. (2011) studied heart transplant patients and showed that 
CDCs have an intrinsic origin using molecular methods such as qRT-PCR, short tandem 
repeat (STR) analysis and fluorescence in situ hybridisation [82]. However, there are 
two points which need to be considered in this work. First is the sample size which is 
very small and is not significant for statistical analysis (n=2) and the other issue is that 
all of the cases were in a physiological state, even though they were transplanted, thus it 
is possible that pathological stimuli such as MI might generate different results [83]. 
Finally, Barile et al. (2007) transplanted BM donor cells in which GFP was under the 
control of the cKit promoter into irradiated mice, and after experimental MI, the 
majority of the Csphs made from the recipient mice showed GFP expression; this study 
   
22 
 
suggested that in pathological conditions, BM cells can repopulate the CSC pool and 
contribute into the Csph culture [84]. Therefore, these studies suggested that the purity 
of Csphs and CDCs in terms of cardiac origin is likely to depend on the physiological or 
pathological state of the heart. However, it is still not clear what the true origin of the 
resident cardiac stem cells is, and further lineage tracing by using different transgenic 
animal models would increase our knowledge regarding this matter. 
 
 EDC and Csph culture from the MI model 1.6.6 
Ye et al. (2012) showed that EDCs derived from 1, 2 & 4 weeks post-MI, took less time 
to form a confluent monolayer of cells in comparison to no surgery controls (14±1, 
13±1 and 18±2 days from 1, 2 and 4-week post-MI hearts, respectively), versus to 
explants derived from sham-operated and non-operated hearts (21±1 and 32±2 days, 
respectively). However, no significant difference was observed between the groups at 4 
weeks post-MI. This study also showed that the number of Csphs formed was 
significantly greater at 1-week (5.12×10
5
±0.45×10
5
/heart) and 2-week 
(3.75×10
5
±0.52×10
5
/heart) post-MI versus sham-operated (2.20×10
5
±0.70×10
5
/heart) 
and non-operated hearts (1.67×10
5
±0.26×10
5
 cells/heart) (p<0.045). Ye et al. (2012) 
also showed that Csphs derived from MI mice engrafted in the ischemic myocardium 
and differentiated into smooth muscle and endothelial cells. MI-derived Csphs were 
also able to promote angiogenesis and reduce the infarct size after transplantation in the 
MI models, suggesting that MI has improved the efficacy of Csphs in vitro and in vivo 
[56].  
 
 The role of EDCs, Csphs and CDCs in neovascularisation 1.6.7 
Several studies have shown the pro-angiogenic potential of EDCs [70,73], Csphs 
[42,67,85] and CDCs [65,68,74,79,80,86] in vitro or in vivo or both. There is evidence 
of successful cell engraftments in recipient heart tissues and promotion of a significant 
increase in the capillary density of the ischemic myocardium. EDCs, Csphs and CDCs 
have all been shown to express endothelium-related cell markers such as CD31, CD34, 
Vegf, Flk1 and Eng in vitro, to improve myocardial function and increase capillary 
density in the peri-infarct region through paracrine mechanisms in comparison with no-
   
23 
 
cell recipient or sham-operated control groups. EDCs, Csphs and CDC also have a 
limited autocrine capacity to differentiate towards endothelial, smooth muscle cells and 
cardiomyocytes post-transplantation in MI models although the autocrine pathway 
seems to be not very efficient [68,70,83]. Some studies have compared the efficacy of 
Csphs with CDCs: for instance, Li et al. (2010) showed that transplantation of human 
Csphs into the mouse model of MI enhances cardiac function significantly better than 
CDCs [67]. In another study using a pig model of anteroseptal myocardial infarction, 
injection of CDCs or Csphs enhanced the cardiac function and attenuated myocardial 
remodelling in comparison with the placebo group; however, the authors concluded that 
Csphs were superior in improving hemodynamics, regional function, and in attenuating 
ventricular remodelling [43]. As discussed above, the benefit of CDC culture is due to 
its faster proliferation and higher therapeutic cellular yield than Csphs (3 folds vs. 1.2 
fold increase in CDC vs. Csph growth rate after 7 days of culture) [67]. On the other 
hand, Csphs produce more growth factors in vitro, such as Vegf, compared with CDCs 
that could improve neo-vessel formation. However, Csphs have a large size (50-200 µm 
in diameter) which limits their application due to the risk of embolism following intra-
coronary delivery [43]. Even CDCs which are considered to be relatively large cells 
(20.6±3.9 µm diameter), could potentially cause microvessel blockage, as some 
microvessels are 7-10 µm in diameter [86]. Furthermore, the addition of 100U/ml of 
heparin into the cell suspension solution, prior to cell transplantation is important to 
reduce cell-related thrombus formation [86]. Tang et al. (2009) showed that 4 weeks 
after transplantation of cardiosphere-derived Lin
−
/cKit
+
 progenitor cells in a mouse 
model of MI, the capillary density of the peri-infarct region increased in comparison 
with mice which received only the culture medium [73]. In another study the authors 
showed that CD31 expression was enhanced by 44% in the peri-infarct region of CDC-
transplanted rat models after 16 weeks of MI in comparison to controls [80].  
However, the main barrier in the field of cardiac cell transplantation therapy is low cell 
survival after cell transplantation, this is irrespective of the applied cell type. It has been 
reported that cell retention in many studies is low. Variable cell retention could be due 
to a number of factors: (i) technical differences of cell culture protocols; (ii) animal 
models of MI; (iii) cell delivery route; and (iv) the harsh anoxic conditions of the host 
tissue (ischemic myocardium) [87]. Moreover, the constant activity of the heart and 
consequent mechanical forces and venous drainage could also decrease the cell 
retention efficacy [88]. Thus low cell survival could be detrimental for both autocrine 
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and paracrine routes of neo-vessel formation by CDCs. To this end some strategies have 
been applied in order to adapt cells prior to transplantation. In relation to CDCs, 
hypoxia pre-treatment could potentially increase their tolerance following cell 
transplantation into the harsh ischemic region. In 1994, Rumsey et al. used oxygen-
sensitive phosphorus to measure the oxygenation of the healthy and infarcted rat heart 
in real time and showed that after cardiac infarction the heart is divided into three 
regions based on oxygen pressure: (i) Remote region, with almost physiological level of 
O2, equivalent to 5%; (ii) peri infarct zone, which extends only several millimetres and 
has the range of 3% O2; and (iii) the core of the infarct which has nearly 0-0.2% oxygen 
[89] (Figure 1-9). 
 
 Hypoxia and Hif proteins  1.7 
The range of normoxia is very narrow in mammalian cells as the risk of oxidative 
damage due to hyperoxia and metabolic deterioration due to insufficient O2 (hypoxia) 
are extremely detrimental. In general, hypoxia means a reduction in the oxygen level in 
the cellular microenvironment and may result from vascular dysfunction or malignancy. 
Hypoxia activates a number of genes which are important to adapt cells to survival in 
low levels of O2. Mammalian cells have a system to respond to hypoxic conditions very 
quickly and efficiently which is initiated by Hif proteins, reviewed in [90]. Hifs are 
sequence-specific DNA-binding proteins that can promote or repress the expression of 
downstream genes which are involved in O2 homeostasis. Genes that are under the 
control of hypoxia have been implicated in functions such as cell survival, cell 
proliferation, apoptosis, glucose metabolism and angiogenesis [91]. Overall, Hifs trigger 
a cascade of gene activation which helps cells to adapt to low concentrations of O2. This 
adaptation is useful to mammalian cells in the context of embryonic development, 
angiogenesis and ischemic disorders, or it may be detrimental in the context of 
tumorigenesis or apoptosis. Table 1-1 summarises the common terminology and the 
relative oxygen level. 
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Condition pO2 (mmHg) % O2 
Normoxia (ambient) 159 21% 
Mild hypoxia 8-38 1-5% 
Hypoxia <8 <1% 
Anoxia <0.08 <0.1% 
Table ‎1-1 Frequently used terminology and the relative oxygen level. Table is adapted from 
[90]. 
 
Figure ‎1-9 Oxygen quenching in a rat MI model, showing that the heart is divided into three 
regions: 1) remote region with physiological oxygen levels (5% O2); 2) the peri-infarct/border 
zone containing 3% O2; and finally, the injured region with 0-0.2% O2. The image is modified 
from [89]. 
 
 Hif proteins  1.7.1 
Three isoforms of Hif-α have been identified in mammals: Hif-1α; Hif-2α; and Hif-3α. 
Hif protein expression is regulated at transcriptional, translational and post-translational 
stages. Hif-1α is highly sensitive to protein degradation in normal oxygen 
concentrations, reviewed in [90]. Figure 1-10 shows the inactivation of Hif-α in 
normoxic conditions. In hypoxia, Hif-α is stabilised mainly due to the inactivation of 
Hif-α hydroxylation enzymes (PHD and FIH) and enters into the nucleus where it binds 
to Hif-1β (ARNT) to produce a stable complex which is now able to activate the target 
genes [92]. The specific promoter sequence that Hif-α protein recognises is called an 
hypoxia-response-element (HRE) and contains 5’-RCGTG-3’, in which R refers to A or 
G [93]. Erythropoietin and Vegf are some typical examples of Hif-α target genes which 
activate erythropoiesis and angiogenesis, respectively [90]. 
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Figure ‎1-10 Hif-1α‎ regulation‎ in‎ Normoxia‎ and‎ Hypoxia. While O2 is available in the 
cellular niche hydroxylation of proline residues by PHD 1-3 enzymes occurs and modifies the 
structure of Hif-1α, which is then introduced to the VHL tumour suppressor gene and ubiquitin-
mediated proteosomal degradation (Left). In contrast Hif-1α is stable if O2 availability is 
decreased. Hypoxia inhibits proline and asparagine hydroxylation, which allows Hif-1α to 
accumulate and dimerise with Hif-1β in the nucleus and eventually activate the transcription of 
target genes involved in the adaptation of cells to hypoxic conditions.  
 
 Hypoxia signalling in adult stem cells 1.7.2 
HSCs in BM are the classic example of adult stem cells which are capable of 
replenishing all types of myeloid blood cells. One of the important hallmarks of the BM 
microenvironment is hypoxia. It has been shown that the hypoxic niche of BM is 
essential for its resident stem cell maintenance and improves clonogenicity, reviewed in 
[94]. In addition to HSCs, the hypoxic niche also plays important roles in other adult 
stem cell populations such as the sub-ventricular zone of the hippocampus, which 
contain neural stem cells (NSCs). Moreover, Hif proteins are up-regulated in several 
cancer stem cells and this affects their proliferation, metastasis, vasculogenesis, survival 
and differentiation, reviewed in [95]. In addition, inhibition of Hif-1α eradicates 
lymphoma and acute myeloid leukaemia (AML) by eliminating cancer stem cells [96]. 
Therefore, hypoxia and Hif proteins appear to be important regulators of stem cell 
maintenance and proliferation. In fact, hypoxia has variable effects on stem cell 
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proliferation. For instance, Grayson et al. (2007) showed that culturing human 
mesenchymal stem cells (hMSCs) in low oxygen (5%) resulted in a nine fold increase in 
cell expansion compared to normoxia [97]. However, in another study Holzwarth et al. 
(2010) showed that MSC cultured in 1% O2 did not proliferate as fast as MSC cultured 
in atmospheric oxygen (21% O2) [98]. On the other hand, some studies have shown the 
benefit of hypoxic culture on the maintenance of stem cell pluripotency and the 
expression of embryonic stem cell markers such as Oct4. It has been shown that 
culturing human embryonic stem cells in 2% O2 maintained their pluripotency for up to 
18 months [99]. Taking all this together, it seems that the effect of hypoxia on the stem 
cell phenotype is cell type and cell culture dependent. Therefore, to elucidate better the 
effect of hypoxia on stem cells, it is specifically recommended to examine different O2 
levels on different characteristics of the candidate stem cell directly.  
 
 Hypoxia and cardiac progenitor cells 1.8 
Recently, a physiological cardiac hypoxic niche was identified in the epicardium and 
subepicardium, as these regions have the smallest capillary density. It was shown that 
50% and 10% of epicardial and sub epicardial cells, respectively, express Hif-1α in 
uninjured murine hearts. These cells also have clonogenic and multilineage 
differentiation capacity to form endothelial, cardiomyocyte and smooth muscle cells in 
vitro [100]. Another item of evidence to support the hypoxic niche in the epicardium 
and subepicardium regions is that cells of these regions mostly rely on cytoplasmic 
glycolysis rather than mitochondrial oxidative phosphorylation to generate energy, so 
they have been named as glycolytic cardiac progenitors (GCPs) [100]. Hif-1α knock-
down in these cells significantly reduced their proliferation and spontaneous 
differentiation potential. These findings suggest the similarity of the epicardium and 
subepicardium niche to the BM hypoxic niche. Hif proteins are likely to be the key 
regulators of self-renewing stem/progenitor cells within the hypoxic niche of the 
epicardium and sub epicardial regions [100]. But it is not yet clear whether GCPs could 
contribute to cardiac remodelling and myocardial repair after infarction. However, there 
is a possibility that hypoxia could activate migration of any types of cardiac progenitors 
towards the injured myocardium. For instance, it has been shown that cardiac 
progenitors, Sca-1
+
 cells, migrate towards the injured myocardium after myocardial 
infarction and differentiate into cardiomyocytes and endothelial cells [56]. In vitro 
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studies have shown that the cardiac stem cell responds to hypoxic stimuli based on the 
duration of the culture. For instance Van Oorschot et al. (2011) showed that short- and 
long-term hypoxic culture have different effects on human cardiomyocyte progenitor 
cells (hCMPCs). In their study, short-term hypoxia increased the migratory and 
invasiveness of hCMPCs. Although long-term culture did not initiate differentiation of 
hCMPCs into endothelial or mature cardiomyocytes, it significantly increased their 
proliferation and growth factor secretion (such as Vegf) [101].  
 
 Hypoxia preconditioning of EDCs and CDCs 1.8.1 
SDF-1 is a transcriptional target of the Hif-1α protein. Following the stabilisation of 
Hif-1α, the migration and homing of circulating CXCR4 expressing progenitor cells to 
ischemic tissue was enhanced. Furthermore, the inhibition of SDF-1/CXCR4 signalling 
pathway decreased progenitor cell recruitment to the site of injury [102]. Tang et al. 
(2009) showed that preconditioning of the cardiosphere-derived cell Lin
-
 cKit
+
 
progenitors (CLK) by severe hypoxia (0.1%) induces their recruitment (2.5 fold) to 
ischemic myocardium through the SDF-1/CXCR4 pathway. Tang et al. (2009) showed 
that it takes only 4 hours of hypoxic culture for CLK to show an increased expression of 
CXCR4. They also showed that the migratory activity of CLK towards the injured 
region was increased under the control of Hif-1α and CXCR4 activation. In this study, 
CLK pre-treated with severe hypoxia (0.1% O2) produced more chemokines (TCA-3, 
SDF-1, 6Ckine), vascular growth factors (Vegf, osteopontin, bFGF, erythropoietin, 
stem-cell factor) and cardiac differentiation growth factors (Activin A, TGF-β, and 
Dickkopf homolog-1) more efficiently than CLK treated with normoxia. Interestingly, 
intravenous injection of preconditioned CLK improved the LVEF and left ventricular 
fractional shortening in CLK pre-treated with hypoxia [73]. In a similar study, Yan et 
al. (2012) showed that after pre-treatment of adult murine CPCs (purified cKit
+
 EDCs) 
with severe hypoxia for 6 hours, cell survival was increased in a serum-depleted 
condition and the expression of Bcl2 (an anti-apoptotic gene) increased three fold in 
comparison to normoxia-treated CPCs [72]. After the transplantation of hypoxia pre-
treated CPCs into the ischemic myocardium, cell retention and survival were improved 
and the infarct size was reduced. The authors also showed that hypoxia increased the 
pro-angiogenic potential of CPCs by inducing an elevated release of Vegf and SDF-1 
into the cell culture medium [72]. The benefits of physiological O2 on human EDCs and 
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CDCs have also been shown. Li et al. (2011) showed that EDC proliferation was 
doubled following the culture of EDCs in 5% O2 in comparison with normoxic 
counterparts. They also showed that ex-vivo expansion of human CDCs in 5% O2 
decreased the incidence of chromosomal abnormalities (1/16 versus 6/16 of CDC 
samples, p=0.02). Although no difference was observed for in-vitro angiogenesis (tube 
formation) between the groups, CDCs grown in 5% O2 showed better engraftment and 
improved myocardial function in the recipient SCID mice [103]. However, Bonios et al. 
(2011) showed that the constitutive expression of Hif-1α blunts the functional benefits 
of CDCs after myocardial transplantation. In vitro angiogenesis and proliferation were 
not changed in CDC with constitutive Hif-1α expression versus the control CDCs. 
However, the expression of some growth factors such as Vegf and Endothelin-1 were 
enhanced in the CDC-Hif-1α group [104].  
In one study CDCs were harvested in a hypoxic environment mimicking the 
environment of the ischemic myocardium accompanied by the oxygen-releasing 
hydrogel system (containing hydrogen peroxide releasing microspheres which could 
release oxygen sustainably at least for 2 weeks). In this method CDCs were co-cultured 
with oxygen-realising hydrogel for different time periods and the results showed 
augmented cell survival and an enhanced differentiation capacity of CDCs towards 
cardiac phenotypes [105]. However, there are some data showing that hypoxia has a 
negative effect on stem cell tissue recruitment. For instance, Eliasson et al. (2010) 
showed that hypoxia (0.1%) decreases HSC proliferation, as cells cultured in hypoxia 
showed reduced  Ki-67 expressing cells (21%) compared to normoxia (29%), indicating 
that hypoxic exposure leads to the accumulation of HSCs in G0. The authors also 
compared the proliferation rate of LSK (Lin
-
, Sca-1
+
 and cKit
+
) cells in hypoxic and 
normoxic conditions and showed that cells cultured in hypoxia had almost a 28 fold 
increase while cells in normoxia had a 168 fold increase in their proliferation rate. They 
also showed that the expression of some cyclin-dependent inhibitors (CDKIs) such as 
p21, p27 and p57 were up-regulated in hypoxic conditions after 24 hours of Hif-1α 
activation [106].  
Taking this together, moderate hypoxia has been shown to be a beneficial treatment for 
CDCs and increase their proliferation, cell survival and retention following 
transplantation into the MI model.  
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 Clinical trials using CDCs in MI patients 1.9 
Recently, the final results of a clinical trial with CDCs from Marban’s group has been 
published as CADUCEUS; Cardiosphere-Derived Autologous Stem Cell to Reverse 
Ventricular dysfunction. In this trial, 17 male subjects with a recent MI (10 weeks) and 
with LVEF ranging between 25-45% received 12.5-25x 10
6
 autologous CDCs through 
the intracoronary route and eight patients received conventional treatments. Results at 1 
year showed no significant change in LVEF between CDC recipients and the control 
group; however, CDC recipients showed some significant improvements, such as the 
reduction of the infarct size (p<0.001). Moreover, both scar mass (-12±6.8 g) and viable 
mass (+22.6±9.4g) significantly improved in CDC-treated patients over the reporting 
period of one year. Conversely, in the control group, there were no significant changes 
in scar mass or viable myocardial mass. An important finding in this trial is that CDCs 
could be safely transplanted into the patients with an ischemic myocardium. The authors 
concluded that these results provide important evidence of the potential of CDCs to 
enhance regional improvement in MI patients; however, further studies needed to be 
done in order to validate these preliminary findings and improve CDC functional 
efficiencies [77,107].  
In another clinical trial of heart-derived stem cells, Stem Cell Infusion in Patients with 
Ischemic Cardiomyopathy (SCIPIO), 16 patients received autologous cKit
+
 cells (0.5-
1x10
6
) derived from atrial biopsies four months after cell harvesting through the 
intracoronary route and seven patients were assigned to the control group. The strategy 
of cell delivery in this study was to deliver cKit
+
 cells when the patients are in a critical 
condition due to ischemic myocardial disease in order to treat heart failure [108]. Using 
MRI and echocardiography the results showed that the cardiac function of the patient 
treated with cells improved significantly. In eight patients LVEF improved significantly 
in comparison to the control group (42.5% vs. 30%) [108]. The main limitations of 
these studies ((i) no placebo control group and (ii) the small sample size) make 
interpretation of the results difficult.  
To summarise, three different stages of CDC culture: EDCs; Csphs; and CDCs are able 
to improve cardiac function in different clinically relevant animal models. Sub-
populations of EDCs, Csphs and CDCs have limited autocrine pro-angiogenic and 
cardiogenic potential. It is believed that CDCs use paracrine mechanisms to activate 
angiogenesis and cardiogenesis, but do not show significant cell retention. 
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Preconditioning of human and murine CDCs with hypoxia has been shown to improve 
their engraftment and increase their angio/cardio-genic potential after injection into the 
MI models, although there are some reports which question the efficacy of these 
preclinical models. And finally, the clinical trials with CDCs showed that CDCs are safe 
to be used in MI patients leading to some important improvements such as an increase 
in viable myocardial mass and a decrease in scar size.  
 
 Aims of thesis 1.10 
Different groups have shown that CDCs offer a potential cell source for cellular 
transplantation and neovascularisation therapy. CDCs contain populations of progenitor 
cells that express some key markers of mesenchymal stem cells (cKit, Sca-1) that may 
be critical for this function. In my thesis I have investigated whether preconditioning 
CDCs with 3% O2 (a mild hypoxia approximately equivalent to the level of oxygen in 
the infarct border zone) could enhance their stem cell component. In addition, in light of 
the recent debate regarding the extent to which Csphs and CDCs are cardiac progenitors 
or cardiac fibroblasts, I used lineage tracing to characterise the CF component of EDCs, 
Csphs and CDCs. In the final results chapter, I investigated the effect of mild hypoxia 
on the pro-angiogenic potential of CDCs by using an established in-vivo angiogenesis 
model. 
Therefore the aims addressed in this thesis are: 
1. To determine whether pre-treatment with 3% O2 affects the stem cell phenotype 
of neonatal and adult murine CDCs; 
2. To use lineage tracing to investigate the contribution of cardiac fibroblasts (CFs) 
to EDCs, Csphs and CDCs  in culture; 
3. To use lineage tracing to investigate the contribution of cardiac fibroblasts to the 
scar forming tissue in vivo; 
4. To determine whether pre-treatment of CDCs with 3% O2 can promote their pro-
angiogenesis potential using a sub-dermal matrigel plug assay in vivo. 
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Chapter 2  Material and Methods 
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 Suppliers  2.1 
All chemicals and reagents were purchased from the following companies: 
eBioscence; BD Bioscence; Amsbio; Vector Laboratories; Sigma Aldrich; Fisher 
scientific; VMR International; GE Healthcare; Polyscience Inc. Qiagen; Invitrogen; 
Roche; Fisher Scientific; and Santa Cruz. 
All cell and tissue culture flasks, plates, plastic apparatus and general laboratory use 
were purchased from BioRad Laboratories, Grenier, Iwaki and RA Lamb. 
Medium and cell culture supplements were purchased from Gibco Invitrogen, Peprotech 
and Promocell. Oligonucleotides were purchased from Integrated DNA Technologies 
(IDT) and surgical instruments were purchased from Fine Science Tools (FST). 
 
 Mouse strains  2.2 
All animal experiments were performed under UK Home Office Licence and according 
to the national guidelines for laboratory animal care. 
All mice were maintained in a ventilated germ free facility in a 12 hour light/dark cycle 
and fed with standard diet and water. 
 
Rosa26-floxed stop eYFP. [109] This line was originally generated by Srinivas et al. 
(2001). This line contains a stop sequence flanked by LoxP sites up stream to the eYFP 
gene. The expression of eYFP is driven by the ubiquitous Rosa26 promoter and depends 
on the removal of the stop codon by Cre-recombinase activation.  
Collagen1-α2-CreERT. line was generated by Zheng et al. (2002) [110] and was 
obtained from Prof. David Abraham’s Laboratory, UCL. This line expresses tamoxifen-
inducible Cre recombinase (CreERT) and contains 6 kb of the upstream 5
’
 flanking 
region of the Col1a2 promoter fused to a sequence encoding Cre-ER(T2)-IRES-hpAP. 
CAG-farnesylated-eGFP (CAG-farnesyl-eGFP). This line was obtained from Prof. A. 
Medvinski (Edinburgh University). In this line eGFP expression is under the control of 
the CAG promoter and farnesyl maintains eGFP protein at the cell membrane. These 
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mice were used for the CDC culture in order to track eGFP-expressing CDCs in the 
subdermal matrigel angiogenesis assay. 
 
 Genotyping and DNA extraction from ear clips and tail tips 2.3 
Buffer 1 (25mM NaOH and 0.2 mM EDTA) 
2.5ml of 0.5M NaOH + 0.02ml of 0.5M EDTA in 50ml of mill Q H2O and pH was 
adjusted to 12 with NaOH 
Buffer 2 (40 mM Tris-HCl) 
4ml of 0.5 M Tris-HCl in 50ml milli-Q H2O, adjust to pH 5 with HCl. 
For genotyping ear clips were taken from adult mice and tail tips were taken from 
neonates. Tissue samples were incubated for 45 minutes in 100µl buffer 1 in a 
thermomixer at 95ºC and 350-400 rpm to lyse the tissue. Then 100µl of buffer 2 was 
added to neutralize the pH. After vortexing the tubes were centrifuged at 13,000 rpm for 
5 minutes to pellet the debris. Finally the extracted DNA (supernatant) was either stored 
at -20 ºC or used immediately for genotyping. 
 
 Genotyping 2.3.1 
Polymerase chain reaction (PCR) was used for all genotyping experiments. 
 Standard PCR 2.3.1.1 
25μl reaction was used in all PCR reactions in 200μl PCR tubes. Each reaction 
consisted of: 2.5μl reaction buffer (10x), 2.5μl MgCl2 (25mM), 0.2μl hot Taq DNA 
polymerase (AB gene) 0.25μl of forward and reverse primers (20μM), 0.5μl 10mM 
dNTPs and, finally, 2μl of DNA sample with autoclaved dH2O used to make up to the 
final volume of 25μl. All PCR reactions included negative and positive controls and 
were performed according to the cycle schedule in Table 2-2. 
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 Agarose gel electrophoresis solutions and preparation: 2.3.1.2 
Solutions: 
1x TAE buffer: 40mM Tris base-acetate 1mM EDTA 
DNA loading Dye: 0.25% xylene cyanol FF, 0.25%bromophenol blue with 40% sucrose 
in dH2O. 
2% agarose gel was used for all PCR product electrophoresis. The gels were made by 
dissolving 2 grams of agarose powder in 100 ml of 1x TAE buffer and boiled in 
microwave till the agarose dissolved completely. Then the gel was partially cooled 
under tap water and poured into the gel tray with well-forming combs in place. After 
30-45 minutes when the gel was solidified, the combs were removed and the gel placed 
in the electrophoresis tank which was filled with 1x TAE buffer. Loading samples were 
made by mixing PCR product with loading dye (according to the concentration of the 
dye), and pipetted into the wells. 1kb DNA ladder (Invitrogen) was used to assess the 
size of PCR products. The gels were run at 80-85 volts for 50-60 minutes and DNA 
bands were visualised first by immersing the gels in Ethidium Bromide solution 
(1µg/ml in dH2O) for 30 minutes and then exposing to UV light using the GeneGnome 
System. To capture the images GeneSnap Software (Syngene Bio Imaging) was used.  
 
Table ‎2-1 Primer details used for genotyping. 
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Table ‎2-2 PCR program steps for genotyping mouse lines. 
 
 Cardiosphere-Derived Cells (CDCs) culture:   2.4 
All cell culture procedures were carried out in sterile conditions in a cell culture hood 
Media and solutions: 
Complete Explant Medium (CEM). IMDM supplemented with 20% foetal calf or 
bovine serum (heat inactivated), 1% L-Glutamine, 0.1mM 2-mercaptoethanol, 1-unit/ml 
penicillin and 100µg/ml streptomycin.  
Cardiosphere Growth Medium (CGM). DMEM F12 and CEM (35%/65%), 
supplemented with 2% B27, 80ng/ml bFGF, 20 ng/ml EGF, 40nmol/L Cardiotropin -1, 
40nmol/L thrombin and 0.1 mmol/L 2-mercaptoethanol 
 
 Explant culture 2.4.1 
Mouse neonates (3-6 days old) or adult mice (6-8 weeks old) were culled via cervical 
dislocation and whole hearts were dissected with sterile instruments. The hearts were 
stored in ice cold PBS until cultured as explants. Under the cell culture hood the hearts 
were washed three times with ice cold PBS and then digested with 1 ml of 0.05% 
trypsin for 3-5 minutes (neonatal hearts) or 10 minutes (adult hearts). Trypsinisation 
proceeded at the same time as the heart tissue was cut into small pieces using fine 
scissors. Trypsin activity was inhibited by adding the equal volume of CEM and then 
25-30 cardiac explants were put on each fibronectin (1 mg/ml BD) pre-coated 35 mm 
plate and cultured in 2 ml of CEM. Every third day 0.5 ml CEM was added to each 
plate. The explant culture stage was continued till the plates were confluent with an 
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outgrowth of phase bright cells. This time period was 12-14 days for neonatal heart 
explants and 25-30 days for adult mice. To proceed to the cardiosphere culture stage, 
explants were washed with PBS once and then incubated for 2 minutes with Versene 
(Invitrogen) followed by 3-5 minutes of digestion with trypsin for neonates and 
Accutase cell detachment regent (eBioscience) for adults at 37°C. Then all of the 
contents of the plates were transferred into a 50 ml falcon tube and allowed to settle at 
room temperature for 1 minute in order to obtain tissue fragment free explant-derived 
cells.   
 
 Cardiosphere culture 2.4.2 
EDCs were seeded at a density of 10
5
 cells per well of a 24 well plate pre-coated with 
polyD lysine (BD Bioscience) using 2.4 µg/ml for neonatal EDCs and 1.2 µg/ml for 
adult EDCs, and 400 µl of CGM was added per well. Every 4
th
 day 200µl of CGM was 
added to each well. At day 6-7 of culture (neonate) and day 12-14 (adult), loosely 
adherent cardiospheres were gently collected in 50 ml falcon tubes. To obtain a purer 
population, cardiospheres were allowed to settle at the bottom of the tube and the single 
cells remaining in the supernatant were discarded. Then 10 ml PBS was added and the 
sedimentation process was repeated 2 times. Finally, the cardiospheres were spun down 
at 1000rpm for 8 minutes and followed by 2-3 minutes trituration with 1ml pipette in 
order to promote dissociation of cardiospheres.  
 
 Cardiosphere-derived cell culture 2.4.3 
Dissociated cardiosphere cells from one 24-well plate were transferred to one 
fibronectin pre-coated T75 flask. Cells were passaged twice when reaching 80-90% 
confluence. To do this, cells were treated with accutase for 10 minutes at 37°C and 
collected after knocking the flasks harshly to remove adherent cells. In addition, cell 
scrapers were used to remove any remaining cells. Finally, the cells were centrifuged at 
1000 rpm for 8 minutes and seeded on fibronectin pre-coated T75 flasks in 1:2 dilution.  
All EDCs, Cardiospheres and CDCs were cultured at 37°C in humidified air with 5% 
CO2 and atmospheric O2 (for normoxic culture) and 3% O2 (for hypoxic culture). 
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 Cell staining 2.5 
 Immunofluorescent cell staining 2.5.1 
2x10
4
 CDCs were seeded onto 4 chamber glass slides (Lab-Tek, Nunc) and allowed to 
settle for 24 hours. CDCs were then cultured at normoxia or 3% O2. Cells were washed 
with 1x PBS and fixed with acetone for 15 minutes on ice. Then the acetone was 
removed and the chambers were washed three times with ice cold PBS. Cells were 
blocked with blocking solution (5% goat serum, 1% BSA and 0.5% tween 20) for 30 
minutes at room temperature inside a humidity chamber. Then the blocking solution 
was removed and the appropriate primary antibody (diluted in blocking solution) was 
added to the chambers and incubated at 4°C overnight. The slides were washed with ice 
cold PBS three times and the secondary antibody (1/200 dilution in blocking solution) 
was applied for 1 hour at room temperature. Cells were then washed three times in PBS 
and mounted with hard set mountant (vector laboratories) containing DAPI under a 
coverslip. Finally, the slides were kept at 4°C overnight to allow to the mountant to set 
and fluorescent microscopy was performed the following day. 
Primary Antibody Stock Concentration Working 
concentration 
Source 
Cat. No 
Anti-Hif-1α‎(Rabbit) 200µg/ml 1/50 Santa Cruz  
(sc-10790) 
Anti-GFP-alexa 488 2mg/ml 1/50 Invitrogen 
(A21311) 
Secondary Antibody Stock concentration Working 
concentration 
Source 
Cat. No 
Goat anti-Rabbit IgG alexa  
 594 
2mg/ml 1/200 Invitrogen 
(A11012) 
Table ‎2-3 Antibodies used for immunofluorescent cell staining. 
 
 In-vitro cell proliferation and viability assay of CDCs 2.6 
CDCs were seeded at 2x10
4
 cell density per well in a 24-well plate. After resting the 
cells for 24 hours to let them adhere, cells were transferred into normoxia or 3% O2 
incubators. Cell density and viability were measured at different time points: 0; 24; 48; 
and 72 hours with Vi cell XR (Coulter) automated cell viability and total cell counter. 
 Clonogenicity assay with CDCs 2.7 
CDCs in T75 flasks, at passage 1 were cultured in 3% O2 or normoxia. Then the cells 
were treated with accutase for 10 minutes at 37°C. Cell suspensions were collected in 
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50 ml falcon tubes and centrifuged at 1000 rpm for 8 minutes. The cell pellet was re-
suspended in 1ml PBS and viable cells were quantified with an automated cell counter 
(Vi cell). Using 96-well plates, the FACS aria cell sorter automatically put 1cell/well. 
After 1 hour, wells which have received a single cell were labelled and all plates were 
transferred to a normoxic incubator (overnight) to let the cells settle. Then the 
clonogenicity of CDCs was assessed for 42 days. In each experiment three 96-well 
plates were used for each condition.  
 
 Flow cytometry 2.8 
 Immunophenotyping of murine CDCs  2.8.1 
CDCs at passage 2 were incubated with accutase for 10 minutes at 37°C. The cell 
suspension was collected in a 50 ml falcon tube and cell pellets were collected after 
centrifuging at 1000 rpm for 8 minutes. The resultant cell pellet was quantified with the 
Vi-cell automated cell counter. 1x10
5 
cells in 100µl volume were added to one round 
bottom glass FACS tube. Then the appropriate primary antibody was added to each tube 
(Table 2-4). Separate tubes were allocated for the appropriate IgG isotype and negative 
controls. All tubes were incubated on ice for 20 minutes and protected from light. Then 
all samples were washed three times with BD Bioscience wash assist. In case of 
unconjugated antibodies, cells were stained with the appropriate secondary antibody and 
incubated again on ice for 20 minutes, protected from light. Finally, the cells were 
washed three times and DAPI (1µg/ml) was added. FACS analysis was performed with 
LSRII or FACS Canto (BD Bioscience). FITC was detected using 488/520 channels, 
Alexa 647 was detected with 638/660 channel, Dapi, PE-Cy5.5 and PE were detected 
using 407/450, 488/710 and 488/585 settings.  
Each analysis was performed with 3x10
4
 events and all viable cells were included in the 
final data analysis. All FACS data were displayed as dot plots or histograms and the 
gates were allocated based on negative and isotope controls. In all FACS experiments 
each marker was tested with three technical replicates. 
 ELISA (Enzyme-Linked Immunosorbent Assay) 2.9 
5x10
4 
CDCs at passage 2 were seeded per well of a six-well plate and 3ml of CGM was 
added into each well. Cells were incubated in normoxia or 3% O2 for 48 hours. Three 
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technical replicate wells were used for each condition. At 80-90% cell confluency, the 
cell culture medium was removed and centrifuged at 1000 rpm for 8 minutes to remove 
cell debris. Vegf levels in the cell supernatant were measured after a 2-step dilution with 
Vegf ELISA kit, following the manufacturer’s instructions (RD system) and the optical 
density was measured with MultiScan Ascent, Thermo Labsystems at 560 nm. Finally, 
the results were normalised against the standard controls provided with the kit and the 
results presented as pg/ml of the supernatant. 
Primary Antibody Stock concentration Working concentration Source & 
Cat. No 
Sca-1 0.2mg/ml 1µl in 100µl eBioscience (558162) 
cKit 0.2mg/ml 1µl in 100µl eBioscience (14-1172-82) 
CD90 0.5mg/ml 1µl in 100µl BD Pharmingen (553006) 
CD31 0.5mg/ml 1µl in 100µl BD Pharmingen (550274) 
CD34 0.5mg/ml 1µl in 100µl BD Pharmingen (560230) 
Flk1 0.5mg/ml 1µl in 100µl BD Pharmingen (561252) 
Eng 0.5mg/ml 1µl in 100µl eBioscience (14-1051-85) 
CD45 0.5mg/ml 1µl in 100µl eBioscience (11-0451-81) 
Secondary 
Antibody 
Stock concentration Working concentration Source 
Goat anti-Rat 
Alexa-647 
2mg/ml 1µl in 100µl Invitrogen (A-21247) 
Table ‎2-4 The primary (Rat antibodies) and secondary antibodies used to 
immunophenotype CDCs. 
 
 Quantitative RT-PCR 2.10 
 Primer design 2.10.1 
Primer sequences used in this study were obtained from the primer Bank website. 
Further assessment of each primer pair in terms of cDNA sequence of the gene of the 
interest was obtained from the NCBI genome browser and BLAST search in order to 
confirm their specificity and coverage of exon boundary regions. This step was 
important to eliminate products that derived from possible genomic contaminations. 
 RNA isolation  2.10.2 
Two methods were used for RNA isolation (Trizol and Qiagen RNA isolation kit) from 
approximately 10
6
 neonatal or adult derived CDCs at passage 2. 
Trizol is a hazardous chemical therefore all steps with Trizol were carried out in a 
designated hood. Due to the vulnerable nature of RNA, all tips were filter protected and 
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UV light was used for at least 20 minutes followed by cleaning the working area with 
RNase Zap wipes (Invitrogen) prior to RNA and qRT-PCR procedures in order to 
eliminate any possible RNase contamination. 
 
 RNA isolation with Trizol 2.10.3 
CDCs at passage 2 were incubated with accutase for 10 minutes at 37°C. For each 3% 
O2 on normoxia conditions, cell suspension from 1 T75 flask at 80-90% confluency was 
transferred into 50 ml falcon tubes and centrifuged at 1000 rpm for 8 minutes. Then 1 
ml trizol was added to the cell pellet and incubated for 5 minutes. After transferring the 
suspension into an Eppendorf tube, 200µl chloroform was added and shaken vigorously 
for 15 seconds. Following 2-3 minutes’ incubation at room temperature and 
centrifugation at 12,000 G for 15 minutes, the upper layer was transferred into a new 
tube and 500µl isopropanol was added; after a vigorous mixing for 30 seconds the 
samples were incubated for 10 minutes on ice. Following another centrifugation (12,000 
G for 15 minutes, 4
°
C) and removing the supernatant, 500 µl of 75% ethanol (diluted 
with RNA-free Diethlpyrocarbonate (DEPC) treated dH2O) was added. After vortexing 
for 20 seconds and spinning down at 7,500 G for 5 minutes 4
°
C, the ethanol was 
removed and the RNA pellet was air dried for 5 minutes. Before drying completely, 
RNase-free water was added to the pellets. After measuring the amount of RNA in each 
sample, all RNA samples were treated with DNase turbo (Life Technologies) to 
minimize genomic DNA contamination. 7.5µg of RNA was mixed with 5µl of DNase I 
Reaction Buffer. Then 1 unit of DNase enzyme was added and the mixture and total 
volume were made up to 50 µl. After 30 minutes’ incubation at 37˚C, 5µl of 
inactivation buffer was added. The solution was centrifuged at 7,500G at 4˚C then the 
supernatant removed and the concentration of RNA in each sample was measured with 
nanodrop (ND-1000 Thermo spectrophotometer) at 260 nm absorbance. The purity of 
the RNA was assessed based on the ratios displayed. If A260/A280 was above 2.0 and 
A260/A230 was between 1.8-2.2, the samples were considered as pure RNA and were 
used directly for cDNA preparation. 
 Complementary DNA (cDNA) preparation 2.10.4 
cDNA preparation was performed using the high capacity cDNA reverse transcription 
kit (Applied Bioscience). The procedure started with 1µg RNA in 10µl DEPC-dH2O, 
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then 2µl of 10X reverse transcription buffer, 2µl 10X random primers, 0.8µl of dNTP, 
2µl of reverse transcriptase enzyme were added and the final volume made up to 20µl 
with DEPC treated dH2O. Using BioRad C1000 thermal cycler the mixture was 
incubated for 10 minutes at 25°C and followed by 120 minutes at 37°C and 85°C for 5 
minutes. Finally, the samples were cooled down to 4°C and stored at -20°C till required. 
 qRT-PCR analysis of CDCs 2.10.5 
All experiments were carried out in 10µl reaction in a 384-well plate containing 5μl 
SYBR Green Master Mix (Sigma), and 10 μM (1µl) of forward and reverse primers 
(listed in table 2-5). The final volume was made up to 10µl by adding 3µl of DEPC- 
treated dH2O. The thermal profile for all SYBR Green qRT-PCR reactions was 95°C for 
10 min, followed by 40 cycles of 95°C for 10s and 60°C for 30s using an ABI Fast Real 
Time PCR System (7900 HT). All samples were analysed in triplicate with three 
housekeeping genes used as reference controls (Gapdh, B-actin and Rps19). 
Gene Sequence‎5’-3’ Expected 
size bps 
Tm 
°C 
Efficiency 
 
Gapdh F: AACTTTGGCATTGTGGAAGG 132 60 95% 
R: AGAACATCATCCCTGCATCC 
Β-Actin F: GGCTGTATTCCCCTCCATCG 154 60 98% 
R: ACATGGCATTGTTACCAACTGG 
Rps19 
 
F: GCTTGCCTCTAGTGTCC 75 60 97% 
R:TGAGACCAATGAAATCGCCAA 
Hprt F: TCAGTCAACGGGGGACATAAA 124 60 93% 
R: CTGGTTAAGCAGTACAGCCCC 
Sca-1 F: TCAGGAGGCAGCAGTTATTGTG 160 60 95% 
R: CGTGAAGACTTCCTGTTGCCA 
cKit F: CTCCCCCAACAGTGTATTCAC 90 60 95% 
R: TAGCCCGAAATCGCAAATCTT 
Abcg2 F:GATGAACTCCAGAGCCGTTAGGAC 169 60 94% 
R: AACCTGGCCTTAATGCTATTCTG 
Eng F: CTGCCAATGCTGTGCGTGAA 191 60 95% 
R: ACTTGGCCTACGACTCCAGCC 
Vegf F: CTTGTTCAGAGCGGAGAAAGC 125 60 97% 
R: AACGAACGTACTTGCAGAGTG 
Table ‎2-5 The list of primers used for qRT-PCR analysis of CDCs. All primers are from 
pga.mgh.harvard.edu. Primer efficiency was measured automatically with applied bio systems 
real-time PCR software using 5 dilutions of DNA sample from neonatal and adult CDCs 
(100ng, 10ng, 1000pg-100pg and 10pg). 
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 Histological staining procedures 2.11 
Solutions: 
10x Phosphate Buffered Saline (PBS). KCl (2g), NaCl (80g), Na2HPO4 (14.4g) and 
KH2PO4 dissolved in 800ml of ddH2O and the pH adjusted to 7.4 with HCl and the final 
volume made up to 1 litre with milli-Q H2O. 
0.2% Para Formaldehyde (PFA)/PBS. 0.2g of para-formaldehyde powder was added to 
100ml of 1x PBS and dissolved at 60°C. 
Scott’s tap water.  30.0g of MgSO4 and 2.0g Sodium bicarbonate, dissolved in 3 litres of 
Tap water 
 
 Interaperitoneal (IP) injection of tamoxifen 2.11.1 
In order to activate Cre-ERT, 5 interaperitoneal injections of 2 mg (10mg/ml) 
Tamoxifen, diluted in peanut oil (Sigma) over 5 consecutive days were administered in 
adult mice (6-8 weeks). At 48 hours following the last injection the mice were 
euthanized and the hearts were processed for tissue staining.  
 
 Tissue processing and preparation of frozen samples 2.11.2 
Sub-dermal matrigel plugs and heart tissues were dissected from adult mice (age 6-8 
weeks) after cervical dislocation. The tissue was washed in ice cold PBS twice and 
fixed with 0.2% PFA/PBS at 4°C overnight. The next day the tissue was incubated in 
30% sucrose/PBS with gentle agitation at 4°C. Finally the tissue was frozen down with 
OCT freezing medium on dry ice and transferred to a -80
o
C freezer until sectioning. 
 
 Cryosectioning of frozen tissue. 2.11.3 
All frozen tissue blocks were sectioned using a Microm HM 560 Cryostat (Thermo 
Scientific). Frozen tissue blocks were kept at -20°C for 30 minutes prior to sectioning. 
8-12µm-thick serial sections were prepared for heart tissue and 10-25µm-thick serial 
sections were prepared for matrigel plugs. Sections were mounted on polylysine glass 
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slides (VWR International). Then the slides were left to dry for 30-45 minutes at room 
temperature before storing in slide mailers in a -80°C freezer. 
 
 Immunohistochemistry with Vectastain ABC system 2.11.4 
Matrigel plug cryo-sections were removed from the -80°C freezer and allowed to reach 
room temperature for 30 minutes inside the slide mailers in order to minimise 
condensation. Then the slides were air-dried outside of the slide mailers (RT) for 30-45 
minutes. When the slides dried completely they were washed with 1x PBS and circled 
with a hydrophobic barrier pen. The sections were blocked with a blocking solution (5% 
Rabbit serum diluted in 1x PBS). To block unspecific biotin binding sites the sections 
were blocked with Avidin/Biotin buffers (Vector Laboratories). The sections were 
incubated with Avidin block for 15 minutes and washed with PBS. Then the sections 
were treated with Biotin block for 15 minutes and washed again. All sections were then 
incubated with primary anti-CD31 antibody (BD Pharmingen, diluted to 1/50 with 
blocking solution) overnight at 4°C. The next day, the slides were washed for three 
times with 1x PBS (each 5 minutes) and then incubated with secondary rabbit anti rat 
antibody (Vector Laboratories 1/200 diluted in blocking solution) for 30 minutes at 
room temperature. All sections were washed again for 3x5 minutes in 1x PBS and 
incubated with ABC reagent for 30 minutes. After 3 x 5 minutes washes with 1x PBS, 
all sections were incubated for 1 minute at room temperature with the liquid DAB kit 
(BioGenex). Then the slides were quickly rinsed under tap water and then stained with 
Mayer’s haematoxylin counterstain (RA Lamb) for 3 minutes and rinsed under running 
tap water. Then the sections were dehydrated with 50%, 70% and 100% ethanol 
respectively (5 minutes each), and finally, the slides were incubated in histoclear for 10 
minutes and mounted with histomount (National Diagnostics) and allowed to dry in the 
fume hood. 
 
 H & E staining 2.11.5 
Cryosections from matrigel plugs and murine hearts were stained in Mayer’s 
Haematoxylin for 2-3 minutes and then rinsed in tap water for 2 minutes. Then the 
slides were treated with Scott’s tap water for 10-15 seconds to allow the sections to turn 
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into a blue colour. After one more wash with tap water the slides were then stained with 
Eosin for 45 seconds. Then the slides were washed once in tap water and dehydrated 
through the series of ethanol steps (50%, 70% and 100% ethanol for 5 minutes each). 
Finally, the slides were treated with histoclear for 10 minutes and mounted with 
histomount and the slides left to dry in the fume hood. 
 
 Immunofluorescent staining of heart and matrigel plugs 2.11.6 
Matrigel plug cryo-sections and heart sections were removed from the -80°C freezer 
and allowed to reach room temperature for 30 minutes inside the slide mailers in order 
to minimise condensation. When the sections dried completely outside the slide mailers 
in room temperature, they were washed with 1x PBS and circled with a hydrophobic 
barrier pen. The sections were blocked with blocking solution (5% Goat serum + 1% 
BSA and 0.5% Tween 20 diluted in 1x PBS). The sections were then incubated with the 
appropriate primary antibody (table 2-6) at 4°C overnight. After 3x5 minute washes in 
PBS, the sections were incubated with the appropriate secondary antibody for 1 hour at 
room temperature. After the final 3x5 minute washes with PBS, the sections were 
mounted with DAPI prolong gold mountant (vector laboratories) and allowed to dry 
overnight at 4°C before analysis. 
 
 Double Immunofluorescent Staining 2.11.7 
Directly conjugated antibodies including (SMA-Cy3 or anti GFP-alexa 488) were added 
to sections and after 1 hour’s incubation at room-temperature , the unconjugated 
antibodies including CD31, CD11b, FSP1, vimentin and Col1α were used and the co-
localisation was assessed. Negative or no primary control sections were prepared for all 
primaries above to assess the specificity of the staining. Please see tables 2-6 and 2-7 
for more details. 
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Primary antibody 
Cat. No. 
Working 
concentration 
Incubation Secondary Antibody 
Cat. No. 
CD31(550274) 
BD Pharmingen 
1/50 Overnight @4°C Anti-Rat alexa-594  
(Invitrogen A11007 
SMA-Cy3.3 
Sigma(C6198) 
1/200 30 minutes room 
Temperature 
n/a 
CD11bBD 
Pharmingen 
(553308) 
1/100 30 minutes room 
Temperature 
Anti-Rat alexa-594  
(Invitrogen A11007) 
GFP-alexa 488 
Invitrogen (A21311) 
1/25 30 minutes room 
Temperature 
n/a 
GFP (Ab13970) 
Abcam 
1/100 Overnight @4°C Anti-chicken alexa-488 (Life 
technologies A11039) 
GFP (TP401) 
Amsbio 
1/100 Overnight @4°C Anti-rabbit alexa-594 
(Invitrogen A11012) 
FSP1(07-2274) 
Milipore 
1/200 Overnight @4°C Anti-rabbit alexa-594 
(Invitrogen A11012) 
vimentin (Ab24525) 
Abcam 
1/200 Overnight @4°C Anti-chicken alexa-488 (Life 
technologies A11039) 
Col1α2 
Abcam 
1/100 Overnight @4°C Anti-Rabbit alexa-594 
(Invitrogen A11012) 
Table ‎2-6 Primary and secondary antibodies used to stain cryosections of heart and sub-
dermal matrigel plugs. All secondary antibodies were diluted in 1/200 ratio in the blocking 
solution using serum of the species in which the secondary antibody had been raised. 
 
Experiment Antibody set one( primary 
Ab + secondary Ab) 
Antibody set two 
(YFP or GFP) 
Tissue type 
Vimentin+eYFP Vimentin (24525) + Anti-
chicken alexa-488 (A11039) 
GFP (TP401) 
+ Anti-rabbit alexa-
594 
(A11012) 
Adult murine heart 
FSP1+eYFP FSP1(07-2274) + Anti-rabbit 
alexa-594 
(A11012) 
GFP (Ab13970) 
+ Anti-chicken 
alexa-488 (A11039) 
Adult murine heart 
CD31+eGFP CD31(550274) + Anti-Rat 
alexa-594 
(A11007) 
GFP-alexa 488 
(A21311) 
Matrigel plug 
αSMA+eGFP SMA-Cy3.3 
(C6198) 
GFP-alexa 488 
(A21311) 
Matrigel plug 
CD11b+eGFP CD11b (553308) + Anti-Rat 
alexa-594 
(A11007) 
GFP-alexa 488 
(A21311) 
Matrigel plug 
Table ‎2-7 The combination of antibodies used in double immunofluorescent staining 
experiments. 
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 Mouse model of in vivo angiogenesis using sub-dermal matrigel plugs 2.12 
 Matrigel preparation 2.12.1 
Growth factor reduced Matrigel (BD Bioscience) was thawed at 4°C and kept on ice to 
maintain its liquidity. Other equipment including all pipettes, tips and syringes were 
kept at 4°C in order to prevent matrigel solidification during preparation, cell 
innoculation and subdermal injection. 
 
 Pre injection preparation 2.12.2 
Prior to sub-dermal injection the small animal heat pad (Harvard apparatus) was cleaned 
with 70% ethanol and the ventilator was checked for functionality. A detailed record of 
the mice was taken including the genotype, sex and age.  
 
 Induction of anaesthesia 2.12.3 
The mice were placed one by one into the anaesthesia induction chamber (97% O2/3% 
isoflurane, flow rate: 3 litres per minute) for 2 minutes. Then the mice were transferred 
to an anaesthetic nose cone on the thermal pad to maintain body temperature at 37°C. 
Isoflurane was reduced to 2.5% at a rate of 2 litres per minute. The flanks were shaved 
and cleaned with a cotton bud soaked in 70% ethanol.    
 
 Sub-dermal cell/matrigel injection with neonatal CDCs 2.12.4 
Neonatal CDCs at passage 2 derived from CAG-farnesylated-eGFP mice were washed 
and prepared as a single cell suspension in growth factor reduced matrigel diluted with 
PBS (200µl matrigel+100µl PBS). 2x10
6
 cells were suspended in 300µl ice cold 
Matrigel and were kept for up to 20 minutes on ice prior to sub-dermal injection into 
C57BL/6 mice, 6 weeks old. At 14 days following matrigel injection the animals were 
humanely killed and matrigel plugs were dissected and washed twice in ice cold PBS 
before being frozen in the OCT freezing medium on dry ice. Samples were kept in the   
-80
o
C freezer until required. 
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For vessel quantification with neonatal derived CDCs, the matrigel plugs were serially 
sectioned (3-6 sections per slide) and every fifth slide was chosen for CD31 staining. 
One representative section from each slide was imaged and vessel density was 
measured by manual counting. The total numbers of vessels were normalised against the 
surface area of the matrigel used. 
 Sub-dermal cell/matrigel injection with adult CDCs 2.12.5 
CDCs at P2 derived from CAG-farnesylated-eGFP adults (6-8 weeks old) were cultured 
in normoxia or 3% O2 for 48 hours. CDCs were then washed and prepared as a single 
cell suspension in undiluted growth factor reduced matrigel. 2 x10
6
 cells were 
suspended in 300μl Matrigel and stored in ice for up to 20 minutes prior to sub-dermal 
injection. After 14 days the animals were humanely killed and matrigel plugs were 
dissected. Plugs were washed twice in ice cold PBS, fixed with 0.2% PFA overnight at 
4
°
 and then treated with 30% sucrose/PBS overnight at 4
°
. Finally the plugs were frozen 
by OCT freezing medium on dry ice and kept in a -80
o
C freezer until required. 
For vessel quantification with adult-derived CDCs, the matrigel plugs were serially 
sectioned with approximately (3-6 sections per slide) and every fifth slide was chosen 
for CD31 staining. One representative section from each slide was imaged and vessel 
density was measured using image J software. The results were normalised against the 
whole surface area of the matrigel used. Whole surface areas of the matrigel were 
measured using the Axio vision software (version 4.8) and Carl Ziess stemi microscope. 
 
 In-vivo perfusion analysis of sub-dermal matrigel plugs with adult-derived 2.12.6 
CDCs 
In a separate experiment 2x10
6
 adult-derived CDCs from CAG-farnesylated-GFP mice 
were cultured in normoxia or 3% O2 and suspended in 300µl growth factor reduced 
matrigel sub-dermally into adult mice recipients (6 weeks old, C57BL/6). After 14 days 
of the implant injection, 100µl of 50µg of fluorescein-labelled esculentum (tomato) 
isolectin (Vector Laboratories) was injected through the tail vein. 15 minutes later, the 
animals were killed humanely, and the plugs were removed and fixed as mentioned 
above. One ear from each mouse was removed and washed in PBS and imaged directly 
to assess the perfusion; isolectin expression with the vessels of the ear was used to 
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confirm the functionality of the perfusion test, prior to examining the perfusion of the 
matrigel plugs. The matrigel plugs were processed in the same way as sub-dermal 
matrigel plugs with adult CDCs (please see section 2.12.5) and kept in the -80 freezer 
(in light-protected boxes) until required. 
 
 Microscopy and imaging  2.13 
Light microscopy was used to assess cell morphology and clonogenicity using a Zeiss 
Axiovert 200 inverted microscope. Histochemical stained sections were imaged using 
Ziess Axioplan and Zeiss Stemi microscopes. For fluorescent-stained sections a Ziess 
Axio Imager II with apotome was used. A Nikon confocal A1-R microscope was used 
for live cell fluorescent imaging and for spectral analysis of some fluorescent-stained 
sections. All of the images were taken by digital camera and analysed by ZEN 2013 
software for the images taken with Zeiss microscopes, NIS element software was used 
for the images taken by Nikon microscopes. Image J was used for quantification and for 
measuring the staining intensity. 
 
 Statistical analysis 2.14 
To analyse the data SPSS software (version 19, SPSS Inc) was used. To test for normal 
distribution of data the Shapiro-Wilki normality test was used and if the data were not 
normally distributed, the data were transformed by taking the log of the data before 
statistical analysis. The transformed data then were assessed by the Shapiro-Wilki test 
again to assess their normality and, finally, the subsequent statistical tests were 
performed. For multiple group data analysis (groups >2) one-way ANOVA was used 
and subsequent Post-Hoc (Tukey test) was used to compare two independent groups. In 
all experiments paired t-test and p value of <0.05 was defined as being statistically 
significant. 
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Chapter 3  The effect of 3% O2 culture on 
neonatal CDCs proangiogenic and stem cell 
potential 
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 Introduction 3.1 
As outlined in the main introduction to the thesis (see sections 1.5.4-7) CDCs have been 
shown to promote heart repair following myocardial infarction (MI). However, the low 
survival of transplanted cells into recipient hearts poses a major limitation. This may 
partly be due to the harsh ischemic condition of the infarcted heart tissue. Strategies 
designed to overcome this problem such as pre-treating CDCs with physiological O2 
levels [103] or severe hypoxic conditions [73] have been investigated. Tang et al. 
(2009) showed that severe hypoxia (0.1%) can increase murine CLK’s ability to 
survive, though up-regulation of CXCR4/SDF1 and CLKs showed augmented cell 
migration (in vitro). CLKs which have been treated with 0.1% O2 showed more efficient 
recruitment into the ischemic myocardium and the infarct size, vascular density and 
myocardial function were significantly better than in mice treated with cell culture 
under normoxic conditions[73]. Furthermore, physiological oxygen (5% O2) treatment 
improved EDC production from human cardiac explants and diminished chromosomal 
aneuploidies. The authors also showed that human-derived CDC cultured in 5% O2 for 3 
days decreased reactive O2 levels and reduced cell senescence. In vivo studies showed 
that human CDC cultured in 5% O2 (whole CDC culture duration) showed better cell 
engraftment and better recovery in comparison to CDC cultured in normoxia [103]. 
However, the effect of 3% O2 on CDC characteristics and pro-angiogenic potential is 
not known. As discussed in section 1.6 this is important to address because the infarct 
border zone which contains 3% O2 and is the region of interest for myocardial cell 
delivery in preclinical and clinical studies. Culturing CDCs in 3% O2 could be 
beneficial in three ways: (i) it is very close to the O2 level of the infarct border zone, 
which may help to adapt CDCs prior to transplantation; (ii) activation of Hif-1α in 
CDCs cultured in 3% O2 may improve CDC survival and facilitate their pro angiogenic 
potential; (iii) as 3% O2 is a mild hypoxia condition, extended CDC culture is possible 
to achieve more efficient cardiosphere and CDC yields. This chapter aims to address the 
role of 3% O2 culture in CDCs, by testing its effect on CDC culture and the possible 
modifications of the expression of stem cell (Sca-1, cKit, Abcg2) mesenchymal (Eng, 
CD90) and endothelial (CD31, CD34, Flk1) cell markers. 
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 Results 3.2 
CDCs were obtained from neonatal hearts (3-6 days old) and cultured in normoxia or 
3% O2. Figure 3-1 schematically represents different stages of CDC culture in neonatal 
and adult CDCs.    
Figure ‎3-1 Different stages of Csph and CDC culture. (A) A small heart explant at day 6, 
with stromal cells migrating out of the dense explant; (B) the same explant at day 14 with 
surrounding phase bright cells, myocardial tissue gradually disappears in parallel with 
increasing explant-derived cell (EDC) density; (C) fully formed Csphs at day 6 (arrows) and, 
finally, (D) a monolayer cell culture of CDCs – this image is of CDCs at passage 2 (P2), the 
Scale bar is 500µm. (E) Schematic representation of CDC culture. 
 
 Optimizing CDC culture with 3% O2  3.2.1 
CDCs were prepared as described in chapter 2 (Sections 2.4.1-3) and the culture details 
are summarised in Figure 3-1. I first investigated whether 3% O2 could improve EDC 
and Csph yield. In this experiment, explants were cultured in 3% O2 or normoxia from 
the date of tissue harvest and the readouts were: (i) extent of phase bright cell outgrowth 
from cardiac explants; and (ii) number of Csphs generated in normoxia and 3% O2. 
Explant culture was 14 days in normoxia and 3% O2 groups. The average number of 
explants analysed per experiment was 111±21 in normoxia and 96±22 in 3% O2 culture. 
Csph quantification was from 12 wells of 24-well plates.  
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Figure ‎3-2 The effect of 3% O2 on different stages of CDC culture. CDC culture consists of 
three stages including: 1) explant culture; 2) cardiosphere; and 3) CDC culture. As shown in the 
figure each stage was cultured in hypoxia and then the cardiosphere yield were quantified in 
subsequent stages. This experiment was repeated three times. 
 
 3% O2 increases phase bright cell outgrowth but delays Csph maturation   3.2.2 
Cardiac explants from 3-6 day-old neonates (strain C57BL/6) were cultured in 3% O2 
and normoxia for 2 weeks. The length of EDC outgrowth was measured at 4 points 
from the heart explant tissue and presented as the mean outgrowth distance (in 
micrometres). Despite the positive effect of 3% O2 on increasing EDC outgrowth 
(1097±226 µm in normoxia vs. 1502±250 µm in 3% O2, p<0.05), further culture in 3% 
O2 decreased Csph number and delayed Csph formation time from 6±1 days in 
normoxia to 10±2 days in 3% O2 (281±44 Csphs in normoxia vs 201±32 in 3% O2 
p<0.05). Figure 3-3 shows the effect of 3% O2 treatment on EDC and Csph culture. My 
findings are in agreement with Li et al. (2011)[103], who showed that physiological O2 
(5%) increased EDC outgrowth from human cardiac explants. These results also 
showed that culturing Csphs in 3% O2 is not as efficient as normoxia in terms of Csph 
yield. It is also likely that removing plates from hypoxic incubator in order to change or 
add fresh media would have introduced oxygenation of cell supernatant, as a result, the 
level of Hif-1α stabilisation and downstream gene expression and cytokine production 
involved in Csph formation may have been changed. However, as a result of the 
detrimental effect of prolonged 3% O2 culture on Csph maturation, I chose not to 
continue experiments using EDC culture in 3% O2. 
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Figure ‎3-3 3% O2 increases EDC outgrowth from neonatal cardiac explants but delays 
Csph formation. Cardiac explants cultured in normoxia and 3% O2 for two weeks and the 
length of EDC outgrowth were measured for each explant at 4 different points and presented as 
the mean outgrowth in micrometres. 3% O2 slightly increased EDC outgrowth in comparison to 
normoxia. (A) Explant outgrowth in normoxia and (B) in 3% O2. To evaluate Csph formation, 
10
5
 EDCs which had been cultured in normoxia or 3% O2, were plated in each well of 24-well 
plates and cultured in normoxia or 3% O2 for approximately 2 weeks. While Csphs were fully 
formed at day 6 in normoxia (C) and were ready for CDC culture, Csphs cultured in 3% O2 
were not mature (D) and remained attached to the plates. E and F show the summary of three 
independent experiments. (F) The summary of three independent quantifications of Csphs 
cultured in normoxia (at day 6) and 3% O2 (at day 6 and 12). (* p value <0.05) 
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 3% O2 stabilises Hif-1α‎protein in CDCs 3.2.3 
It is already known that Hif-1α protein is stabilized in mammalian cells cultured in 
hypoxic environments. Therefore, any evidence of Hif-1α protein stabilization would 
validate the effects of a hypoxic environment. Hif-1α stabilization in CDCs was 
evaluated by immunocytochemistry using a specific Hif-1α antibody in three 
independent experiments. Passage 2 neonatal CDCs cultured in normoxia or 3% O2 for 
72 hours were analysed and quantified based on the stabilization of Hif-1α protein and 
the results are summarised in Figure 3-4.C. The numbers of cells expressing Hif-1α was 
quantified in 20 microscopic fields of view (x60) and normalised against the total cell 
number and presented as the mean percentage ± SEM. Results showed that 69.8±1.8% 
of CDCs express Hif-1α following 72 hours of culture in 3% O2 vs 6.7±4.3% in 
normoxia, p<0.05.  
 
Figure ‎3-4 Hif-1α‎ protein‎ stabilization‎ in‎ passage‎ 2‎ neonatal‎CDCs‎ cultured‎ in‎ 3%‎O2. 
CDCs stained with anti-Hif-1α specific antibody and detected with an anti-rabbit secondary 
antibody conjugated with alexa 594 (red). CDCs were cultured in (A) normoxia or (B) 3% O2 
for 72 hours and Dapi (blue) was used to stain nuclei. (C) A summary of three independent 
quantification of Hif-1α positive cells in 20 different microscopic fields from each experiment. 
It appears that Hif-1α is stabilized in the majority of P2 murine CDCs after 72 hours of 3% O2 
culture. Inset image B is the no primary control. Scale bar = 50 μm.            
C 
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 The effect of 3% O2 on P2 neonatal CDC proliferation and viability  3.2.4 
Hif-1α is shown to activate hypoxia-mediated apoptosis and reduces proliferation in 
embryonic stem cells [111]. However, it seems that the effect of hypoxia on cell 
proliferation is cell- and context-dependent. Therefore, I performed proliferation and 
viability assays to assess the effect of 3% O2 on CDC proliferation and viability. 
Passage 2 neonatal CDCs cultured in normoxia or 3% O2 for 24, 48 and 72 hours were 
enzymatically detached and assessed for viability and proliferation using automated cell 
counter Vi-Cell XR 2.03 (Beckman/Coulter). Results showed no difference in viability 
or cell proliferation in normoxia and 3% O2 (Figure 3-5). The total cell count revealed 
that CDCs grow at a similar rate in normoxia and 3% O2 culture. This experiment was 
done three times independently, which suggested that 3% O2 treatment of CDCs did not 
increase cell death in comparison to normoxic culture and would be suitable for pre-
conditioning of CDCs prior to injection into the infarct border zone in heart repair 
therapy.  
           
Figure ‎3-5. Evaluating the effect of 3% O2 on total cell count and viability of neonatal 
CDCs. Viability and total cell count were analysed with the automated cell counter (Coulter) 
after single cell suspension in PBS. (A-C) Three independent experiments evaluating viability 
of neonatal CDCs cultured in normoxia and 3% O2. The results revealed that 3% O2 has no 
significant effect on the viability of CDCs. (D-F) Three independent experiments evaluating 
total cell count of CDCs cultured in normoxia and 3% O2, shows that 3% O2 had no significant 
effect on the total cell count. The bar graphs show the mean (and standard error) of three 
technical replicates in each case.  
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 The effect of 3% O2 on CDC clonogenicity 3.2.5 
Physiological (5 % O2) and severe hypoxia (0.1% O2) have been shown to improve 
cardiac stem cell production and potency for myocardial repair [73,103]. However, 
application of severe hypoxia (0.1%) used in one of these publications led to a high 
mortality of CDCs (Gangjian Qin, personal communication) so I investigated if 3% O2 
as a mild hypoxic cell culture environment could increase CDC clonogenicity. To 
analyse clonogenicity, neonatal CDCs at passage 1 were cultured for 72 hours in 
normoxia or 3% O2. 100µl of cell suspension (diluted to 1 cell/100µl of media) were 
added to each well of 96-well plates. All wells which received one cell were identified 
under the microscope and clonogenicity was monitored over the following 6 weeks in 
normoxia. At day 42 the number of colonies were quantified and normalized against the 
total number of wells with one cell and results presented as clonogenicity percentage ± 
SEM. This experiment was performed independently three times and results showed 
that 3% O2 did not significantly change CDC clonogenicity. Figure 3-6 shows a 
representative single cell (3-6.A), the colony formed after 14 days from the same cell 
(3-6.B) and (3-6.C) is the summary of clonogenicity percentage derived from three 
independent studies. Table 3-1 summarises the results of three independent 
clonogenicity experiments. 
                               
Figure ‎3-6 The effect of 3% O2 on the clonogenicity of passage 2 neonatal CDCs. Single 
cell suspensions of CDCs were prepared and 100μl of cell suspension (diluted to 1cell/100μl of 
media) was manually placed in each well of a 96-well plate. (A) A single CDC at day 0. (B) The 
colony formed from the same cell after 14 days: the edge of the colony is highlighted with a 
blue line. Scale bar =200 µm. C) The graph summarise three independent clonogenicity 
experiments with neonatal CDCs cultured in normoxia and 3% O2.  
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Experiments Normoxia 3% O2 
Expt.1 8.48±1.4% 6.8±1.4 
Expt.2 7.07±4.4 7.4±1.9 
Expt.3 5±2 5.9±2.7 
P value 0.9 
  
Table ‎3-1 The summary of three independent clonogenicity assays performed with 
neonatal mouse CDCs at passage 2 cultured in 3% O2 or normoxia. CDCs cultured in 3% 
O2 or normoxia for 72 hours at passage 1, then single cells were manually placed in each well of 
a 96-well plate and clonogenicity assessed after 6 weeks. Data presented as mean percentage ± 
SEM, derived from 3 technical replicates. Paired t-test showed that there is no significant 
difference between normoxia and 3% O2. 
 
As this study is aiming to assess the effect of 3% O2 on progenitor and endothelial sub-
populations of CDCs, I next assessed expression of stem cell and endothelial markers at 
mRNA and protein levels. qRT-PCR is an efficient method for assessing the level of 
gene expression in in-vitro and in-vivo studies; however, choosing suitable 
housekeeping genes is crucial in gene expression analysis. 
 
 Selection of housekeeping genes for qRT-PCR experiments with CDCs 3.2.6 
cultured in normoxia and 3% O2 
Due to the mixed population of CDCs, validating housekeeping genes with a relatively 
constant level of expression in normoxia and 3% O2 is very important as it directly 
influences the interpretation of qRT-PCR.  During the gene expression analysis of stem 
cell markers (Sca-1, cKit, Abcg2) and endothelial genes (Vegf & Eng), in CDCs treated 
with normoxia and 3% O2, I noticed that the Hprt housekeeping gene had the least 
stable Ct values at different time points of the 3% O2 culture, which was consistent in 
three independent experiments. Simultaneously, a group at Oxford University reported 
that Hprt is not a suitable housekeeping gene for studies with CDCs [112]. Therefore, in 
subsequent qRT-PCR studies the Hprt gene was excluded from the list of housekeeping 
genes used for data normalisation. However in general I noticed that the Ct value of all 
genes increased at 72 hours in comparison to the other time points, (either in normoxia 
or 3% O2 culture). This could be due to some technical issues such as cell pellet 
preparation and RNA isolation at 72 hours. It is also possible that the increased Ct 
levels at this time point  is due to the effect of high cell density on gene expression. In 
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this respect Pallen and Tong (1991) showed that high cell density in fibroblast culture 
increased cell density-dependent growth-arrest [113] and in another study high cell 
confluency increased DNA methylation (∼50%) of the MGMT CpG island in fibroblast 
cells and modified significantly gene expression levels [114]. Table 3-2 summarises the 
Ct values from three independent qRT-PCR analyses with neonatal CDCs treated with 
normoxia and 3% O2 for different time points. 
 
Table ‎3-2 Summary of the Ct values from four candidate housekeeping genes: Gapdh, B-
Actin, Rps19 and Hprt, in qRT-PCR experiments performed with RNA isolated from neonatal 
CDCs cultured in normoxia or 3% O2 for 3, 6, 24, 48 and 72 hours. As shown in the table, Ct 
values from the Hprt housekeeping gene was the least stable of the housekeeping genes; 
therefore, the Hprt gene was excluded from the list of housekeeping genes.  
 
 The effect of 3% O2 on gene expression in neonatal CDCs   3.2.7 
Using qRT-PCR I analysed neonatal CDCs at passage 2 cultured in 3% O2 or normoxia 
for 3, 6, 24, 48 and 72 hours. I compared the gene expression profile of 3 stem cell 
markers Sca-1, cKit, Abcg2, and the mesenchymal/endothelial marker Eng as well as the 
pro-angiogenic factor, Vegf. This experiment was independently preformed three times 
and data was normalised against Gapdh, B-actin and Rps19 at each time point. Figure 3-
7 and table 3-3 summarises the results of all three experiments. Among stem cell 
Exp. 
Time 
points Gapdh B-actin Rps19 Hprt 
Exp.1 
3 hours 
3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 
16.9±0.3 16.5±0.2 14.4±0.56 14.3±0.3 - - 19.3±0.2 18.1±0.3 
6 hours 16.4±0.26 16.2±0.12 14.1±0.32 14.7±0.5 - - 19.7±0.11 19.4±0.43 
24 hours 16.2±0.45 16.3±0.3 14.7±0.14 13.4±0.4 - - 21.5±0.24 19.5±0.2 
48 hours 15.8±0.25 16±0.4 14.4±0.2 14.5±0.4 - - 20.4±0.21 19.4±0.3 
72 hours 19±0.41 18.40±0.5 18.2±0.38 17.7±0.2 - - 22.6±0.23 22.5±0.4 
Exp.2 
3 hours 18.6±0.27 18.2±0.21 15.4±0.31 14.9±0.3 17.7±0.21 17.6±0.2 22.3±0.41 20.6±0.4 
6 hours 18.3±0.25 18.6±0.3 14.9±0.48 15.2±0.4 17.4±0.52 17.3±0.2 21.9±0.21 20±0.3 
24 hours 18.7±0.17 18.2±0.18 15.9±0.24 15.3±0.3 17.4±0.37 17.9±0.4 23.4±0.34 21.1±0.4 
48 hours 18.7±0.24 18.4±0.4 15.3±0.31 15.2±0.14 17.3±0.3 16.9±0.4 24.3±0.41 21.7±0.3 
72 hours 19.9±0.48 20.2±0.4 17±0.22 16.8±0.34 18.4±0.41 18.2±0.3 23.9±0.46 24.1±0.5 
Exp.3 
3 hours 18.1±0.51 17.9±0.3 14.5±0.28 14.2±0.4 18.4±0.46 18.7±0.1 21.7±0.15 21.3±0.4 
6 hours 18±0.23 18±0.3 14.4±0.24 14.2±0.34 17.3±0.21 18.1±0.3 22.4±0.32 21.6±0.43 
24 hours 17.4±0.31 18.1±0.32 14.1±0.44 13.8±0.52 17.5±0.28 17.8±0.4 23.1±0.24 20.4±0.6 
48 hours 17.5±0.36 17.3±0.38 13.9±0.32 1.5±0.28 17.4±0.1 17.1±0.3 22.6±0.17 21.8±0.43 
72 hours 18.2±0.34 18.5±0.48 14.8±0.41 15.1±0.3 18.5±0.2 18.2±0.4 24.4±0.1 24.4±0.5 
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markers, Sca-1 showed the highest expression at 48 hours in experiment 1 and at 24 
hours in experiment 2 but in experiment 3 the highest expression of Sca-1 was observed 
after 6 hours of 3% O2 culture. Although variability was observed in all experiments, 
paired t-test analysis showed that culturing neonatal CDCs in 3% O2  for 3-6 hours 
increased Sca-1 expression and culture for 6 hours in 3% O2  increased cKit expression 
significantly. Also the levels of Vegf and Eng increased significantly in comparison to 
the normoxia counterparts at 24 and 48 hours, respectively. In general, the expression of 
the majority of the genes decreased after 72 hours of culture in 3% O2 and normoxia 
which could be due to the fact that the cells reached confluency at 72 hours and cell-cell 
contact inhibits cell proliferation and induces quiescence. Also, as discussed above this 
may impact on gene expression in general and the 72hour time point data may be less 
robust than the earlier time points.  
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Figure ‎3-7 qRT-PCR experiments showing gene expression levels‎(ΔCt) in neonatal CDCs at passage 2 cultured in 3% O2 versus normoxia for 3, 6, 24, 
48 and 72 hours. Sca-1, cKit, Abcg2, Eng and Vegf expression was analysed using qRT-PCR at 5 different time points. Ct values were normalised against 
Gapdh, B-actin and Rps19 at all-time points and then 3% O2 values were compared to the counterpart control cells cultured in normoxia. Results are presented as 
the mean ΔCt of each gene calculated from three technical replicates per experiment.  
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 Sca-1 
 
Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 
Experiments 3 hours 6 hours 24 hours 48 hours 72 hours 
Expt.1 8.6 6.8 8 6.4 9 6.25 8.1 5.85 9.5 8.9 
Expt.2 5.6 3.7 5.4 3.95 5 3.37 5.3 3.85 6 6.7 
Expt.3 7.5 6.04 7.7 5.95 8 7.1 7.9 7.8 8.6 8.5 
p value 0.005 0.002 0.08 0.1 1 
cKit 
 
Normoxia 3% O
2
 Normoxia 3% O
2
 Normoxia 3% O
2
 Normoxia 3% O
2
 Normoxia 3% O
2
 
Experiments 3 hours 6 hours 24 hours 48 hours 72 hours 
Expt.1 19.5 19.3 19 18.1 9 6.25 19.3 19.4 20.3 21 
Expt.2 27.2 27.3 26.5 26.1 5 3.37 26.2 26.4 - - 
Expt.3 17 16.7 17.5 16.9 8 7.1  -  - 18.5 18.9 
p value 0.38 0.04 0.08 
  
Abcg2 
 
Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 
Experiments 3 hours 6 hours 24 hours 48 hours 72 hours 
Expt.1 9.4 8.7 9.7 8.7 8.7 7.17 8.3 7.1 10.2 10.3 
Expt.2 4.5 4.6 4.2 4.1 4 2.8 4 3.7 4.8 5.1 
Expt.3 10.7 10.5 11 10.1 10.9 11 10.1 10.2  - -  
p value 0.3 0.1 0.2 0.34 
 
Eng 
 
Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 
Experiments 3 hours 6 hours 24 hours 48 hours 72 hours 
Expt.1 7.9 6.6 7.1 5.66 6.9 5.6 7.4 6.6 8.8 8.9 
Expt.2 3 2.7 3.8 3.7 3.6 2.5 3 2 3 2.56 
Expt.3 6 5 6.3 5.7 5.6 5.2 6.1 5.6  - -  
p value 0.09 0.2 0.07 0.03 
 Vegf 
 
Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 
Experiments 3 hours 6 hours 24 hours 48 hours 72 hours 
Expt.1 6.2 6.1 7 6.7 6.6 5.7 7.2 7 8.7 8.78 
Expt.2 4.1 4 4.8 4.5 4.1 3.5 4 4 4.4 5 
Expt.3 8 8 7.6 7.5 8.3 7.5 7.4 6.5 -   - 
p value 0.18 0.07 0.01 0.3 
 
Table ‎3-3 The effect of 3% 
O2 on the expression of Sca-
1, cKit, Abcg2, Eng and 
Vegf in passage 2 neonatal 
CDCs using qRT-PCR. The 
table shows the relative 
expression of Sca-1, ckit, 
Abcg2, Eng and Vegf genes 
cultured in 3% O2 in 
comparison to normoxia 
from 3 hours up to 72 hours. 
Each value in the table is the 
mean of three technical 
replicates and there are a 
total of three biological 
replicate experiments (data 
summarised in Figure 3-7). 
Data were normalised against 
three housekeeping genes: 
Gapdh; B-actin; and 
Rps19and analysed using the 
ΔCt of each gene in 3% O2 
versus the normoxia control 
group. Therefore, the lower 
the value, the higher the 
expression. Paired t tests 
were used to assess 
significant differences in ΔCt 
values. The significant 
differences (p<0.05) are 
highlighted in red. 
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 3% O2 leads to variable protein expression of endothelial, mesenchymal and 3.2.8 
stem cell markers in neonatal CDCs. 
To evaluate further the increase seen in Sca-1 gene expression at the RNA level in P2 
CDCs following treatment with 3% O2, I used flow cytometry to determine whether 
there was a similar increase in Sca-1 expression at the protein level. To place this in 
context I also used a panel of endothelial (Flk1, CD34, CD31), mesenchymal (Eng, 
CD90), haematopoietic (CD45) and stem cell (cKit) markers. Figure 3-8 shows 
representative FACS plots and summarises the results of all three independent 
experiments as a percentage of positive events for all cell populations analysed. 
Although CDCs cultured in 3% O2 showed a trend towards higher levels of Sca-1 and 
Flk1 compared with normoxia, these differences did not reach statistical significance, 
likely due to the variability between replicate experiments (Table 3-4). Also the protein 
levels of cKit, CD90, CD45, CD31 and CD34 showed little change between normoxia 
and 3% O2. cKit mRNA showed a slight increase at 6 hours of culturing in 3 % O2 
(p=0.04) but, its protein expression remained unchanged between normoxia and 
hypoxia. However, there is a noticeable discrepancy between Eng and cKit mRNA and 
protein levels. Eng appeared to be up-regulated at the mRNA level following treatment 
with 3% O2 (48 hours, p=0.03), but there was no change in the number of Eng positive 
CDCs in the FACS assay. This difference could be due to protein degradation or a 
delayed translation rate in Eng or cKit expressing sub-population of CDCs. It is possible 
that culturing neonatal CDCs in 3% O2 for 72 hours was not sufficient enough in order 
to increase cKit and Eng protein, although this time point was initially was chosen 
based on qRT-PCR experiments in order to allow enough time for protein translation of 
the elevated genes. As shown in table 3-4 there is a noticeable degree of variation of 
protein expression between CDC preparations. For example, Sca-1 expression in 
normoxia ranged from 9.8% to 28.5%. The highest variability was observed in the 
CD90 and Sca-1 expression patterns and the lowest variability was seen in the cKit and 
CD45 expressing cells. CD31 and CD34 expression remained below 10% in both 3% 
O2 and normoxia groups except experiment 1, where CD31 expression was 16-18%. 
CD45, the common leukocyte antigen, remained unchanged and at low levels in 
normoxia and 3% O2. CD45 expression analysis showed that the majority of CDCs are 
not derived from haematological contamination and they are likely to have originated 
from the heart tissue.  
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Figure ‎3-8 Flow cytometric analysis of murine neonatal CDCs at passage 2 harvested for 72 hours in normoxia and 3% O2. CDCs were analysed 
for the expression of Sca-1, cKit, Eng, CD90, CD45, CD31, CD34 and Flk1. A) Dot plots are showing populations of CDCs at passage 2 expressing the 
representative markers in normoxia and 3% O2. CD45 the pan-leukocyte marker was expressed only in a small fraction of P2 CDCs. B,C and D are the 
summary of three independent FACS experiments showing the proportion of the cells expressing each marker.  
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Table ‎3-4 Summary of 3 independent FACS analysis performed with neonatal murine CDCs at passage 2 cultured in normoxia and 3% O2. 
Culturing CDCs in 3% O2 has changed the expression of some genes such as Sca-1, cKit, Flk1 and CD45 slightly, but not significantly. As shown in the 
table Sca-1 and Flk1 showed slight increase in 3% O2 compared to normoxia but these differences did not reach to significant level due to the variability 
among the groups. Data presented as mean percentage ± SEM, derived from 3 separate replicates. Paired t-test was performed using the technical means 
from each experimentand no significant difference observed between the groups. 
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 Discussion 3.3 
In this chapter I investigated the effect of 3% O2 on neonatal CDCs and analysed its 
influence on different stages of CDC culture, gene expression and immunophenotyping. 
However, my studies of gene expression analysis at mRNA and protein levels showed 
inter-culture variation in stem cell (Sca-1, cKit, Abcg2), mesenchymal (Eng, CD90) and 
endothelial (CD31, CD34, Flk1) markers of neonatal CDCs, cultured in normoxia and 
3% O2. Although I tried to reduce inter-culture variability by following the same cell 
culture protocol, the following reasons could explain the inter-culture variability: (i) the 
sex of pups, although Drowley et al. (2009) showed that the sex of muscle stem cell 
donors has no effect on the regenerative capacity of recipients [115], but Crisostomo et 
al. (2007) discovered that female MSC-treated rat hearts had a greater recovery [116]. 
Due to the high yield of CDCs which I needed for my experiments, I never focused on a 
specific sex of pups which could have generated variability in CDC culture. (ii) Age of 
the pups: it has been shown that BM stem cells from young donors have better cellular 
engraftments after transplantation into rats after MI [117]. In this chapter I used pups 
aged 3-6 days which could be another reason for variable results with CDCs. For future 
experiments it would be useful to use pups of the same sex and age (same day) for all 
CDC experiments. 
 
 Validation of hypoxia 3.3.1 
As many cellular responses to hypoxia are mediated by Hif-1α, I validated the 
stabilisation of this protein in CDCs treated with 3% O2 for 72 hours and observed that 
the majority of CDCs (69.8%) show stabilisation of Hif-1α protein (figure 3-4). It 
would be more informative to assess Hif-1α at different time points, in this respect Tang 
et al. (2009) showed that Hif-1α has the highest stabilisation in CDCs at 10-12 hours in 
severe hypoxic conditions (0.1%). However, the gold standard of assessing Hif-1α is 
western blot experiments – unfortunately, my experiments with Hif-1α western blotting 
and its stabilisation timing analysis was not successful, possibly due to its very short 
half-life (5-8 minutes)[73]. Vegf is a well-known direct target gene of the Hif-1α 
pathway, reviewed in [90]. Following the transfer of CDCs to 3% O2, I found that Vegf 
mRNA reached a peak of expression after 24 hours compared with the normoxia-treated 
cells. However, Steinbrech et al. (2000) showed that Vegf expression in osteoblasts in 
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culture  increased in 35-40 mmHg (hypoxia), beginning from 6 hours after exposure and 
peaking (3 folds) at 24 hours[118]. I only observed a modest 1.5 to 1.9 increase in Vegf 
mRNA levels in CDCs cultured in 3% O2 for 24-48 hours, pre-treating CDCs with 
severe hypoxic conditions such as (0.1-1% O2) could increase Vegf more significantly. 
 
 The effect of 3% O2 on different stages of CDC culture 3.3.2 
To evaluate the effect of 3% O2 on different stages of CDC culture, I observed that 
culturing neonatal explants in 3% O2 increased EDC outgrowth significantly compared 
to normoxia (figure 3-3), this result is consistent with Li et al. (2011), which showed 
that EDCs grow faster in physiological O2 (5%) than in normoxia [103]. As hypoxia is 
shown to stimulate cell migration via the perk/atf4/lamp3-arm pathway [119],  it is 
possible that 3% O2 may increase cell migration out of the explant. However, careful 
analysis of the cytokines involved in paracrine activities of EDCs in normoxia and 3% 
O2 could explain this finding. My results showed that culturing Csphs in 3% O2, 
delayed their maturation significantly. I observed that culturing cells in 3% O2  generally 
increases the acidity of the supernatant (based on the yellow colour of the supernatant of 
the cells cultured in 3% O2, data not shown), and it is already known that cellular 
acidity enhances apoptosis [120]. As discussed above, hypoxia increases cell migration, 
and this could possibly explain how Csph-forming cells in hypoxia favour cell 
spreading and invasion rather than cell accumulation. In this matter Koh et al. (2011) 
showed that overexpressing hypoxia associated factor (HAF) cells grow slowly and had 
diffused colonies in comparison to the controls. This was due to the effect of HAF on 
switching from the Hif-1α to Hif-2α pathway [121]. Hif-2α is shown to affect cellular 
migration and invasion and is shown to be activated in prolonged hypoxia culture, 
reviewed in [90]. As Csph-forming cells had been in 3% O2 since the explant culture, 
thus the Hif-2α pathway may have been activated and had caused cell migration rather 
than accumulation. Furthermore, it is possible that the acidity of the media cultured in 
3% O2 reduced the Csph maturation efficiency. According to the CDC culture protocol, 
every 4 days 200 µl of Csph media are added to the plates. To prevent acidification of 
the media, adding more media with shorter intervals could be useful.  
Analysing the effect of 3% O2 on P2 CDC showed that culturing P2 CDCs in 3% O2 for 
72 hours did not show any significant difference in CDC proliferation and 
clonogenicity, this finding is consistent with Li et al. (2011) and Van Oorschot et al. 
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(2011) [101,103]. Li et al. (2011) concluded that proliferation of CDCs at early 
passages (P1-P3) in physiological O2 did not change CDC proliferation, although 
proliferation was higher in later passages (P4-P5) [103]. Van Oorschot et al. (2011) also 
showed that short-term hypoxia culture (1% O2/5 days) did not change cardiac 
progenitor proliferation; however, prolonged hypoxic culture (<6 days) increased cell 
growth and migration [101]. To increase CDC yields, culturing CDCs at a later passage 
could generate better yields; however, careful immunophenotyping of CDCs at a later 
passage seems to be necessary as it is likely that passaging and prolonged cell culture 
change their stem cell phenotype.  
However, there are some other issues that needed to be addressed about the nature of 
Hif proteins and possible implications for CDC culture variability: (i) stability of Hif-1α 
protein. Hif-1α is shown to have the shortest half-life of approximately 5-8 minutes 
among all the other proteins [122]. I always changed the medium in a laminar flow 
hood under room air, which took approximately 3-4 minutes. The hypoxic incubator 
required almost 5 minutes to re-equilibrate with 3% O2. Therefore, the fluctuation in O2 
during the medium change and O2 recalibration may affect the quality of the expression 
of the markers at protein and mRNA level; also changing cell culture medium could 
introduce oxygenation of cell supernatant which could affect the expression of Hif-1α 
downstream genes in CDCs. Further experiments with stricter controls of the O2 level 
could be useful to decrease the level of variability in CDC surface marker expression. 
(ii) Hif-2α which is shown to be another isoform of Hif-1α has some antagonist effect 
on Hif-1α, reviewed in [90]. For instance, while Hif-1α stabilization produces cell cycle 
arrest by inhibiting the MYC activation and decreasing cell proliferation [123], 
activation of Hif-2α exclusively exhibits enhanced MYC activity and cell proliferation 
[124]. Further experiments will be necessary to elucidate which isoform of the Hif 
protein is dominantly active in CDCs following 3% O2 culture. (iii) It has been shown 
that Hif expression can be selectively regulated by post-translation activities and 
epigenetic modifications, reviewed in [125], which could influence Hif-1α expression 
and subsequently downstream genes. Due to the heterogeneity of CDCs it is possible 
that Hif-1α is selectively regulated in different sub-types of CDCs which leads to the 
variable expression of surface markers. As I also noticed, not all CDCs cultured for 72 
hours in 3% O2 had their Hif-1α stabilised (figure 3-4). 
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 The effect of 3% O2 on superficial markers of neonatal CDCs 3.3.3 
In order to assess the effect of 3% O2 on the phenotype of different sub-populations of 
P2 CDCs, I investigated if 3% O2 could increase the expression of stem cell (Sca-1, 
cKit, Abcg2), mesenchymal (Eng, CD90) and endothelial (CD31, CD34, Flk1) markers. 
To do this I used a quantitative RT-PCR approach which depends on data normalisation 
using housekeeping genes. 
 
 Defining the proper combination of housekeeping genes for 3% O2 studies 3.3.3.1 
with CDCs 
The effect of hypoxia on the expression of housekeeping genes in neonatal and adult 
CDCs has been studied [112]. Housekeeping genes are considered to have a constitutive 
level of expression regardless of the age and culture condition, genes such as Gapdh, β-
actin, Hprt, and ribosomal proteins are some examples of housekeeping genes which 
have been used extensively in gene expression analysis such as qRT-PCR. In one study 
the authors evaluated the most reliable housekeeping genes in CDCs cultured under 
normoxia, hypoxia or with prolyl-4-hydroxylase inhibitors (PHDIs) derived from both 
neonatal and adult rats. The aim of study was to determine the effects of ageing and 
different culture conditions on the stability of the housekeeping gene for CDCs. The 
results revealed that Gapdh was the most constant housekeeping gene for normoxia 
studies, whereas β-actin was the most stable housekeeping gene under hypoxia. The 
authors also showed that three housekeeping genes β2M, Hprt-1 and Rplp-1 stability 
was age-dependent. However they concluded that it is better to combine values from 2 
housekeeping genes Gapdh and β-actin for hypoxia studies with CDCs[112].  
During the analysis of qRT-PCR results I noticed that the Hprt housekeeping gene did 
not produce stable Ct values at the different time points of the 3% O2 culture. However, 
Yao et al. (2012) showed that Hprt has no fluctuations of Ct values among other 
housekeeping genes in neural progenitor cells cultured in normoxia or hypoxia [126]. 
Yao et al. (2012) used neural stem cells from rats which could represent different 
transcriptome to CDCs, besides they have compared different time points of hypoxic 
preconditioning with a single normoxic control group. Maybe comparing each specific 
time point with the same normoxic counterpart could give a better idea of the effect of 
hypoxia on different housekeeping genes. 
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 The effect of 3% O2 on CDC stem cell markers  3.3.3.2 
It has been shown that a considerable population of CDCs express cardiac stem cell 
markers such as cKit and Sca-1 [63,110]. The benefit of hypoxia preconditioning in 
CDCs has been shown in humans [97] and mice[65]. qRT-PCR analysis of Sca-1  
showed that 3 to 6 hours of 3% O2 treatment, significantly increased Sca-1 transcript 
expression in P2 CDCs, (p=0.005 and 0.002 respectively). However the protein level of 
Sca-1 expressing CDCs cultured in 3% O2 did not change. Although in all experiments 
there was a noticeable trend towards an increase in Sca-1 expression following culture 
in 3% O2, this did reach significance, likely due to variability of the data. It is  possible 
that more FACS  experiments with CDCs cultured in 3% O2 and normoxia could 
provide more significant results. It has been shown that hypoxia increased Sca-1-
expressing mesenchymal stem cells and enhanced their adipogenic potential [128]. 
Activation of downstream genes of Hif-1α depends on the hypoxia response element of 
the target gene, which contains the core sequence (5’-ACGTCG-3’) and in some genes 
such as erythropoietin, HRE contains 50 base pairs, reviewed in [129]; therefore, I 
investigated the promoter region of the Sca-1 gene in ensembl genome browser and I 
could not find a potential HRE in the promoter region, but I observed three potential 
HREs in intron 2, 3 and exon 3, which may be involved in Hif-1α dependent regulation 
of Sca-1 and  could possibly explain why 3% O2 increased Sca-1 expression. Functional 
HRE have previously been found in intronic regions; for instance, Tazuke et al. (1998) 
reported the existence of functional HRE in intron 1 of the insulin-like growth factor 
binding protein 1 (IGFBP-1) gene [130]. In another study, lactate dehydrogenease-B 
gene (LDH-B) of fundulus was shown to contain an HRE in intron 2 [131]. However, 
the significance of my findings requires more investigations, including a more detailed 
study of the direct and indirect effect of Hif-1α on the expression of Sca-1. 
I also observed that culturing P2 CDC in 3% O2 changed cKit mRNA expression 
slightly at 6 hours (p=0.03) at mRNA but not at protein level. These results are 
consistent with Jögi et al. (2002) who showed that hypoxia increased cKit expression in 
neuroblastoma cells [132]. However, it is in contrast with Li et al. (2011), who did not 
see any significant change in cKit expression of human CDCs cultured in 5% O2 
[103].It would be interesting to assess the effect of severe hypoxic conditioning could 
be tested on CDCs to analyse cKit expression, but the cell survival and viability of cKit-
expressing cells should be investigated simultaneously as cKit-expressing cells among 
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CDCs are not abundant. qRT-PCR analysis showed that Abcg2 mRNA expression did 
not change after culturing P2 CDCs in 3% O2 for 3-72 hours. This is in contrast to 
previous findings showing that hypoxia increases bone marrow side populations, Abcg2 
expressing cells, 24 fold in comparison to normoxia  [133]. Therefore it would be 
interesting to assess the Abcg2 expression and side population content of CDCs in 
normoxia and 3% O2 by Hoechst dye staining, which could be done by FACS on CDCs 
treated with 3% O2 and normoxia.  
 
  The effect of 3% O2 on mesenchymal markers of CDCs 3.3.3.3 
Exposure to 3% O2 had no effect on the expression on CD90 in neonatal CDCs, which 
is in agreement with Valorani et al. (2012) who did not observe a significant difference 
in mesenchymal markers such as CD90 and CD73 in adipose tissue progenitors cultured 
in normoxia and hypoxia (2% O2 for 7 days) [134]. But my findings are in contrast with 
Adesida et al. (2012), who showed that culturing BM stromal cells in 3% O2 for 14 days 
depleted CD90 expression in comparison to normoxia [135], but this was a much longer 
time course. Although Eng mRNA expression was variable in three independent 
experiments, 3% O2 treatment significantly increased Eng mRNA expression at 48 
hours following the transfer to 3% O2 (p=0.03), but endoglin protein expression was not 
increased. This could be due to three reasons: (i) the expression of Eng in a hypoxic 
environment is up-regulated due to co-operation between the TGF-β signalling and 
hypoxia pathway [136]. Therefore Eng might need TGF-β signalling ligands in order to 
be up-regulated more significantly in CDCs cultured in 3% O2. (ii) It is possible that to 
activate Eng a more hypoxic environment is necessary; to answer this it would be useful 
to test if culturing CDCs in severe hypoxia could increase Eng mRNA and protein. As 
Eng is shown to have an important role in angiogenesis, enhancing cell viability and 
inhibiting apoptosis, reviewed in [137], more expression of Eng could possibly help to 
obtain more therapeutic quantities of CDCs in a shorter time in clinical studies.  
 The effect of 3% O2 on endothelial markers of CDCs 3.3.3.4 
I observed that 3% O2 had variable effects on the expression of endothelial markers 
(CD31, CD34 and Flk1) in CDCs. However, in three independent qPCR experiments, 
Vegf and Eng showed a significant increase in passage 2 neonatal CDCs pre-treated 
with 3% O2. This is consistent with data from Hu et al. (2008), who showed that 
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hypoxia preconditioning (0.5%, 24 hours) improves mesenchymal stem cell engraftment 
into MI models and increases Flk1 expression [138]. My investigations with FACS 
analysis of CD31 expression in P2 CDCs cultured in normoxia and 3% O2 showed no 
significant difference between the two groups. Hu et al. (2008) showed that the 
preconditioning of mesenchymal stem cells with hypoxia increased the proportion of 
CD31/Hoechst positive cells. Han et al. (2010) also showed that hypoxia 
preconditioning increased the number of CD31-expressing embryonic stem cells [139]. 
The differences between my experiment and these two studies are mainly the type of 
cells and the severity of hypoxia. For instance, in Hu et al.’s work, bone-marrow-
derived mesenchymal cells were cultured in a 0.5% O2 environment. It is possible that 
the hypoxic effect on the endothelial proportion of BM MSCs more is easily detectable 
than CDCs, because BM MSCs contain a significant number of endothelial progenitor 
and CD31-expressing cells while CDCs contain low numbers of CD31-expressing cells 
(table 3.4) and any change in CD31-expressing cells might not have been detected. As 
mentioned above, Han et al. (2010) used embryonic stem cells which are at the 
pluripotent stage with a different epigenetic structure, which could possibly make them 
capable of differentiating into different cell types such as endothelial progenitor cells. I 
observed that CD34, an endothelial cell marker, remained unchanged in normoxia and 
3% O2 in P2 neonatal CDCs. My finding is in agreement with Valorani et al. (2012), 
who showed that culturing adipose tissue mesenchymal stem cells in 2% O2 did not 
change the CD34-expression potential [134]. However, to validate my data, more 
characterisation of CDCs with 3% O2 and normoxia seems to be necessary; for instance, 
using multicolour FACS would provide more information regarding CDC-
immunophenotyping analysis. 
It would also be very interesting if we could analyse the co-expression of Hif-1α or Hif-
2α with other stem cell (Sca-1, cKit, Abcg2) and endothelial (CD31, CD34 and Flk1) 
markers. This could possibly tell us more about the paracrine and autocrine pathways 
that contribute to expression of stem cell and endothelial markers in CDCs. Hif-1α and 
Hif-2α activate different genes on some occasions, reviewed in [90], which would 
inform future experimental designs with CDCs and hypoxia  preconditioning. This will 
be helpful in terms of investigating which hypoxia pathway is more involved in CDC 
biology when cultured in 3% O2. It would also be useful to do FACS and qRT-PCR 
analyses at different time points. Possibly CDCs at earlier time points and earlier 
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passages (for example, P1 CDCs treated for 24 or 48 hours in 3% O2) may show 
increased expression of angiogenic and progenitor markers. 
Culturing P2 CDCs in 3% O2 increased EDC outgrowth from neonatal cardiac explants 
and increased the stem cell marker gene expression of Sca-1 and cKit. 3% O2 also 
increased endothelial marker gene expression (Vegf and Eng). Although 3% O2 had a 
modest influence on endothelial markers, this may be very important in pro-angiogenic 
heart repair in clinical treatments. However, due to the clinical relevance of the pro-
angiogenic potential of adult CDCs, I investigated the effect of 3% O2 on adult-derived 
CDCs, which is discussed in chapter 4.   
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Chapter 4  The effect of 3% O2 culture on adult 
CDCs proangiogenic and stem cell potential 
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 Introduction 4.1 
So far my studies showed that the pre-treating of neonatal CDCs with 3% O2 for up to 
48 hours increased their pro-angiogenic and stem cell sub-populations in vitro by 
enhancing Sca-1, cKit, Eng, Vegf gene expression at mRNA level, although changes at 
protein level were less clear. However, neonatal CDCs are not used in patients. As the 
final goal of CDC studies is to provide a safe method of producing an autologous cell 
source for MI patients, I studied whether 3% O2 has the same effect on adult CDCs as 
findings from adult cells will have more clinical relevance. The work described in this 
chapter therefore includes the establishment of adult CDC culture from C57BL/6 mice 
in normoxia and 3% O2, together with the re-validation of all of my findings with 
neonatal CDCs in chapter 3 and doing complementary immunophenotyping of adult-
derived CDCs with FACS. The aim of this chapter is to assess whether culturing adult-
derived CDCs in 3% O2 benefits their pro-angiogenic and stem cell characteristics in 
vitro. 
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 Results 4.2 
 Optimisation of adult CDC culture 4.2.1 
Adult CDCs were derived using the protocol used for neonatal CDC culture with some 
modifications. Briefly, I used adult mouse hearts (6-8 weeks old) digested with trypsin, 
minced and cardiac explants plated on fibronectin-coated dishes. After several days, 
stromal cells grow from the explant, over which round phase bright cells migrate. Once 
confluent, all EDCs (stromal and phase bright cells) were removed after enzymatic 
digestion and plated on to Csph culture media with several growth factors. Following 
two weeks of Csph culture, loosely adherent Csphs were removed by gentle trituration. 
Csphs were then plated on fibronectin pre-coated flasks and passaged twice in media 
containing 20% foetal calf serum. In general, I observed that CDC culture from adult 
mouse hearts (C57BL/6 strain) is not as efficient as neonatal CDC culture and it is not 
always successful, especially at the Csph stage. Therefore, I made some modifications 
to the adult CDC culture protocol in order to obtain an optimal Csph and CDC yield. 
For instance, I observed that mincing adult cardiac tissue for 10 minutes instead of 3-5 
minutes and harvesting smaller cardiac explants improve the phase bright cell 
production in explant derived cells. Likewise, the addition of 1 ml medium at three-day 
intervals during the explant culture was advantageous for phase bright cell outgrowth. 
While counting EDCs prior to the Csph stage, I noticed that there was a lot of debris 
and dead cells left from the adult explant tissue culture; therefore, careful cell counting 
and viability assessment were carried out by automated cell counter to gain accurate 
EDC counts. Using the optimised protocol I noticed that adult explants needed more 
time (25-30 days) to become confluent in comparison to neonates (12-14 days). EDCs 
were seeded in polylysine-D-coated wells at a seeding density of 10
5
 EDCs per well of 
24-well-plate to form cardiospheres. By day 12-14, Csphs formed completely and were 
then expanded as CDCs for 2 passages.  
 
 Preparing CDCs from atria and ventricles of the adult murine heart  4.2.2 
It has been reported that human atria from patients with chronic ischaemic heart disease 
generate more efficient EDCs compared to the ventricles [140] and Mishra et al. (2010) 
showed that, overall, human atria contain more cKit
+
 cells than ventricles (right atrium: 
5.2%, left atrium: 0.3%, right ventricle: 1.4% and left ventricle 1.4%) [79]. It is believed 
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that the minimised stress in the atrial wall favours cardiac progenitors and is permissive 
for their increased proliferation, reviewed in [141]. Therefore, to optimise adult CDC 
culture to obtain a better yield of CDCs, I compared the different stages of CDC culture 
between the atria and ventricles from C57BL/6 young adults (6-8 weeks old). The aim 
of this study was: (i) to define the productive explant capacity; and (ii) to measure the 
number of fully formed Csphs from the atria and ventricles. Both atrial and ventricular 
explants and Csphs were cultured for the same time (explants 25-30 days and Csphs 12-
14 days). Eight plates with an average of 20 adhered explants in each plate were 
randomly selected for each experiment from atrial and ventricular culture. In total, 510 
explants (170±23) from atrial explant cultures versus 492 explants (164±34) ventricular 
explants were analysed from three separate experiments and the number of productive 
explants (those which showed stromal and phase bright cell outgrowth) were 
normalized against the total number of adhered explants. Fully formed Csphs were 
quantified from eight wells for each experiment at the end of cardiosphere culture. 
 
Figure ‎4-1. Evaluating explant productivity (A) and Csph yield (B) from atrial and 
ventricular tissues. (A) A summary of three independent experiments showing the mean 
percentage +/-SEM of productive explants, from atrial explant cultures versus ventricular 
explants. The mean number of explants per experiment was 170±23 atrial explants and 164±34 
ventricular explants. Explant productivity was normalised to the total attached explant number 
and expressed as the productive percentage of explants for each experiment. The proportion of 
productive explants generated from atrial tissue was significantly higher than from the 
ventricles. (B) A summary of three independent experiments showing the mean number of fully 
formed Csphs at day 14 from atrial and ventricular explant-derived cells plated at 10
5
 cells/well 
of 24-well plate. To assess the significance difference between the groups paired t-test was used 
and data showed that atrial EDCs produce significantly more Csphs in comparison to ventricular 
EDCs. In each experiment, at least 3 atria or ventricles were used from 6-8 week old mice. 
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Figure 4-1 shows that in all three experiments a significant difference was observed 
between atria and ventricles in explant productivity and Csph production. Combining 
the explant productivity from atria and ventricles (23-27% vs. 12-14%) gave a total 
explant productivity of 19.6% in young adult mice, aged 6-8 weeks from C57BL/6 line 
which is consistent with Davis et al. (2009) who showed  20% explant culture 
productivity with C57BL/6 mice [71]. Due to the higher yield of EDCs and Csph from 
the atrial culture, I decided to use atria only in the subsequent CDC culture from adult 
hearts.  
 
 Defining an effective 3% O2 pre-treatment duration for adult P2 CDCs 4.2.3 
In chapter 3, I observed that passage 2 neonatal CDCs show elevated levels of Sca-1, 
Eng, Vegf mRNA at different time points following their transfer to culture in 3% O2. 
qRT-PCR analysis of stem cell (Sca-1), mesenchymal (Eng) and endothelial (Vegf) 
markers of neonatal CDC preconditioned in 3% O2 showed that the expression of these 
genes increased at different time points between 3 and 48 hours. As neonatal CDCs 
were confluent after 72 hours of 3% O2 culture and all genes of interest had either 
returned to baseline or below, in the subsequent adult CDC culture described in this 
chapter, 3% O2 treatment was only continued for a maximum of 48 hours.  
In order to investigate the effect of 3% O2 culture on adult CDCs, three factors were 
evaluated: (i) the effect of 3% O2 on clonogenicity, viability and proliferation; (ii) the 
effect of 3% O2 on the expression of stem cell, mesenchymal and endothelial markers; 
and (iii) the level of Vegf in supernatant of P2 CDCs cultured in 3% O2 for 6, 24, and 
48 hours. 
 
 Stabilisation of Hif-1α‎protein‎in‎adult‎P2‎CDCs‎following‎48‎hours‎of‎3%‎O2 4.2.4 
culture 
As discussed in section 1.6, Hif-1α protein is stabilised in mammalian cells cultured in 
hypoxic environments. Therefore, any evidence of Hif-1 protein stabilisation in all 
experiments associated with hypoxia is fundamental for the validation of the hypoxic 
environment. To assess hypoxia-associated protein in CDCs, Hif-1α stabilisation was 
evaluated by immunocytochemistry by using the specific Hif-1α antibody in adult-
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derived P2 CDCs cultured for 48 hours in normoxia and 3% O2. Figure 4-2 shows the 
stabilisation of Hif-1α in adult CDCs at P2 cultured in 3% O2 for 48 hours. 
Figure ‎4-2 Hif-1α protein stabilization in adult passage 2 CDCs cultured in normoxia and 
3% O2 for 48 hours. CDCs stained with anti-Hif-1α specific antibody and detected with an 
anti-rabbit secondary antibody conjugated with alexa594 (red). Cells were cultured in (A) 
normoxia and (B) 3% O2 for 48 hours. Hif-1α protein appears to be stabilised in cytoplasm and 
nuclei of CDCs in 3% O2; however, cells appear to have a variable response, as some CDCs do 
express Hif-1α neither in the nucleus nor in cytoplasm. And some cells in normoxia expressed 
detectable levels of Hif-1α. Nuclei were stained with Dapi (blue). Inset image A is the no 
primary control with same scale bar = 100μm. 
 
 The effect of 3% O2 on adult CDC clonogenicity 4.2.5 
My findings showed that neonatal CDCs are clonogenic and the rate of clonogenicity in 
normoxia and 3% O2 were 5-8.5% and 5.9-7.4% respectively. I also investigated if 3% 
O2 as a mild hypoxic cell culture environment that could modify adult CDC 
clonogenicity. To test this, adult CDCs at passage 1 were preconditioned with 3% O2 for 
48 hours, and then were sorted using an automatic cell sorter (FACS Aria) and one 
single cell placed automatically in each well of a 96-well plate. For extra assurance all 
wells were observed with light microscopy straight after cell sorting and all the 
clonogenicity sample cultures were continued in normoxia. Clonogenicity was 
monitored for 6 weeks and at day 42 the number of colonies was quantified and the 
clonogenicity percentage calculated. This experiment was performed independently 
three times and results showed that preconditioning of CDCs at passage 1 with 3% O2 
for 48 hours did not significantly change their clonogenicity as the rates were 
comparable. Figure 4-3 shows a representative single cell in the well of a 96-well plate 
(Fig 4.3.A) and a colony that formed after 14 days from the same cell (Fig 4.3.B). Table 
4-1 summarises the results of three independent clonogenicity experiments with adult 
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CDCs, which have been cultured in normoxia and 3% O2 for 48 hours while they were 
at the P1 stage. 
Figure ‎4-3 The effect of 3% O2 on Adult CDC clonogenicity. Single cells from P1 CDCs 
exposed to either normoxia or 3% O2 were sorted automatically using a FACS Aria sorter and 
placed in each well of 96-well plates. Clonogenicity was assessed weekly by light microscopy 
for 6 weeks. (A) A single adult CDC at day 0; (B) A colony from the same cell after 14 days; 
the edge of the colony is highlighted with a blue line. Scale bar =200 µm. 
 
Experiments Normoxia 3% O2 
Expt.1 11±2.1 13.5±5.8 
Expt.2 7.2±2 15.6±5.4 
Expt.3 8.3±4.7 12.1±5.1 
P value 0.1 
           
Table ‎4-1 Summary of three independent clonogenicity experiments performed with adult 
murine CDCs preconditioned for 48 hours in normoxia and 3% O2. CDCs at Passage 1 
were cultured in normoxia and 3% O2 for 48 hours. Then, using the cell sorter; one single cell 
was placed in each well of 96-well plates and clonogenicity measured after 6 weeks of culture. 
Data are presented as mean percentage of clonogenicity ± SEM from three technical replicates 
for each run. Paired t-test was used to assess the significant difference between biological 
replicates.   
 
 The effect of 3% O2 on adult P2 CDC proliferation and viability  4.2.6 
In the literature there are different opinions about the effect of hypoxia on cell 
proliferation and viability. My experiments from neonatal CDCs cultured in 3% O2 for 
24, 48 and 72 hours showed no significant difference in terms of viability and cell 
proliferation in comparison to normoxia counterparts. To test the effect of 3% O2 on the 
viability and proliferation of adult CDCs, I performed a proliferation and viability assay 
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using the automated cell counter Vi-Cell XR 2.03 (Beckman/Coulter). Passage 2 adult 
CDCs (seeded at the same cell density of 2 x 10
5
/per well) were cultured in normoxia 
and 3% O2 for 48 hours. CDCs were enzymatically detached at 24 and 48 hours of 
culture and assessed for viability and proliferation. This experiment was performed 
independently three times and Table 4-2 and Figure 4-4 summarise the results of these 
experiments. The data suggested that 3% O2 treatment of CDCs leads to increased CDC 
proliferation rate after 24 hours (p=0.02) but did not change the cell proliferation at 48 
hours. Adult CDC viability remains stable for 48 hours without any significant change 
between normoxia and 3% O2 groups.   
 
Figure ‎4-4 Evaluating adult passage 2 CDC total cell viability and cell count in normoxia 
and 3% O2 for 24 and 48 hours in three independent experiments. Viability and total cell 
count were analysed with automated cell counter (Coulter) after single cell suspension in PBS. 
Bar graphs show mean +/-SEM from 3 technical replicates. 
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Table ‎4-2 Summary of three independent analyses of proliferation (A) and cell viability 
(B) performed with P2 adult murine CDCs (aged 6-8 weeks) cultured in 3% O2 and 
normoxia. CDCs at P2 were cultured in 3% O2 and normoxia with the same cell seeding 
density. (A). Adult P2 CDC total cell count assessed at 2 different time points (24 and 48 
hours). Data are presented as the mean total cell viability or total cell count ±SEM. Paired t test 
showed that total cell count increased significantly in 24 hours cell culture only. (B) Adult CDC 
cell viability was assessed at two different time points including 24 and 48 hours. Data 
presented as mean viability percentage ±SEM. It appears that viability remained un-changed. 
The full dataset for this experiment is depicted in figure 4-4. 
 
 The effect of 3% O2 on passage 2 adult CDC gene expression 4.2.7 
Using qRT-PCR, I analysed adult CDCs at passage 2 treated with 3% O2 and normoxia 
for 3, 6, 24 and 48 hours and compared the gene expression profile of Sca-1, cKit, 
Abcg2, Eng and Vegf. This experiment was independently performed three times and 
although results were variable, there was a significant up-regulation in expression of 
Sca-1(6 hours, p=0.04), Abcg2 (3 hours, p-0.03), Vegf (6 hours, p=0.03 and 24 hours, 
p= 0.02) and Eng (24 hours, p=0.03), but generally a notable reduction of gene 
expression observed at 48 hours of culture. The significant increase in Sca-1 mRNA 
expression was observed at 6 hours in all experiments, although in all time points the 
ΔCt value of Sca-1 in CDCs cultured in 3% O2 was lower than the normoxia counter 
parts. cKit mRNA level did not appear to change following 3% O2 treatment (Δct values 
were almost same as the normoxia control groups in the 3 experiments), however the 
amount of cKit mRNA was not detectable in experiment 2 (48 hours) and 3(24 hours), 
therefore not enough data were available for paired t-test in these two time points. 
Abcg2 mRNA which was not changed in neonatal CDCs following exposure to 3% O2 
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increased significantly at 3 hours of 3% O2 culture in adult-derived P2 CDC. Eng 
expression was also moderately elevated at 24 hours following 3% O2 treatment in 
comparison with the normoxia group. Vegf also had a variable response to 3% O2 
culture, yet in all three experiments there was an up-regulation in the level of Vegf of at 
6 to 24 hours of cell culture. Figure 4-5 and Table 4-3 depict qRT-PCR results from 
neonatal CDCs cultured in 3% O2 in comparison with its normoxia counterpart. 
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Figure ‎4-5 Gene expression changes in adult CDCs at passage 2 cultured in normoxia and 3% O2 for 3 to 48 hours. Sca-1, cKit, Abcg2, Eng and Vegf 
expression was analysed using qRT-PCR at 4 different time points in three independent experiments. The ΔCt values of target genes are summarised in the 
graphs, blue bars (normoxia), red bars (3% O2) showing mean +/-SEM of 3 technical replicates and data were analysed as summarised in Table 4-3. 
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Sca-1 
  3 hours 6 hours 24 hours 48 hours 
Experiments Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 
Expt.1 5 5 5.2 4.4 5.4 4.4 5.1 4.7 
Expt.2 6.4 5.1 6 4 6.3 4.8 6.1 5.5 
Expt.3 4 3.9 4.2 2.9 4.5 2.8 4.5 3 
P value 0.3 0.04 0.96 0.1 
cKit 
  3 hours 6 hours 24 hours 48 hours 
Experiments Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 
Expt.1 24.3 23.9 24.6 24.7 23.4 23.1 25 25 
Expt.2 24 23.6 24.2 23.9 24.4 24     
Expt.3 19.5 19.5 19 18.9 - - 19.4 19.2 
P value 0.7 0.7     
Abcg2 
  3 hours 6 hours 24 hours 48 hours 
Experiments Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 
Expt.1 8.3 8 8.5 8.1 8.6 8.2 8.5 8.4 
Expt.2 8.3 8.1 8 7.8 8.3 8.1 8.4 8.1 
Expt.3 1.39 1.34 1.5 0.5 1.4 1.35 1.39 1.1 
P value 0.03 0.1 0.1 0.4 
Vegf 
  3 hours 6 hours 24 hours 48 hours 
Experiments Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 
Expt.1 23 22.5 23.2 22 23 21 23.2 23 
Expt.2 16.6 16.6 16 15.1 16.2 15.1 18.5 18.5 
Expt.3 8.1 7.9 7.9 6.3 7.9 6.1 8.1 7.5 
P value 0.3 0.03 0.02 0.2 
Eng 
  3 hours 6 hours 24 hours 48 hours 
Experiments Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 Normoxia 3% O2 
Expt.1 3.3 3 3.3 2.8 3 2 3 3 
Expt.2 6.3 4.5 6 4.9 6.1 4.7 8.4 8.1 
Expt.3 3 2.7 3 2.4 2.7 2 3 2.8 
P value 0.2  0.05 0.03 0.5  
 
Table ‎4-3 Time-course analysis of the effect of 3% O2 on the expression of Sca-1, cKit, 
Abcg2, Eng and Vegf in passage 2 adult CDCs. Analysis of gene expression using qRT-PCR 
with ΔCt values (shown in table) generated following normalisation against the average Ct from 
three housekeeping genes: Gapdh; B-actin; and RPL-19. The table shows the relative 
expression of Sca-1, cKit, Abcg2, Eng and Vegf in CDCs cultured in 3% O2 from 3 to 48 hours. 
Each ΔCt value shown is the mean of three technical replicates. Paired t test was performed 
using the mean value for each biological replicate and the significant differences, (p<0.05) are 
highlighted in red. 
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 3% O2 increases Vegf protein in the supernatant of adult-derived P2 CDC  4.2.8 
CDCs are shown to contain some pro-angiogenic potential [65,68,74,79,80,86], and 
show increased Vegf mRNA expression following exposure to 3% O2. Therefore, to 
validate the hypoxic environment in CDC culture and test the secreted levels of Vegf, I 
analysed the level of Vegf protein in CDC-conditioned media. Using Elisa, the level of 
Vegf was measured in adult P2 CDCs cultured in normoxia and 3% O2 at 6, 24 and 48 
hours. The same cell density of P2 CDCs was seeded in each well (5 x 10
4
 cells/well of 
6-well plates) and the same volume of media was added (3 ml/well). 250 µl of media 
were collected at 6, 24 and 48 hours from CDCs cultured in normoxia and 3% O2. 
Results showed that 3% O2 culture of P2 CDCs significantly increased Vegf protein in 
the media in comparison with normoxia. As shown in figure 4-6 the level of Vegf 
protein in supernatants increased in normoxia from 172±14 pg/ml to 267±15.6 and 
388±7 pg/ml at 6 and 24 hours respectively, but the highest level of Vegf was observed 
at 48 hours of 3% O2 culture, 422.7±13 pg/ml. Figure 4-6 shows the level of Vegf at 
three different time points in comparison with the control group (48 hours normoxic 
culture).  
 
Figure ‎4-6 The level of Vegf protein in supernatant of adult P2 CDCs cultured in 
normoxia( 48 hours) and 3% O2. Adult P2 CDCs cultured in normoxia and 3% O2 with same 
cell density and same total volume of cell media. At each time point an aliquot of the media was 
used to measure Vegf level by Elisa. The graph clearly shows that the Vegf expression level 
from P2 CDCs cultured in 3% O2 has an appreciably higher level of Vegf protein in comparison 
to normoxia group (*p<0.05). 
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 The effect of 3% O2 on stem cell (Sca-1, cKit), Mesenchymal (CD90, Eng) 4.2.9 
and endothelial (CD31, CD34, Flk1) markers of adult P2 CDCs 
FACS data showed that, Sca-1 expression was up regulated in all three experiments in 
3% O2 compared to normoxia which validates the data from neonatal derived CDCs. 
cKit expression remained stable in both groups in all three experiments which confirms 
the data from qRT-PCR analysis of cKit gene expression. Eng and CD90 also showed 
stable expression in normoxia and 3% O2. However, Eng mRNA expression has 
previously been shown to be up-regulated in a hypoxic environment (1% O2, 4-6 hours, 
3.5 and 1.5 folds respectively) in trophoblast-derived cell lines [142]. CD31 expression 
was relatively low in three experiments and no significant change observed between 3% 
O2 and normoxia. Unfortunately, in experiment 2, due to technical errors CD34 was not 
detectable, but 3% O2 appeared to increase CD34 in experiments 1 and 3. However, this 
difference was not significant in experiment 1, only in the third experiment. Therefore, 
further investigations with CDCs cultured in 3% O2 and normoxia is necessary to 
elucidate the effects on CD34 expression levels. Flk1, although expressed at low levels, 
showed a significant increase in CDCs cultured in 3% O2 compared to normoxia (table 
4-4). In this respect it has previously been shown that hypoxia (0.5% O2 for 24 hours) 
increases Flk1 expression in murine MSN [143]. Overall, my findings from the 
immunophenotyping of CDCs share similarities with neonatal CDCs (chapter 3) and 
those published in the literature [83,144]. Figure 4-8 shows representative FACS plots 
and table 4-4 summarises the results of all three independent experiments as a 
percentage of positive events for all the cell populations analysed.
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 Sca-1+  and cKit+ CDCs are predominantly CD45- 4.2.10 
Flow cytometry demonstrated that passage 2 adult Sca-1
+
 and cKit
+
 CDCs were 
predominantly negative for the haematopoetic marker CD45 (1.8±0.2 and 0.6±0.12 
respectively – figure 4-7). This result demonstrates that Sca-1 and cKit-expressing 
CDCs are predominantly distinct from cells of haematological origin. 
 
Figure ‎4-7 Sca-1+ and cKit+ adult CDCs, at passage 2 are predominantly negative for 
CD45. Flow cytometry analysis reveals that a very low population of adult CDCs at passage 2 
expresses the pan-leukocyte marker CD45. Dot plots (A) & (B) showing 1.8% and 0.6% of 
adult CDCs at passage 2 co-express Sca-1 and cKit with CD45 respectively. (C), (D), (E) and 
(F) are isotype controls for PECy7, FITC, PE Cy 5.5 and unstained control respectively. Data 
are presented as mean percentage ± SEM. 
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Figure ‎4-8 Flow cytometric analysis of murine adult CDCs at passage 2 harvested for 48 hours in normoxia and 3% O2. A) CDCs were analysed for the 
expression of Sca-1, cKit, Eng, CD90, CD45, CD31, CD34 and Flk1. B,C and D are the summary of three independent FACS experiments showing the 
proportion of cells expressing each marker. Data was summarised and analysed as shown in Table 4-4. 
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Table ‎4-4 Summary of 3 independent FACS analyses performed with adult murine CDCs at passage 2 cultured in normoxia and 3% O2. Data represents 
the number of immuno-positive cells as a percentage of viable cells. Sca-1 and Flk1 are increased significantly after 48 hours of 3% O2 treatment, but culturing 
CDCs in low oxygen had  no significant effect on the expression of the other markers. All FACS experiments are summarised in Figure 4-8. Data presented as 
mean percentage ± SEM, derived from 3 separate replicates per experiment. Paired t-test was performed to compare biological replicates. Significant values are 
highlighted in red.  
Normoxia 3%  O2 Normoxia 3%  O2 Normoxia 3%  O2 Normoxia 3%  O2 Normoxia 3%  O2
Expt.1 12.36±0.5 15.8±0.5 13.23±1.1 14.3±0.7 52.4±0.7 55.4±1.5 49.4±2.3 53.1±1.8 3.9±0.6 5.3±1.0
Expt.2 39.3±0.7 43.8±4 7±0.5 7.7±0.8 59.2±3.6 56±3 37.6±4 41.8±1 4.96±0.8 6.1±0.5
Expt.3 15.9±0.6 20.4±1.4 4.3±0.8 4.9±0.9 51.6±4 56.1±1.3 67.6±1 67.3±1 3.2±1.9 5.6±1
P value
Experiments
Sca-1 c-kit Eng CD90 CD45
0.006 0.05 0.5 0.5 0.1
Normoxia 3%  O2 Normoxia 3%  O2 Normoxia 3%  O2 Normoxia 3%  O2 Normoxia 3%  O2 Normoxia 3%  O2
2.5±0.1 2.4±0.3 8.8±0.6 11.2±0.8 3.6±0.15 5.7±0.6 2.3±0.3 1.4±0.2 33.1±0.6 43.1±1.4 3.8±0.4 2.4±0.2
1.1±0.5 1.1±0.3 - - 1.5±0.37 3.7±0.6 0.2±0.1 0.6±0.3 18.3±0.4 23±0.1 5.4±1.02 3.3±1.1
1.6±0.6 1.4±0.5 24.5±2 32.2±2.3 1.4±0.2 2.9±0.15 - - - - - -
CD31
-
CD34 Flk1 Sca-1/cKit Sca-1/Eng cKit/Eng
0.1 - 0.01 - -
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 Sca-1 expression increases following extended passaging of adult CDCs 4.2.11 
As qRT-PCR and FACS analysis of CDC treated with 3% O2 showed a significant 
increase in Sca-1 expressing a sub-population of CDCs, I next assessed whether 
prolonged CDC culture influences Sca-1 expression.  
To test this hypothesis Sca-1 expression in adult CDCs was assessed with flow 
cytometric-based immunophenotyping at passages 2 and 4. Interestingly, FACS data 
showed a dynamic increase in the numbers of Sca-1 expressing cells following the 
extension of the in-vitro passaging of adult CDCs to P4. This experiment was 
independently performed three times. In all the experiments there was a significant 
increase in the number of Sca-1 expressing cells in P4 in comparison with P2. Figure 4-
9 shows the summary of three independent FACS results depicting this change, while 
table 4-5 summarises the results of all three experiments. 
                               
Figure ‎4-9 Flow cytometric analysis of P2 and P4 adult CDCs showing up regulation of 
Sca-1 following extended passaging. CDCs were expanded until passage 2 and 4 then, cells 
were sampled and analysed for the expression of Sca-1. The images clearly show that Sca-1 
expression is appreciably increased from passage 2 to passage 4. Data are derived from three 
independent experiments and data are presented as mean percentage (from three technical 
replicates) ± SEM. Summary and analysis of data are shown in Table 4-5.  
Experiments P2 P4 
expt.1 22.3±± 1.1 42± 1.7 
expt.2 38.2± 1.1 57.2± 2.7 
expt.3 18.9± 0.4 33.2± 3.4 
p value 0.01 
 
Table ‎4-5 A summary of three independent flow cytometric analyses of Sca-1 expression 
from adult murine CDCs at P2 and P4 stages. Results showed that Sca-1 expression is 
significantly increased following prolonged CDC culture. Data are derived from three 
independent experiments and presented as mean percentage ± SEM. Paired t-test was used to 
analyse changes between biological replicates.  
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 Discussion 4.3 
 The efficiency of adult murine CDC culture 4.3.1 
Davis et al. (2010) showed that CDC culture is an efficient method to obtain cardiac 
progenitor cells, but they reported a variable success rate between different mouse 
strains such as C57BL/6, MerCreMer-Z/EG [71]. The authors reported that only 20% of 
cardiac explants derived from adult C57BL/6 mice were able to form phase bright 
outgrowth. This is consistent with my findings with the adult C57BL/6 cardiac explant 
culture, where I found that 19.6% of explants generated phase bright cells. Davis et al. 
did not report any difficulties with Csph stage culture using EDCs from adult C57BL/6 
mice [71]. However, it is reported that Csphs grow slowly when EDCs are seeded at a 
low density and at least 40,000 EDCs are required for a successful Csph culture [140]. 
Using the established CDC protocol based on neonatal CDC culture, I seeded 10
5
 adult 
EDCs per well of 24-well plate to culture Csphs, but fewer Csphs were generated at two 
weeks in comparison to neonatal Csphs. After EDC quantification with the 
haemocytometer I noticed that, along with EDCs, there are lots of cellular fragments 
and cardiac tissue remnants, which may have led to an overestimation of cell seeding 
density, so I added the automated cell quantification step and correlated the seeding 
density with the number of viable cells, which influenced positively the Csph yield.    
 
 Possible reasons for low efficiency of adult CDC culture in comparison with 4.3.2 
neonatal CDCs 
There are a number of possible explanations for the low yield of CDCs from adult 
hearts compared with neonatal hearts. Although Chan et al. (2012) [140] reported that 
there is no effect of age on EDC and CDC growth from human cardiac samples, they 
compared only adults over a limited age range (65> age >65). Possibly culturing CDCs 
from different animal models, with different age ranges, could answer this question. It is 
possible that adult EDCs and Csphs proliferate more slowly than neonatal cells. It is 
reported that resident human CPCs are most abundant in the neonatal stage (<30 days) 
compared with children (age 2 to 13 years) and rapidly decrease over time; and also 
CPCs from younger children express more Ki67 (a marker for proliferating cells) than 
older CPCs [79]. In this respect, measuring the doubling time of phase bright cells and 
Csph-forming cells of adult and neonates could help to address this point. There may 
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also be technical issues affecting the CDC yield. It is already reported that EDC culture 
from C57BL/6 is difficult and technical variation in culture conditions such as initial 
explant enzymatic digestion, or the seeding density alters the efficiency of the CDC 
culture [71]. In our lab the established CDC culture protocol is based on neonatal CDCs 
in which all EDCs including stromal and phase bright cells are dissociated with 
enzymatic digestion using trypsin. I observed a considerable number of floating cells at 
the Csph culture stage following trypsin digestion. Therefore, I replaced trypsin with a 
milder cell disassociation enzyme: accutase, which decreased the numbers of dead 
floating cells at the Csph stage. 
 
 Adult murine atria generate a higher yield of EDCs and Csphs than 4.3.3 
ventricles 
My findings from comparing EDCs and Csph formation from atria and ventricles 
showed that atria generate higher yields of EDC and Csphs in comparison to ventricles. 
This is in agreement with Chan et al. (2012) [140], who showed that EDCs could be 
expanded from all atrial biopsies, but sufficient cells were obtained from only 8/22 
ventricular biopsies. This could be due to the less contractile activity of the atria in 
comparison to the ventricles as Leri et al. (2005) noted that CSC distribution within the 
heart appears to be related to the minimised levels of wall stress regions such as the 
atria and apex. The difference between the cellular components of the atria and 
ventricles could also affect EDC outgrowth from explants. In this respect, Burstein et al. 
(2008) compared secretory, morphological and proliferative indexes of canine atrial 
versus ventricular fibroblasts and showed that atrial fibroblasts express greater αSMA 
and proliferate faster than ventricular fibroblasts. Therefore, it is possible the abundance 
of atrial fibroblasts facilitates phase bright cell migration by paracrine mechanisms 
[145]. It would be interesting to measure the level of growth factors and cytokines 
expressed in the supernatant of atrial versus ventricular explant culture and investigate 
the possible correlation between the EDC outgrowth rate and released paracrine 
pathways. Several pathways have been shown to be involved in cell migration such as 
CXCR4/SDF1 [146] and TGF-β [147].  
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 Defining the optimal 3% O2 culture duration for adult CDCs 4.3.4 
It has already been shown that hypoxia increases stem cell proliferation and 
clonogenicity and due to the relevance of the application of adult CDCs in ischemic 
heart regeneration, in this chapter I investigated whether the preconditioning of adult 
CDCs with 3% O2 favours CDCs in terms of the proliferation, and expression of stem 
cell, mesenchymal and endothelial cell markers. My observations of neonatal CDCs 
(described in the previous chapter) showed that 3% O2 increases EDC proliferation and 
up-regulates Sca-1, Abcg2, Vegf and Flk1 expression. This indicates that 3% O2 
improves the in-vitro stem cell and pro-angiogenic potential of neonatal CDCs. 
Therefore, in the first step I decided to find the best possible 3% O2 culture duration for 
adult CDCs. 
 
 The effect of 3% O2 on adult CDC clonogenicity, viability and proliferation  4.3.5 
Culturing adult CDCs for 48 hours in 3% O2 did not change their clonogenicity but 
increased their proliferation rate slightly after 24 hours of cell culture. Interestingly their 
viability remained same between normoxia and 3% O2 which suggest that the hypoxic 
environment has no significant impact on cell viability in 24 or 48 hours of culture. 
However, it is known that the effect of hypoxia on cell proliferation is cell specific; for 
instance, 1% O2 increases the proliferation and clonogenicity of neural stem cells [148] 
but decreases the proliferation and clonogenicity of mesenchymal stem cells [98]. As 
discussed in chapter 3, it is also possible that 3% O2 is not sufficient to increase the 
clonogenicity and viability in adult CDCs. Therefore, it would be interesting to assess 
the effect of combining severe hypoxia cultures followed by 3% O2 on CDC 
proliferation and clonogenicity. As it has been shown that Hif-1α is more efficiently 
active below 2% O2 and Hif-2α has more activity above 2% O2, this could potentially 
stabilise both Hif-1α and Hif-2α which could activate the downstream activities of both 
genes and possibly the CDCs could get the benefit of the activation of both downstream 
pathways. Probably in future experiments, selecting specific sub-populations of CDCs 
(e.g. cKit
+
 or Sca-1
+
) would provide a better understanding of the effect of 3% O2 on 
their proliferation and clonogenicity. 
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 Possible implications of 3% O2 culture in phenotypic heterogeneity of adult 4.3.6 
murine CDCs  
qRT-PCR and FACS analysis of stem cell (Sca-1, cKit, Abcg2), mesenchymal (Eng, 
CD90) and endothelial (CD31, CD34, Flk1) markers revealed inter-culture variation 
between CDCs at passage2 as well as temporal variation in response to 3% O2. This 
finding is very similar to my results from studies on the neonatal CDCs and was 
discussed in the previous chapter. Sca-1 was the only marker which was expressed at 
higher levels in adult CDCs in comparison with neonatal CDC (p<0.05). CD31, Flk1 
and Eng were all expressed at lower levels in adult CDCs compared with neonatal 
CDCs (p<0.05 for all three markers), suggesting that adult murine CDCs have a smaller 
angiogenic sub-population in comparison with neonatal CDCs.  
 
 Sca-1 expression in expanded adult CDC culture 4.3.7 
Interestingly, FACS data showed that with prolonged CDC culture, Sca-1 expression 
increased progressively (table 4-5). My findings are in agreement with Zuba-Surma et 
al., who showed that Sca-1
-
 skeletal muscle progenitors become Sca-1
+
 following 
expansion in the culture and reaches 98% of the total cells following 3 passages [149]. 
The elevation of Sca-1 expression following increasing CDC passage could be due to 
the fact that Sca-1 expressing CDCs proliferate faster than other CDC sub-populations 
following prolonged culture as Zuba-Surma et al. (2006) showed that Sca-1
+
 cells 
proliferated faster than Sca-1
- 
cells [149]. It would be interesting to analyse the 
proliferation rate and doubling time of sorted Sca-1
+
 versus Sca-1
-
 CDCs to test this 
possibility. It is also possible that adult murine atria contain more Sca-1
+
 cells than 
neonatal hearts so consequent CDC cultures reflect levels of Sca-1 expressing cells in 
the cardiac tissue. In this respect Hidestrand et al. (2008) showed that Sca-1-expressing 
cells are more abundant in regenerating the aged (24 months old mice) than young adult 
(4 months old) tibialis anterior muscle [150]. According to Janson et al. (2013) serial 
passaging can be used as a model of in-vitro cell ageing studies [151]; therefore, it is 
possible that prolonged CDC culture has the same effect on Sca-1 expression by an in-
vitro ageing mechanism. My experiments showed that culturing CDCs in 3% O2 also 
led to an increase in Sca-1 expression. However, there could be a possible difference 
between Sca-1
+
 cells induced by 3% O2 and serial passaging. Sca-1 is expressed in 
mixed stem cells, progenitor and differentiated cells [127]. It would be interesting to 
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investigate the possible difference between Sca-1-expressing CDCs induced by 3% O2 
and serial passaging. Functional experiments such as clonogenicity and differentiation 
capacity to other lineages such as endothelial and cardiomyocytes could help to 
characterise Sca-1
+
 CDCs. In this respect I further assessed Sca-1 expressing CDCs 
with other markers by flow cytometric analysis and noticed that the proportion of Sca-
1
+
/Eng
+
 CDCs cultured in 3% O2 increased from 33.1±0.6% in normoxia to 43.1±1.4% 
in 3% O2 (p <0.05). Furthermore, Sca-1-expressing cells were predominantly distinct 
from myeloid cells as they were mostly CD45
-
. However, to validate these findings, 
Sca-1 cells from aged mice and higher passages could also be assessed for co-
expression of other angiogenic and stem cell markers.
 
My studies of adult CDCs and their response to 3% O2, showed that 3% O2 favours 
murine adult CDCs in terms of the stem cell phenotype (by increasing sub-populations 
of Sca-1 and Abcg2) and pro-angiogenic potential (by increasing the expression of Eng, 
Vegf and Flk1). The results from this chapter suggested a potential treatment for cardiac 
stem cell pre-treatment in order to increase the pro-angiogenic sub-populations of CDCs 
and their application in clinical studies. However, the mice models used in this study 
were healthy and, therefore, in order to have a more clinically relevant scenario, it 
would be better to culture CDCs from diseased models such as the MI model and 
further characterise them in 3% O2 and normoxia. 
Fibroblasts in atria are shown to proliferate faster than ventricles [145] and there is 
evidence in the literature which suggests Csphs resemble fibroblasts and have little 
cardiogenic potential [78] and, finally, Zakharova et al. (2010) used 
immunocytochemical analysis of dissociated Csphs and showed that 17% of the cells 
expressed αSMA and 6% expressed vimentin [85]. As I am using atria to culture CDCs, 
there is a likelihood of culturing fibroblasts with CDCs. As the final aim of CDC culture 
is to provide a safe autologous cell source for MI patients, it is important to investigate 
the fibroblast content at different stages of CDC culture. This can be done by using 
transgenic mice in which cardiac fibroblasts are labelled with specific genetic tags and 
is described in the next chapter.    
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Chapter 5  Lineage tracing of cardiac 
fibroblasts in murine hearts and CDC culture 
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 Introduction 5.1 
As discussed in section 1.5.7, EDCs, Csphs and CDCs have been shown to be pro-
angiogenic, cardiogenic, clonogenic and capable of multilineage differentiation. 
However, the validity of the Csph culture method has been questioned and different 
laboratories have shown different outcomes. Csphs derived from neonatal WK rats were 
reported to contain a significant population of hematopoietic progenitor cells (CD45
+
); 
moreover, non-haematological Csph cells (CD45
-
) in this published study, expressed 
collagen Iα2 and may therefore be fibroblasts [78]. However, enhanced variable level of 
Collagen 1 expressing cells in explants and the Csph stage may be due to technical 
differences between different laboratories during the preparation of Csph cells. The  
Marban group proposed that the inclusion of  non-standard steps such as filtering the 
EDC in order to omit tissue fragments, and using harsh enzymatic digestion to remove 
all EDCs (instead of light digestion to remove phase bright cells only) and using a 
different cell culture medium all had a detrimental effect on the CDC preparations [83]. 
My studies using murine neonatal and adult CDCs, used a standard preparation method 
and validated that CDCs are clonogenic (tables 3-1 and 4-1) and express stem cell, 
endothelial and angiogenic markers (tables 3-4 and 4-4), have shared some similarities 
with work from the Marban laboratory [68,70,71,83] and the work of Chen et al., and 
Carr et al. [80,140]. However, my CDCs as well as those from other laboratories share 
some characteristics with mesenchymal cells and cardiac fibroblasts such as the 
expression of markers of mesenchymal cells (CD90). As myofibroblasts have been 
shown to form spheres [152] further investigations are required to characterise the 
fibroblast content of Csphs and CDCs.  
Carr et al. (2011) showed that 10±2% of rat CDCs express DDR2 (a fibroblast marker) 
[80] and it is also shown that murine hearts contain 27% of DDR2-expressing cells [25]. 
CFs from atria are shown to have more proliferative and secretory activities in 
comparison with CFs derived from ventricles [145]. As the source of adult CDC culture 
in this study is atria, therefore assessing CF derived cells within CDC culture seems to 
be necessary. However, studying CF is complicated as fibroblasts and CFs lack specific 
markers, therefore to study fibroblasts it is useful to study them with a combination of 
markers reviewed in [15]. In the literature, there is contrasting evidence for the 
fibroblast content of Csphs and CDCs. For instance, it has been shown that Csphs 
overwhelmingly express Collagen 1 [78] but, in other work, researchers showed that 
CDCs at passage 2 derived from human congenital heart patients are Collagen 1 
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negative [79]. To address the question of the fibroblast content of Csphs and CDCs, I 
used a mouse model that permitted lineage tracing of fibroblasts (figure 5-1). This type 
of approach leads to the activation of a reporter gene (such as GFP or eYFP) in a 
specific cell population that can be used to track this cell population and its progeny 
over time. One commonly used lineage tracing system is the Cre-recombinase/loxP 
system. This complex consists of a Cre-recombinase enzyme driven by a specific 
promoter (allowing tissue or cell-type specific expression) and a reporter gene 
containing a floxed stop cassette (a region that prevents expression of the reporter gene 
which is flanked by 2 LoxP sites). A LoxP site consists of a 34-base-pair sequence and 
acts as a recognition site for Cre-recombinase. Binding of Cre-recombinase to 2 LoxP 
sites leads to the inversion or excision of the floxed DNA sequence depending on LoxP 
site orientation. In this way, Cre-recombinase can excise a specific genomic region 
which is flanked between 2 LoxP sites and this step can be used to activate the 
expression of a reporter gene (figure 5-1). Temporal activation of Cre-recombinase is 
achievable through the fusing of a mutated hormone binding site of an oestrogen 
receptor with Cre-recombinase. For instance, CreERT is obtained by fusing of Cre-
recombinase with a mutated oestrogen receptor domain that leads to CreERT activation 
in the presence of Tamoxifen [153]. Cre activity is monitored using a genetic marker 
such as eYFP that can be used to identify activated cells and all daughter cells (figure 5-
1).  
Collagen I is produced by fibroblasts and is one of the main components of ECM, 
reviewed in [15]. In this chapter I have used a tamoxifen inducible Col1a2-CreERT; 
Rosa26-floxed STOP eYFP transgenic mouse model (Figure 5-1) to trace and quantify 
CFs in cardiac tissue and at different stages of CDC culture. 
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 Results 5.2 
 Transgenic Col1a2-CreERT; Rosa26-floxed STOP eYFP mouse model 5.2.1 
The Col1a2-CreERT
 
mouse was first reported by Zheng et al. (2002) [110] and was 
obtained from Prof. David Abraham’s Laboratory (UCL). The Col1a2-CreERT 
transgene contains 6 kb of the upstream 5
’
 flanking region of the Col1a2 promoter fused 
to a sequence encoding Cre-ERT-IRES-hpAP. Zheng et al. (2002) showed by 
histological examination of Col1a2-CreERT; Rosa26-floxed STOP eYFP transgenic 
mice, that the LacZ reporter gene was essentially restricted to fibroblast cells in 
different tissues such as the skin, lung, kidney, skull, liver, and epicardium and intestine 
[110]. Using LacZ staining, Zheng et al. (2002) showed the expression of Collagen 1 
expressing cells within the pericardium, suggesting the in-vivo activation of Cre 
recombinase in the heart. I therefore tested whether the Col1a2-CreERT line could be 
used to mark CFs. I did this by using a different reporter gene that expressed eYFP 
(Figure 5-1). Col1a2-CreERT mice were crossed with Rosa26-floxed STOP-eYFP 
reporter mice [109] in which eYFP has been introduced into the ubiquitously expressed 
Rosa26 locus. In the presence of functional Cre-recombinase the STOP cassette 
upstream to the eYFP coding sequence is excised and the eYFP gene is expressed. 
Figure 5-1 depicts schematically the steps of Cre-recombinase activation and eYFP 
expression in CFs following administration of Tamoxifen.  
 
Figure ‎5-1 Schematic representation of Cre-mediated recombination of the Rosa26 floxed 
STOP-eYFP allele in Col1a2-Cre-ERT mice. Col1α2-Cre-ERT mice were crossed with 
Rosa26-floxed STOP eYFP reporter mice to generate Col1a2-Cre-ERT; Rosa26-floxed STOP 
eYFP mice. The expression of eYFP is driven by the ubiquitously expressed Rosa26 promoter 
and is conditional on the removal of the upstream LoxP flanked ‘STOP’ region. IP injection of 2 
mg tamoxifen/day for 5 consecutive days activates Cre-recombinase to remove the floxed STOP 
region. As a result, all cells expressing Col1a2 and their progenies will express eYFP, and this is 
anticipated to localise to CFs and their descendent cells.  
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 Activation of Cre-recombinase and eYFP reporter expression in CFs 5.2.2 
Studying CFs is complicated because evidence is emerging that CFs are a highly 
heterogeneous cell population. In this study I investigated co-localisation of two 
fibroblast markers: vimentin and FSP1 with endogenous eYFP expression in Col1a2-
CreERT; Rosa26-floxed STOP eYFP mice, using both healthy and MI models (please 
see section 2.11). To validate the eYFP expression in collagen 1 expressing cells, heart 
sections from tamoxifen treated Col1a2-CreERT; Rosa26-floxed STOP eYFP mice were 
stained with an anti-collagen 1 antibody. Anti-GFP was used to stain cells expressing 
eYFP and the co-localisation of these two markers was quantified in three Col1a2-
CreERT; Rosa26-floxed STOP eYFP male mice (6-8 weeks old) 48 hours after the last 
tamoxifen injection (please see section 2.11). The results showed that eYFP is 
expressed in collagen 1 expressing cells in the heart. However, not all collagen 1 
expressing cells were positive for the eYFP marker. Detailed quantifications showed 
that 37.3±2.1% of collagen 1 expressing cells express eYFP and 59.2±1.8% of eYFP 
expressing cells also co-expressed collagen 1. Figure 5.2 depicts the degree of co-
expression of eYFP and collagen 1. 
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Figure ‎5-2 Co-expression of eYFP and collagen 1 in tamoxifen-treated Col1a2-CreERT; 
Rosa26-floxed STOP eYFP heart sections. To assess the specificity of eYFP expression in 
collagen 1 expressing cells, heart sections from Col1a2-CreERT; Rosa26-floxed STOP eYFP 
mice were stained with primary anti-collagen 1 α and anti-GFP antibodies and then the 
secondary antibodies conjugated with Alexa 594 and Alexa 488 respectively. (A) Dapi/eYFP, 
(B) Dapi/Collagen, (C) merged, the white arrow depicts the co-localisation of both YFP and 
Collagen 1, (D) shows the summary analysis of Collagen 1 and YFP co-expressing cells from 
three Col1a2-CreERT; Rosa26-floxed STOP eYFP mice. As shown in the figure, endogenous 
eYFP expression in CFs was not detected in all Collagen 1 expressing cells. The inset in image 
C is a no primary control. The scale bar = 50 µm. 
 
 Co expression of eYFP with FSP1 and vimentin in healthy murine 5.2.3 
myocardium 
To analyse further whether eYFP is activated in the other sub-populations of CFs and 
represents a suitable genetic marker for CF lineage tracing studies, heart sections from 
tamoxifen-treated Col1a2-CreERT; Rosa26-floxed STOP eYFP mice were stained with 
anti-FSP1 and anti-vimentin in combination with anti-GFP (please see chapter 2, 
sections 2.5.1 & 2.11.7). Quantitative analysis of FSP1, vimentin and eYFP expression 
on cardiac sections from Col1a2-CreERT; Rosa26-floxed STOP eYFP transgenic mice, 
showed that 37.5±9%, 40.3±5.5% of FSP1 and 38.6±3.4%, 46±6.6% of vimentin 
expressing cells co-localised with YFP expression in the atria and ventricles, 
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respectively. Figure 5-3 depicts representative images showing the co-expression of 
FSP1/eYFP, and vimentin/eYFP in Col1a2-CreERT; Rosa26-floxed STOP eYFP hearts 
compared with the hearts from Rosa26-floxed STOP eYFP mice, which served as the 
biological negative control (Figure 5-4).  
 
Figure ‎5-3 Immunofluorescent staining of healthy hearts (n=6) with FSP1/eYFP, 
vimentin/eYFP in tamoxifen-treated Col1a2-CreERT; Rosa26-floxed STOP eYFP mice. 
Representative vimentin/eYFP co-expression in ventricles (A-C) and atria (D-F), tissue stained 
with anti-GFP (green), anti-vimentin (red) and nuclei stained with DAPI. Representative 
FSP1/eYFP co-expression in Ventricles (G-I) and atria (J-L) were stained with anti-GFP (green) 
and anti-FSP1 antibody (red), nuclei stained with Dapi. The inset image in L shows a no 
primary control. Cells highlighted by white arrow (digital zooms) in C,F and I, are examples of 
the cells which are considered positive for both markers. All cryosections were prepared as 
described in section 2.11.7. All mice were injected with Tamoxifen as described in 2.11.1 The 
scale bar = 50 µm. 
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Table 5-1 summarises six independent quantification experiments to analyse the number 
of FSP1/eYFP and vimentin/eYFP co-expressing CFs in healthy hearts from  
tamoxifen-treated Col1a2-CreERT; Rosa26-floxed STOP eYFP mice.  
 
Figure ‎5-4 Immunofluorescent staining of healthy atria with FSP1 or vimentin with eYFP 
in tamoxifen-treated Rosa26-floxed STOP eYFP control mice. A-C: representative image of 
atrial tissue stained with anti-FSP1 antibody (red), anti-GFP (green) and nuclei stained with 
Dapi. Images (D-F) are representative images showing vimentin expression in adult mouse atria 
stained with anti-GFP (green), anti-vimentin (red), all mice and hearts were treated as before. 
This experiment with Rosa26-floxed STOP eYFP mice showed that there was no eYFP staining 
in the absence of Col1a2-CreERT which confirms the efficiency of the STOP cassette. The pale 
green seen in these images is due to tissue autofluorescence from myocardium. The scale bar = 
20 µm. 
 
 
Table ‎5-1 Quantification of eYFP, FSP1 and vimentin expressing cells in atria and 
ventricle cryosections from Col1a2-CreERT; Rosa26-floxed STOP eYFP healthy mice. 
Detailed analysis of eYFP, FSP1 and vimentin expressing cells in the atria and ventricle showed 
that these three markers are expressed at the same levels in both regions. There is a considerable 
difference between eYFP expression between (A) and (B) which is probably due to the use of 
two different anti-eYFP antibodies that were required to be compatible with the antibodies used 
to detect FSP1 and vimentin. It is likely that the specificity of the YFP primary antibody used in 
co-staining with FSP1 (A) is higher than the one used in co-staining with vimentin (B). 
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 YFP and FSP1 co-expression in the infarct and border zone of Col1a2 5.2.4 
CreERT; Rosa26-floxed STOP eYFP hearts following myocardial infarction 
To investigate the pattern of CF marker expression and assess their contribution to the 
injured heart tissue following MI, I followed the expression of FSP1 and vimentin and 
assessed their co-expression with endogenous YFP in the hearts of Col1a2 CreERT; 
Rosa26-floxed-STOP-eYFP and control Rosa26-floxed-STOP-eYFP mice following (i) 
Tamoxifen-activation of Cre (please see section 2.11.1) and (ii) subsequent myocardial 
infarction. A surgical myocardial infarct was introduced by ligation of the left anterior 
descending coronary artery by Dr. Rachael Redgrave. After 7 days from the last 
tamoxifen injection, 7 mice from the Col1a2 CreERT; Rosa26-floxed STOP eYFP line 
received a surgical myocardial infarct. At either 1 or 2 weeks post-surgery the mice 
were euthanized by cervical dislocation and the hearts were dissected, fixed and 
processed for cryosections (please see section 2.11). Immunohistochemical analysis of 
the healthy region (remote myocardium of the MI hearts showed that there was no 
significant difference in the pattern of eYFP, FSP1 and vimentin between the non-
infarct controls, remote regions and the MI atria (Figure 5-5). However, in order to 
analyse the pattern of eYFP/FSP1 and eYFP/vimentin expression in the border zone and 
the infarct region, I had to overcome the autofluorescence problem that was associated 
with these areas. 
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Figure ‎5-5 Immunofluorescent staining of remote myocardium in an infarcted heart (n=7) 
with FSP1/eYFP, vimentin/eYFP in tamoxifen-treated Col1a2 CreERT; Rosa26-floxed 
STOP eYFP mice. The remote ventricular region (A1-A4) and atria (B1-B4) were stained with 
anti-FSP1 antibody (red), anti-GFP (green) and nuclei were stained with Dapi. Representative 
ventricle remote region (C1-C4) and atria (D1-D4) tissue were stained with anti-vimentin (red) 
and anti-GFP (green), nuclei stained with Dapi. All cryosections were prepared as described in 
section 2.11 and were injected with Tamoxifen as described in 2.11.1. Scale bar = 50µm. 
 
 Elimination of the autofluorescent artefacts in the border zone (BZ) and the 5.2.5 
infarct region (IR) of hearts following MI of Col1a2 CreERT; Rosa26-floxed STOP 
eYFP and Rosa26-floxed-STOP-eYFP mice 
Autofluorescence has emerged as a confounding factor in studies using endogenous 
fluorescent protein expression in muscular organs such as the heart and skeletal muscle 
cells. For instance, Jackson et al. (2004) showed significant levels of autofluorescence 
in skeletal muscles which could be mistaken for enhanced GFP expression [154]. 
Furthermore, Nussbaum et al. (2007) showed the level of autofluorescence in rat MI 
models and concluded the need for caution and appropriate negative controls when 
using immunofluorescence for cell lineage studies in injured hearts [155]. Therefore, to 
resolve autofluorescent issue, confocal microscopy with spectral unmixing was used to 
eliminate autofluorescence from all channels. To do this, the entire emission spectrum 
was scanned by the microscope and the spectral histogram was analysed in the 
unstained infarcted and healthy tissue samples and autofluorescent spectra were 
identified. Then this process was repeated for Dapi, Alexa 488 and Alexa 594 stained 
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sections. Then, the desired spectra which covered the majority of the autofluorescence 
ranges were chosen, and the autofluorescence was removed. Finally the remaining 
spectra matching the real emission from each fluorochrome was used to detect the real 
expression. Figure 5-6 shows the removal of autofluorescence from the infarct region of 
Rosa26-floxed-STOP-eYFP mice. As expected these mice did not express YFP after 
tamoxifen injection in the infarct region which again validates the efficiency of the 
STOP cassette. Figure 5-7 shows the removal of autofluorescence from the border zone 
of Col1a2 CreERT; Rosa26-floxed STOP eYFP mice. 
 
 
Figure ‎5-6 Auto fluorescent background elimination in the infarct region of Rosa26-floxed-
STOP-eYFP mice. Cryopreserved sections of infarct regions from two Rosa26-floxed-STOP-
eYFP mice were analysed with confocal microscopy and the fluorescent spectra from these 
sections were used to analyses fluorescent staining in the border zone and the infarct regions of 
Col1a2CreERT; Rosa26-floxed-STOP-eYFP. A) Dapi, B) YFP, C) autofluorescent, D) FSP1,E) 
merged image with auto fluorescent and F) merged image after removing autofluorescent.  
Scale bar=100µm. 
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Figure ‎5-7 Evaluation of the autofluorescence in the border zone of Col1a2 CreERT; 
Rosa26-floxed STOP eYFP mice, two weeks after MI. 8-week old CreERT; Rosa26-floxed-
STOP-eYFP mice received 5 interaperitoneal injections of tamoxifen (2 mg/ml) and two weeks 
after LAD ligation, the hearts were dissected and stained with anti-GFP and FSP1 conjugated 
with Alexa 594. To eliminate the autofluorescence from the tissue, I used confocal microscopy 
and analysed the spectral emissions from Dapi, Alexa 594 and Alexa 488 stainings. (A) Dapi, (B) 
FSP1, (C) eYFP, (D) autofluorescence, (E) Dapi, FSP1 and eYFP merged with autofluorescence 
and (F) merged without fluorescence. As shown in E and F, the spectral analysis has appreciably 
reduced the autofluorescent background. Co-localization analysis of eYFP and FSP1 showed that 
in the cells of the border zone, there is limited overlapping expression of FSP1 and eYFP. (F) 
Some cells express only FSP1 (highlighted by white arrows) and some co-express FSP1 and 
eYFP (highlighted by the blue arrows).  
 
 The pattern of eYFP/FSP1 and eYFP/vimentin expression in the border zone 5.2.6 
and the infarct region 
After removing the autofluorescence from the samples, I observed that majority of FSP1, 
vimentin and eYFP, do not co-localise in the same cells in the infarct region. However, 
there was a significant increase in the numbers of cells that (individually) expressed these 
markers. These results are in agreement with Schneider et al. (2007), who showed that in 
normal rat and human hearts, FSP1 primarily co-localizes with markers of fibroblasts 
such as vimentin[156]. However, in hypertrophy induced by aortic banding, or stenosis or 
MI, FSP1 expression increased and macrophages and leucocytes within the infarct region 
stained strongly for FSP1[156]. Figure 5-8 illustrates the low level of eYFP/FSP1 or 
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eYFP/vimentin co-expression in the infarct regions of Col1a2 CreERT; Rosa26-floxed 
STOP eYFP mice. 
        
 
Figure ‎5-8 Co localisation of FSP1 or vimentin with eYFP in the infarct region of Col1a2 
CreERT; Rosa26-floxed STOP eYFP mice, two weeks after MI. (A1-A4), a representative 
infarct region stained with anti-FSP1 antibody (red), anti-YFP (green) and nuclei stained with 
Dapi. (A1) Dapi, (A2) FSP1, (A3) eYFP and (A4) Merged. (B1-B4) a representative infarct 
region stained with anti-YFP (green), anti-vimentin (red). All mice and hearts were treated and 
processed as described in section 2.11. (B1) Dapi, (B2) vimentin, (B3) eYFP and (B4) merged. 
Autofluorescence in these images are removed by spectral unmixing, using confocal 
microscopy. The inset in image B4 is a no primary control from the infarct region. Co-
localization analysis of eYFP/FSP1 or vimentin in the infarct region showed that the majority of 
cells do not co-express FSP1 and eYFP nor vimentin and eYFP. Scale bar = 50 µm.
vimentin/eYFP FSP1/eYFP 
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Table ‎5-2 (A) The mean proportion of FSP1 and eYFP expression in Col1a2 CreERT; 
Rosa26-floxed STOP eYFP mice of infarcted hearts. The table represents the summary of 
three independent quantifications of cells in each experimental group. Figures in the table are 
the percentage ± SEM of each cell type from 15-20 microscopic fields (10-12 sections) 
normalized to the total number of Dapi-positive nuclei. The summaries of one-way Anova tests 
showing the significance difference between the groups and the p values from the post-hoc 
(tukey) test on the experimental groups are shown in table B. The significant values are 
highlighted in red. The expression of fibroblast markers significantly increased in BZ and IR of 
MIs in comparison to RR. RR: remote region, BZ: border zone, IR: infarct region, 1W: 1 week 
post-MI, 2W: 2 weeks post-MI. 
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Table ‎5-3 (A) The mean proportion of vimentin and eYFP expression in Col1a2-CreERT; 
Rosa26-floxed-STOP-eYFP mice of non-infarcts and MI models. Figures in the table are the 
mean percentage ± SEM of each cell type from 15-20 microscopic fields (10-12 sections)  
normalized to the number of Dapi-positive nuclei per field of view. The summaries of one-way 
Anova tests showing the significance difference between the groups and the p values from the 
post-hoc (tukey) test on the experimental groups are shown in table B. The proportions of eYFP, 
vimentin and eYFP + vimentin-expressing cells increase significantly in BZ and IR of MIs in 
comparison to RR. 
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Table ‎5-4 Evaluating the efficiency of Col1a2 CreERT; Rosa26-floxed STOP eYFP 
transgenic mice in terms of eYFP co-localisation with FSP1 or vimentin in vivo. (A) The 
table depicts the co-expression of two fibroblast markers; FSP1or vimentin with YFP in healthy 
and MI mice from the atria and ventricles. Data show the mean percentage of eYFP cells which 
express FSP1 or vimentin and conversely. Each number is the mean number of cells ± SEM, 
which is taken from 15-20 microscopic fields (10-12 sections). As shown in (A) approximately 
30% of FSP1 fibroblasts from the normal atria and ventricles expressed eYFP, whilst 
approximately 40% of vimentin positive fibroblasts expressed eYFP, suggesting that the 
majority of FSP1 and vimentin-expressing cells did not express eYFP in healthy hearts. 
However, following MI, the co-expression of both markers with eYFP significantly reduces in 
IR in comparison to the RR. (B) The summary of one-way Anova showing the significance 
difference between the groups (table A) and the post-hoc test on the experimental groups shown 
in table B. (Abbreviations: RR: remote ventricular region, BZ: border zone, IR: infarct region, 
1W: 1 week post-MI, 2W: 2 weeks post-MI). 
 
 Quantification of CFs in healthy and MI hearts and assessing eYFP co-5.2.7 
staining with FSP1 or vimentin 
To summarise, the efficiency of Col1a2 CreERT; Rosa26-floxed STOP eYFP mice in 
CF lineage tracing and the calculation of the proportion of eYFP, FSP1, vimentin, 
eYFP/FSP1 and eYFP/vimentin were performed manually from 15-20 microscopic 
fields for each marker, taken from each mouse (x60 magnification from different 
regions of the atria and ventricles). As different regions in an infarcted heart (remote 
region, border zone and infarct region) contain different cell density therefore, I tried to 
take images from the regions which contained fairly similar cellular number in order to 
make sure that cell density has not a big impact on the final quantifications. Also the 
number of quantified cells for each marker were normalised to the total cell number 
(determined using Dapi positive nuclei per field of view). To assess the significant 
difference between the groups one-way Anova followed by post-hoc Tukey tests were 
performed. Three experimental groups from Col1a2 CreERT; Rosa26-floxed STOP 
eYFP mice are given below: 
1. Healthy mice (n=6) 
2. 1 week post-MI (n=4) 
3. 2 weeks post-MI (n=3) 
In order to assess the efficiency of the STOP codon on Rosa26-floxed-STOP-eYFP mice 
3 control groups were studied as follows. 
1. Healthy mice (n=3) 
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2. 1 week post-MI (n=1) 
3. 2 weeks post-MI (n=1) 
In Rosa26-floxed-STOP-eYFP healthy and MI controls no eYFP expression was 
observed in the heart tissue (figure 5-4 and 5-6), which validated the STOP codon 
efficiency to inhibit unspecific labelling of cells. Further analysis of eYFP, FSP1 and 
vimentin expression showed that there is no significant difference between the 
following groups: healthy atria; infarct atria; healthy ventricle; and remote region 
(tables 5.1-3, Figures: 5-3 and 5-5). However, significant differences were observed 
between the infarct region versus the remote region and also between the infarct region 
versus the border zone (table 5-2 and table 5-3). Cells that showed co-expression of 
eYFP and FSP1 or eYFP/vimentin in the infarct region and the border zone decreased 
significantly in comparison with the remote region and the healthy hearts (table 5-4). To 
summarise the fibroblast content of murine healthy and MI hearts, quantification of 
YFP expressing cells showed that the healthy atria, healthy ventricle, MI atria and the 
remote region contain almost the same levels of eYFP cells but in the infarct zone YFP-
expressing cells are significantly higher (table 5.2 A and 5.3 A). However, only 37.5% 
of collagen I expressing cells were activated to express eYFP using the Col1a2 
CreERT; Rosa26-floxed STOP eYFP transgenic mice. Therefore it is possible that the 
figures are an underestimate of collagen expressing fibroblasts that accumulate in the 
infarct zone. These results validated that CFs are heterogeneous and following 
myocardial infarction their proliferation rate increase significantly within the infarct and 
the border zone in comparison to the remote region.  
Although Col1a2 CreERT; Rosa26-floxed STOP eYFP was not efficient enough to 
detect all collagen 1 expressing cells in vivo, it could help us track cardiac fibroblasts 
and their derivatives at different stages of CDC culture.  
 
 eYFP expression at different stages of CDC culture 5.2.8 
Col1a2 has been shown to be an important type of collagen produced by CFs to form 
ECM, reviewed in [17], and it has already been shown that cardiac explants and Csphs 
express Col1α2 [78]. However there is some controversy over the extent of the CF 
contribution to CDCs. Therefore, having evaluated the efficiency of Col1a2-CreERT; 
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Rosa26-floxed-STOP-eYFP transgenic mice as a tool to track CFs in lineage-tracing 
experiments I investigated the contribution of CF derived cells (by eYFP expression) to 
EDCs, Csphs and CDCs. To this end, nine Col1a2-CreERT; Rosa26-floxed-STOP-eYFP 
mice (6-8 weeks old) were injected intraperitoneally with 2 mg tamoxifen per day, over 
5 days. After 48 hours following the last injection, mice were euthanized by cervical 
dislocation and the hearts were dissected. Atrial explants were cultured on fibronectin-
coated plates. To investigate the contribution of potential fibroblasts to EDCs, Csphs 
and CDCs I used confocal microscopy to analyse eYFP expression. However, I first had 
to resolve the problem of cell autofluorescence in cardiac explants and Csphs. Using the 
spectral unmixing option of the confocal microscope I digitally removed the 
autofluorescence from the cardiac tissue and phase bright cells. Figure 5-9 depicts a 
representative cardiac explant before and after the removal of autofluorescence. 
Detailed analysis of atrial explants from nine Col1a2-CreERT; Rosa26-floxed-STOP-
eYFP mice revealed that phase bright cells do not express eYFP, but stromal cells which 
grow underneath the phase bright cells do express eYFP. To quantify the proportion of 
cells expressing YFP, all EDCs (stromal cells and phase bright cells) were harvested 
with enzymatic digestion after 3 weeks of EDC culture and eYFP expression was 
assessed by FACS. These results showed that 9-11.5% of EDCs express eYFP. 
However, when considering the efficiency of the transgenic model the number of YFP-
expressing cells in the EDC stage would be approximately 28-30%. The FACS data are 
derived from 4 independent experiments and presented as the mean percentage of 
eYFP-expressing cells ± SEM.  
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Figure ‎5-9 eYFP expression in EDCs and Csphs cultured from the atria of Col-CreERT; 
Rosa26-floxed-STOP-eYFP mice. eYFP expression was monitored by confocal microscopy 
with the additional white transmitted light option. High levels of autofluorescence were 
identified and removed using the spectral unmixing option of the confocal microscope. (A) A 
cardiac explant from Col-CreERT;Rosa26-floxed-STOP-eYFP mice with autofluorescence, 
indicated by the red colour. (B) The same explant after removing autofluorescence; and (C) 
eYFP is only expressed in stromal cells and not in phase bright cells. (D) Transmitted light 
image of phase bright cells (day 14). (E) Csphs showing autofluorescence (red) and eYFP (day 
7). (F) eYFP expression in Csphs after removing the autofluorescence. (G) eYFP-expressing 
cells inside the Csphs. (H) Csphs imaged with transmitted light only. (I,J) After week 3, EDCs 
were enzymatically detached and eYFP expression was assessed by FACS. (I) eYFP expression 
is absent in EDCs prepared from C57BL/6 control mice. (J) eYFP expression in EDCs (at week 
3 of culture)  prepared from Col-CreERT; Rosa26-floxed-STOP-eYFP mice shows that 9-11.5% 
of EDCs express eYFP. This experiment was repeated four times independently and results 
presented as percentage eYFP expressing cells± SEM. Scale bar = 500 µm. 
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Having observed eYFP expression in Csphs after 7 days of culture (Figure 5-9), I next 
tried to evaluate how this occurred over time, and how early eYFP
+
 cells were recruited 
to the Csphs. Following Cre-recombinase activation in adult Col1a2 CreERT; Rosa26-
floxed STOP eYFP mice (age 8 weeks) with tamoxifen treatment, Csph culture was 
performed and eYFP expression was analysed with confocal microscopy over 2 weeks. 
Interestingly, the results showed that some cells inside the Csphs clearly express eYFP 
from the earliest stages of Csph formation and were seen at day 4. Figure 5-10 depicts 
eYFP expression in Csphs at day 4 (A,B,C) and day 14 (D,E,F) of culture. 
 
Figure ‎5-10 eYFP expression in Csphs derived from Col1a2 CreERT; Rosa26-floxed STOP 
eYFP mice. Csph culture from atrial explants from Col1a2 CreERT; Rosa26-floxed STOP eYFP 
mice after intraperitoneal injections (2 mg) of tamoxifen once per day over five days. After 48 
hours from the last injection the hearts were removed and the atria were cultured as cardiac 
explants. After 3 weeks the EDCs were removed by enzymatic digestion and plated at 10
5
 cells 
per well of a 24-well plate. eYFP expression was assessed from day 4 to day 14. The images in 
this figure show phase contrast and YFP fluorescence from Csphs at day 4 (A-C) and 14 (D-F) 
of culture. Images in B and E show eYFP expression in Csphs at day 4 (B) and day 14 (E); and 
in merged channels at day 4 (C) and day 14 (F). eYFP was expressed in all stages of Csph 
culture and indicates that Csphs contain fibroblasts or fibroblast-derived cells. This experiment 
was repeated 3 times independently. Scale bar = 500 µm. 
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 eYFP+ EDCs from atria are able to form Csphs 5.2.9 
Having shown that Csphs contain eYFP expressing cells, I next considered whether a 
pure population of eYFP expressing cells could form Csphs. Therefore, I compared 
Csph formation from YFP
+ 
versus YFP
-
 EDCs. In order to do this, EDC culture was 
preformed from 6-8 week old Col1a2-CreERT; Rosa26-floxed-STOP-eYFP mice 
following tamoxifen injection (please see section 2.11.1). After 3 weeks of culture, 
EDCs were disassociated and FACS sorted based on eYFP expression. Thereafter, 
eYFP
+
 and eYFP
-
 EDCs were placed at the same seeding density (10
5 
cells/well of a 24 
well plate) in CGM in three separate wells and cultured for 2 weeks. Interestingly, the 
results showed that eYFP
-
 EDCs formed significantly more Csphs than eYFP
+ 
EDCs, 
yet eYFP
+ 
EDCs also made Csphs but significantly lower numbers than eYFP
-
 EDCs. 
As shown below (figure 5-11,C) eYFP
- 
EDCs made 26-93 Csphs and eYFP
+
 EDCs 
made 19-47 Csphs after 2 weeks of culture per well. However due to the heterogeneity 
of cardiac fibroblasts and incomplete activation of all collagen expressing cells using 
the eYFP reporter, it is likely that the eYFP
-
 fraction of EDCs still contain significant 
number of cardiac fibroblasts.  
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Figure ‎5-11 Evaluating the potential of eYFP+ versus eYFP- EDCs to generate Csphs. A 
summary of four independent experiments showing Csph number from eYFP
-
 EDCs (grey bars) 
and eYFP
+
 EDCs (Green bars). 10
5
 sorted EDCs were seeded in three different wells of a 24-
well plate from each biological replicate and fully formed Csphs from both eYFP
+
 and eYFP
-
 
cells were quantified at day 14. In three replicate experiments, eYFP
-
 EDCs generated more 
Csphs than their eYFP
+
 counterparts. However, in a fourth experiment no significant difference 
was observed between the two groups. (A) Csphs formed from eYFP
-
 EDCs and (B) Csphs 
formed from eYFP
+
 EDCs. Data analysed using student unpaired t test. (* Denotes p<0.05). 
C)This experiment was repeated 4 times independently and results are presented as the mean 
number of Csphs ± SEM formed at day 14. Scale bar = 500 µm. 
 
 eYFP expression in passage 2 CDCs derived from Col1a2CreERT; Rosa26-5.2.10 
floxed-STOP-eYFP mice 
So far my experiments showed that CF-derived cells are present in standard EDCs and 
Csph cultures. As passage 2 CDCs have been used frequently in this research and 
regenerative studies of the heart, it will be very useful to evaluate the fibroblast content 
of P2 CDCs. Previously, I observed that Sca-1 expression in CDCs increases by 
extending the passage number (please see section 4.2.11). This could be due to 
increasing passage numbers leading to increased fibroblast sub-populations of CDCs, as 
it has been shown that in wound healing, PECAM
+
/Sca1
+ 
vascular cells proliferate and 
transform into αSMA+ myofibroblasts and αSMA expression was detected in 17% of 
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Sca-1
+
 and 4.5% of PECAM1
+
/Sca1
+
 cells[157]. Therefore, it is likely that some sub-
populations of CDCs which express Sca-1 could also express fibroblast markers such as 
Col1α2. In this respect, co-expression analysis of stem cell markers (Sca-1 or cKit)  and 
eYFP in P2 CDCs could provide valuable information on the cell identities of CDCs. 
Using FACS immunophenotyping, P2 CDCs derived from the atria of 6-8 weeks old 
Col1a2 CreERT; Rosa26-floxed STOP eYFP mice were assessed for co-expression of 
endogenous eYFP with cKit and Sca-1. FACS results showed that 8.3-12.9% of P2 
CDCs express eYFP. Although I observed variability in eYFP-expressing CDCs in 
different culture preparations, it appears that eYFP CDCs are slightly distinct from Sca-
1 and cKit-expressing cells as the majority of Sac-1
+
 cells and cKit
+
 cells were negative 
for eYFP. Figure 5-12 depicts a representative FACS analysis of P2 CDCs from Col1a2 
CreERT; Rosa26-floxed STOP eYFP mice and shows that 0.7-1.2% and 2.3-6.3% of 
CDCs are cKit
+
/YFP
+
 and Sca-1
+
/YFP
+
 respectively. Table 5-5 summarized the results 
of three independent analyses. 
To elucidate what percentage of Sca-1
+
 and cKit
+
 CDCs express eYFP, I further 
analysed these CDC sub-populations and observed that   19.6% and   10.3% of Sca-1+ 
and cKit
+
 CDCs express eYFP, respectively. Figure 5-13 illustrates the percentage of 
Sca-1 and cKit CDCs at passage 2 which express eYFP. However, considering the 
efficiency of the Col1a2 CreERT; Rosa26-floxed STOP eYFP transgenic mouse model 
the figures are likely to be higher. 
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Figure ‎5-12 eYFP+, eYFP+Sca-1+ and eYFP+cKit+ cells in P2 CDCs from Col1a2 CreERT; 
Rosa26-floxed STOP eYFP mice. Mice received 2mg interaperitoneal injections of tamoxifen 
over 5 consecutive days. CDCs from the atria were expanded until passage 2 and then analysed 
for expression of eYFP, Sca-1 and cKit. Histogram (A) shows P2 CDCs from C57BL/6 mice 
used as a negative control for FACS analysis and confirm no YFP expression. Histogram (B) 
shows that 9.5±2.2% of P2 CDCs express eYFP. Dot plots (C) and (D) show the proportion of 
CDCs that co-express eYFP with Sca-1 (4.2±1.3%) and eYFP with cKit (0.7±0.21%) 
respectively.  
 
 
Table ‎5-5 A summary of three independent FACS experiments for eYFP, Sca-1 and cKit 
expression in P2 CDCs from Col1a2 CreERT; Rosa26-floxed STOP eYFP mice. Results are 
presented as the mean percentage of the total analysed CDCs per experiment ± SEM. *Denote 
run is depicted in figure 5-12. 
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Figure ‎5-13 The proportion of Sca-1+ and cKit+ CDCs which express eYFP in P2 CDCs 
cultured from Col1a2 CreERT; Rosa26-floxed STOP eYFP mice. A summary of three 
independent FACS analyses, showing the proportion of Sca-1- and cKit-expressing CDCs that 
also express eYFP. Results showed that the majority of Sca-1- and cKit-expressing CDCs do 
not express eYFP. 
 
 eYFP expression (derived from Col1a2 CreERT; Rosa26-floxed STOP eYFP 5.2.11 
mice) increases by extending CDC passage number  
I observed that 8-13% of P2 CDCs derived from the atrium of 6-8 week-old Col1a2 
CreERT; Rosa26-floxed STOP eYFP mice express eYFP. However, it would be interesting 
to assess if passaging CDCs could change the proportion of eYFP-expressing cells in 
CDCs. To this end CDCs from Col1a2 CreERT; Rosa26-floxed STOP eYFP mice were 
cultured for 4 passages and eYFP-expression was analysed with FACS at two time 
points. The results showed that eYFP-expression increased in P4 CDCs (12.9± 0.2%) in 
comparison with P2 (9.7±0.4%) (p<0.05 student t test was performed on 3 technical 
replicates). However, my experiment was performed only once and further biological 
replicates are necessary to validate this finding. Figure 5-14 depicts the effect of cell 
passaging on eYFP expression in P2 and P4 CDCs. 
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Figure ‎5-14 The effect of cell passage on eYFP expression in P2 and P4 CDCs derived 
from Col1a2 CreERT; Rosa26-floxed STOP eYFP mice. CDCs cultured from Col1a2 
CreERT; Rosa26-floxed STOP eYFP following Tamoxifen injection (section 2.11.1) and the 
expression of eYFP was measured with FACS. Histogram (A) depicts C57BL/6 P2 CDCs used 
as negative control for eYFP expression. (B) and (C) eYFP expression in P2 and P4 CDCs with 
9.7±0.4% and 12.9±0.2 respectively. The results showed an increase in the proportion of eYFP-
expressing cells in P4 CDCs in comparison with P2 CDCs. However, this experiment was done 
only once and more replicates are necessary to validate these findings. 
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 Discussion 5.3 
My studies in this chapter confirmed that murine hearts contain significant number of 
CFs, therefore it is likely that any cell culture of unselected cells from the heart tissue 
could potentially include considerable quantities of CFs. In this respect, CDC culture 
from cardiac explants is no exception, thus it is important to assess the quantity of CF in 
CDCs. As the rate of fibrosis in the infarct region of the myocardium dramatically 
increases, reviewed in [17], in any cell transplantation study for heart repair it is crucial 
to evaluate the CF content of the donor cells because, if the donor cells contain high 
levels of fibroblasts, this could potentially enhance the fibrosis process in the recipient 
heart. In the work described in this chapter, I tracked the potential CF content of CDC 
culture using transgenic Col1a2 CreERT; Rosa26-floxed STOP eYFP mice, in which a 
eYFP reporter is expressed by the Col1a2 promoter, which corresponds partially 
(37.3±2.1% efficiency) to collagen type 1 expressing cells in the heart (Figure 5.2). To 
identify CFs in the heart, I used FSP1 and vimentin immunostaining. FSP1 and 
vimentin have been reported to be useful markers for CF detection, reviewed in [15]. 
Immunohistochemical assessment of single staining for eYFP, FSP1 or vimentin 
showed that there was no significant difference between the atria and ventricles in the 
numbers of cells showing expression of these markers, which suggests that murine atria 
and ventricles share a similar fibroblast content (table 5-1). The manual quantification 
of total fibroblasts, which was obtained by adding eYFP with FSP1 or Vimentin 
normalised to the total number of cells per microscopic field showed that the atria and 
ventricles have fairly similar fibroblast content (34-36%) (table 5-1). However, co-
localisation analysis of eYFP and FSP1 or vimentin showed that our transgenic mouse 
model is not able to detect all of the other cardiac fibroblast sub-populations in vivo. 
Detailed immunohistochemical analysis of the atria and ventricles from healthy murine 
hearts showed that  30% of FSP1 and 39-42.3% of vimentin-expressing cells were 
labelled with eYFP and, conversely, almost 56% and 58-60% of eYFP cells were 
stained positive for either FSP1 or vimentin respectively (table 5-4).   
There are several reasons which could possibly explain why this model failed to label 
the majority of cardiac fibroblasts: 
The discrepancy between eYFP and FSP1 or eYFP and vimentin-expressing cells seen 
in this chapter could be due to the fact that CFs are heterogeneous cells originating from 
different sources and the fibroblast markers which are being used in CF studies are also 
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involved in other pathways. For instance, FSP1 is shown to be up regulated during 
neuronal differentiation [158], cell motility [159], angiogenesis [160,161], 
cardiomyogenesis [161] and heart repair [156]. It has also been shown that FSP1 is 
expressed in carcinoma cells [162] and macrophages [156]. On the other hand, 
vimentin, which was initially described as an endothelial cell marker [163], is also 
expressed in pericytes and myoepithelial cells [163,164], yet FSP1 and vimentin have 
been widely used to detect cardiac fibroblasts. Collagen 1 is shown to be expressed in 
fibroblasts, osteoblasts and odenoblasts, and its regulation is controlled by different 
genomic regions, reviewed in [165]. The collagen 1 promoter has numerous tissue-
specific transcription activation sites located at different distances from the 5’ 
transcription start site. Some enhancer sites are even located 19.5 Kb upstream to the 
transcription site. In Col1a2 CreERT; Rosa26-floxed STOP eYFP mice a region, which 
was     -19.5-kb to -13.5-kb upstream of the transcription start site, was used to make 
this transgenic line [110]. It is yet possible that part of the heart’s tissue-specific 
enhancer of the Collagen 1 promoter was not included so leading to incomplete 
activation of the Col1a2 promoter in all CFs. According to the authors this enhancer 
derives Col1α2 in fibroblasts, as CFs in the hearts are believed to be heterogeneous; it is 
yet possible that this enhancer is only active in a subset of CFs. 
Another potential reason for the lower than expected proportion of YFP+ CFs seen in 
the healthy hearts (from tamoxifen-activated Col1a2 CreERT; Rosa26-floxed STOP 
eYFP mice) examined in this chapter is due to the incompletely ubiquitous expression 
of the Rosa26 allele. Although the Rosa26 promoter is generally considered to be 
ubiquitously expressed, it is possible that Rosa26 has less activity in CFs. It is also 
possible that a proportion of cardiac fibroblasts have silenced their Rosa promoter by 
methylation mechanisms in Col1a2 CreERT; Rosa26-floxed STOP eYFP mice which 
made it undetectable. Therefore, it would be interesting to assess the methylation status 
of CFs. Consequently, it would be useful to assess the expression of Rosa promoter and 
its epigenetic status in vitro in the CF cell culture. This will assist us in deciding which 
lineage-tracing mechanisms could be optimal to track cardiac fibroblasts. To activate 
Cre-recombinase I used the established protocol in my host laboratory with five 
consecutive IP injections of 2mg tamoxifen. It is possible that the amount of Cre-
recombinase activation was below the threshold required to activate the eYFP reporter 
in all CFs. Therefore, further optimisation of tamoxifen injection in Col1a2 CreERT; 
Rosa26-floxed STOP eYFP mice may be necessary. 4-hydroxytamoxifen is one early 
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functional metabolite of Tamoxifen with more activity [166]. It would be interesting to 
see whether the administration of 4-hydroxytamoxifen enhances Cre recombinase 
activation.  
 
 Myocardial infarction causes autofluorescence in the border zone and in the 5.3.1 
injured region 
Immunohistochemical analysis of infarcted heart sections from Col1a2 CreERT; 
Rosa26-floxed STOP eYFP mice showed that the border zone and infarct region have 
high levels of tissue autofluorescence, which might be mistaken for an enhanced 
expression of any fluorescent reporter. To distinguish between the real eYFP, FSP1 and 
vimentin expression in the border zone and the infarct region, I used spectral unmixing 
with confocal microscopy. Although this approach reduced endogenous 
autofluorescence in the border zone and the injured regions, I observed that there 
remained some unidentified fluorescent spectra. As shown in the literature, tissue 
autofluorescence is either intrinsic (tissue type) or caused by tissue processing with 
different reagents [167]. In one study, researchers showed that the accumulation of 
lipofuscin granules and collagen fibres in skeletal muscles could cause autofluorescent 
artefacts. These cellular wastes are formed due to cell senescence and oxidative stress 
[168]. Therefore, autofluorescence is likely to be inevitable after MI, but it would be 
interesting to see if treatment with sudan black on the myocardial sections could reduce 
the autofluorescent level. It has been shown that treatment of the paraffin section of 
myocardial samples with sudan completely removed the autofluorescence from 
cardiomyocytes [167]. This could be accompanied with spectral unmixing with confocal 
to reduce further the level of autofluorescence.  
 
 Co-localisation of FSP1 and vimentin with eYFP in the border zone and the 5.3.2 
infarct region 
During my investigations of eYFP and FSP1, and vimentin expression from the healthy 
hearts, remote regions, the border zone and the infarct regions, I noticed that eYFP and 
FSP1 or eYFP and vimentin show incomplete co-localisation. To some extent my 
finding is partially in agreement with a previous study showing no co-localisation of 
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FSP1 and Collagen 1 in myofibroblasts in the fibrotic kidney; their study concluded that 
FSP1 was a poor marker to detect Collagen 1 expressing cells in the fibrotic kidney 
[169]. However, I noticed that following MI the expression of these fibroblast markers 
(eYFP, FSP1 and vimentin) significantly increases in the infarct region and border zone 
in comparison with the remote region and healthy hearts (see tables 5-1, 5-2 and 5-3). 
My finding is in agreement with work of other investigators. For instance, it has been 
shown that myocardial injury (MI or aortic banding) increases FSP1 protein expression 
1.8-5.9 fold in comparison with sham operated groups [170,171]. My results also 
showed that following MI the number of total CFs (eYFP, FSP1 and vimentin-
expressing cells) significantly increases in the border zone and the infarct region in 
comparison with the remote ventricular region (tables 5-2 and 5-3). However, there is a 
difference between my results and those of Camelliti et al. [172] who showed that, 
following MI induction in sheep, vimentin density increases in the remote region. In 
contrast, I did not see a significant change in the CF content of remote regions and 
healthy controls (Tables 5-2 and 5-3). This could be due to the different species used in 
these two studies. As shown in table 5-4 the co expression of YFP and FSP1 or 
vimentin significantly decreased in the infarct region versus the remote region which 
suggests the invasion of non-CFs into the infarct region. Indeed, it is known that MI 
activates immune responses and invasion of macrophages into the infarct region, which 
express FSP1 [156] and vimentin [173]. However, to investigate the fibroblast 
contribution to heart repair further, it would be useful to assess the expression of 
macrophage markers such as (CD11b) and collagen following MI. 
There are some reasons that could potentially explain why not all eYFP cells stained 
with Collagen 1. (i) Un-specific activation of eYFP in some cells. Although I have 
always prepared biological controls from the Rosa26-floxed STOP-eYFP line in order to 
assess the specificity of eYFP expression to ensure that they are clear (no YFP 
expression), it is possible that in some cases eYFP has been activated un-expectedly and 
could have been detected as eYFP expression. (ii) Un-specific staining of Collagen 1 
antibody, although technical negative controls for primary and secondary antibodies 
have always been included in all of fluorescent staining, it is possible that some un-
specific collagen 1 staining has been detected and considered as a collagen 1 expressing 
cell .(iii) As I have quantified eYFP and Collagen 1 co-localisation in heart section with 
confocal microscopy, it is possible that I have missed a significant number of cells 
which co-express eYFP and Collagen1 in regions which have not been sectioned, 
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therefore assessing co-localisation of these two markers in single cells preps from 
freshly dissected healthy and infarcted Col1a2 CreERT; Rosa26-floxed STOP eYFP 
hearts with FACS could potentially reveal more accurate results.  
As shown in table 5-1 there is a considerable variation between the number of e-YFP 
and total fibroblast in two halves of the table. This variability is due to the fact that I 
used two different types of eYFP primary antibodies combined with either FSP1 or 
vimentin, in order to make compatible combinations of antibodies. However these 
results also suggest that neither of these anti-eYFP primary antibodies was fully 
efficient to detect all eYFP expressing cells. As discussed above several reasons could 
explain this incomplete co-staining between the antibodies such as; the heterogeneity of 
CFs (not all CFs express collagen-1) or the variable specificity of the antibodies used in 
this staining protocol. 
 
 Possible implications of MI experimental design on eYFP expression in CFs 5.3.3 
In this experiment the LAD ligation surgery was induced 7 days after the last tamoxifen 
injection and the hearts were dissected at 1 or 2 weeks post-MI. It is already known that 
in lineage tracing using the Cre-ER system, it takes just above 24 hours for Cre-ER to 
be detectable in the nucleus [174], although the authors reported variable time points for 
detecting labelled cells in different species following tamoxifen administration. 
Therefore, another approach is to administer tamoxifen after LAD ligation. It is likely 
that tamoxifen administration after surgery could increase eYFP localization within CFs 
with other fibroblast markers due to the fact that MI activates CF proliferation; so that 
recombination and eYFP accumulation may happen more efficiently in dividing CFs 
with active Cre-ER. Ideally, the Col1a2 CreERT; Rosa26-floxed STOP eYFP transgenic 
model could be improved. It would be better to reconsider the 5’ upstream region and 
assess if the sub-cloned region contains the heart tissue-specific transcription enhancer. 
As in the healthy myocardium and MI models, which had 2 and 7 days (respectively) of 
the window period between the last tamoxifen administration and heart dissection, the 
majority of CFs were not targeted with eYFP in both groups. This validates the 
consistency of the transgenic line in targeting Collagen 1 expressing cells. However, it 
would also be interesting to assess the expression of collagen receptors such as DDR2 
co-localisation with eYFP, this could possibly be more helpful than FSP1 and vimentin 
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in further assessing the efficiency of Col1a2 CreERT; Rosa26-floxed STOP eYFP in 
targeting CFs, as DDR2 is believed to be a collagen receptor, reviewed in [15].  
 
 Cardiac fibroblasts are able to form Csphs 5.3.4 
To investigate whether eYFP
+
 EDCs are able to form Csphs, I performed a Csph-
forming assay from FACS sorted eYFP
+
 and eYFP
-
 EDC populations and found that 
both groups are able to form Csphs, suggesting the CFs or their derivatives could form 
Csph. These results are in agreement with a previous study [152] which showed that 
colon-derived fibroblasts can form spheroid aggregates. However, eYFP
-
 EDCs did 
form more Csphs than eYFP
+ 
EDC, suggesting that either eYFP
-
 EDCs have a shorter 
doubling time or release cytokines which encourage cell accumulation and Csph 
formation. However having eYFP
-
 sorted cell fraction does not mean that they are 
fibroblast free cell population, as not all fibroblasts express Collagen 1 and not all 
collagen expressing cells were eYFP-positive in this study. Possibly sorting CDCs using 
alternative fibroblast markers (eg CD90) could tell us if fibroblast free CDCs are able to 
form Csphs. This would also emphasise the role of CFs in Csph formation and the 
consequences of CF depletion in terms of gene expression and cytokine production 
Csph biology. Although my findings indicate that Csph formation is not a very specific 
stem cell characteristic for CDC culture, it has previously been shown that Csphs 
contain more cKit
+
 cells  and express more stem cells related factors than monolayers  
[67]. It would be interesting to analyse and compare the growth factors released by 
eYFP
-
 and eYFP
+
 Csphs. Also it would be informative to perform a more complete 
immunophenotyping of CDCs derived from eYFP
-
 and eYFP
+ 
EDCs, as this will 
provide more information in terms of stem cell sub-populations of CDCs derived from 
CFs. Measuring cell proliferation in eYFP
+
 and eYFP
-
 Csph cells could show whether 
the rate of cell doubling positively influences sphere formation in eYFP
-
 Csph cells. 
 
 Evaluation of eYFP expression at different stages of CDC culture 5.3.5 
The validity of potential cardiac regeneration by Csphs has been questioned by one 
laboratory which suggested that Csphs are not a suitable source for cardiac stem cell 
expansion [78]. The authors divided Csph-forming cells into CD45
-
 and CD45
+
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phenotypes and showed that CD45
-
 CDCs express the fibroblast marker, collagen 1. 
Although these results have been criticized, based on variations of the techniques used 
to prepare Csphs, the possibility that CDCs could contain some fibroblasts still remains 
open. However, another study showed by immunostaining and confocal microscopy that 
CDCs derived from congenital heart patients were negative for collagen 1 [79]. 
Nevertheless, having fibroblasts in Csphs does not mean that they are incapable of 
cardiac regeneration. Equally, lacking fibroblasts does not mean that Csphs and CDCs 
are all able to differentiate to the other cell lineages. Also Smith et al. (2007) showed 
that the existence of mesenchymal cells in CDC culture could be beneficial for cardiac 
sub-populations by providing physical and secretory support [68]. As CDC biology 
aims to provide a sufficient source of cardiac progenitor cells, it is necessary that CDCs 
are characterised in more detail. In this respect, lineage tracing of CFs during three 
stages of CDC culture (EDCs, Csph, CDCs) could provide valuable information and 
provide a better view of CDCs for future experimental designs. Confocal analysis of 
EDCs from tamoxifen treated Col1a2 CreERT; Rosa26-floxed STOP eYFP mice 
showed that phase bright cells derived from explants are completely negative for eYFP 
expression, though approximately 10% of the stromal cells express eYFP (figure 5-9). 
As our lineage-tracing system could not target all the collagen 1 expressing cells 
(37.3±2.1% lineage-tracing efficiency) my interpretation is that there are more stromal 
cells that are derived from CFs and this may be as high as 27%. Previously, Andersen et 
al. (2009) showed by immunostaining that Csph-forming cells, and explant-derived 
cells overwhelmingly express collagen 1 [78]. To address this issue I further analysed 
eYFP expression in Csphs from Col1a2 CreERT; Rosa26-floxed STOP eYFP mice with 
confocal microscopy. My results showed that Csphs are highly autofluorescent and it is 
possible that the autofluorescence could be mistaken for an enhanced expression of any 
fluorescent reporter (figure 5-9). Although I observed some eYFP-expressing cells 
within the Csphs, the majority were eYFP negative (figure 5-11). This is in agreement 
with Li et al. (2010)[67], who indicated that Csphs resemble a microenvironment niche 
with stem cells and an extracellular matrix. Although Smith et al. (2007) [68] concluded 
that phase bright cells are the possible source of Csphs, Csphs can be formed by both 
phase bright and stromal cells. This implies that a type of biological selection which 
recruits collagen 1 expressing cells into Csphs happens during Csph culture. For 
instance, a growth factor released by the Csph microenvironment could attract collagen-
expressing cells. In this respect Li et al. (2010) showed by PCR array and 
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immunostaining that the expression of cell adhesion and ECM markers such as 
COL14A1, COL7A1 and ITGA2 was enhanced in Csphs in comparison with the 
monolayer culture [67]. However, we also need to consider the technical differences in 
Csph culture that could alter the fibroblast content. For instance, it is already shown that 
different approaches in Csph culture could cause significant differences in cardiosphere 
size, number and morphology [71]. As I used harsh enzymatic cell detachment at the 
EDC stage to harvest both stromal and phase bright cells, this could explain eYFP
+
 
stromal cell recruitment into Csphs. Although separating phase bright cells from stromal 
cells is technically very difficult, it would be interesting to assess eYFP expression in 
Csphs which form following a culture of either phase bright cells or stromal cells, 
independently.  
To assess the importance of different stages of CDC culture based on the proportion of 
fibroblast and stem cell content, it would be interesting to quantify the ratio of eYFP-
expressing cells and stem cell markers; this will allow us to focus on a specific stage of 
CDC culture in future functional experiments with a desired combination of fibroblast 
and stem cells in order to save time and increase cardiac progenitor cell efficiency.   
I also analysed the level of eYFP expression in CDCs by FACS and noticed that 8-13% 
of CDCs express eYFP. Therefore, no significant change was observed between the 
expression of eYFP in CDC and EDC (8-13% versus 9-11.5%) (Sections: 5.2.9-5.2.10). 
I also analysed eYFP co-expression with stem cell markers, cKit and Sca-1, and noticed 
that the majority of stem cell sub-populations of CDCs are distinct from eYFP-
expressing cells (figure 5-12). However, due to the limitations of our lineage-tracing 
method and possible influences of CDC culture on fibroblast-marker expression and 
phenotype, adding another CF marker such as DDR2 in FACS experiments could 
provide a better understanding of the CF contribution to different stages of CDC 
culture. Carr et al. [80] reported that 10±2% of rat-derived CDCs express DDR2, but 
the fibroblast content of mouse is likely to be different from rat as it is reported that 
approximately 27% of the cardiac cells were DDR2 positive whereas 56% of the cells 
were α-MHC+ (myocytes) [25]; conversely, the cellular populations of rat hearts were 
markedly different from the 70% non-muscle and 30% muscle cells [175]. Therefore, 
these data suggest that variations in cellular ratios which exist between species could 
generate different ratios of progenitor/fibroblast cells in CDC cultures. 
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I observed that preparing adult mouse CDCs takes a much longer culture time than 
neonatal CDCs (1 month neonatal and 2 months adult CDCs). Therefore, it is important 
to decide which passage number of CDCs is more suitable for cell delivery into the 
infarcted heart for regenerative proposes. Possibly quantifying the level of eYFP-
expressing cells together with a stem cell marker profile in CDCs at different passage 
numbers could help to decide which passage number contains a more balanced number 
of fibroblast and stem cells. Here I compared the level of eYFP-expressing CDCs in 
passages 2 and 4 and noticed that serial passaging increased eYFP-expression from 
9.7±0.4% at passage 2 to 12.9±0.2% at passage 4 (p<0.05). However, due to the 
efficiency of our lineage-tracing system (37.3±2.1%) these figures are expected to be 
higher. It would also be interesting to assess the functionality of CDCs which co-
express eYFP and Sca-1 or cKit at higher passages. For example, this could be done by 
assessing the clonogenicity, multilineage differentiation and angiogenesis potential of 
eYFP-expressing CDCs at different passages, and extend this analysis to YFP/cKit and 
YFP/Sca-1 CDCs. Therefore, we could score different passages: (i) based on the 
quantity of fibroblasts and stem cells; and (ii) the proficiency of cells in in-vitro and in-
vivo functional assays; and, finally, (iii) the ability to promote heart repair in MI 
models. 
In this chapter, by the application of lineage tracing, I showed that CFs contribute to 
Csphs and form sub-populations of CDCs. It is likely that collagen 1 expressing cells 
within the Csphs are derived from stromal cells and not from phase bright cells as I did 
not observe any phase bright cells expressing eYFP; however, unfortunately, the lineage 
tracing was not able to label the majority of CFs in vivo. Using FACS, I showed that 
stem cell populations of CDCs are partially distinct from collagen-expressing cells. 
However, I believe the fibroblast content of CDCs is likely to be higher than shown in 
this chapter. Based on the manual quantification that I have done, almost 30-42% of 
CFs (FSP1- or vimentin-expressing cells) were labelled with eYFP reporter in healthy 
hearts (tables 5-4). This chapter showed the potential of using lineage tracing to 
interpret the fibroblast content of the different sub-populations of EDCs and brought 
more evidence of a CF presence in Csphs and CDCs.  
In chapters 3 and 4, I showed that culturing CDCs in 3% O2 increases stem cell and 
endothelial sub-populations of neonatal and adult CDCs, but whether 3% O2 increases 
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the pro-angiogenic potential of CDCs in vivo is a question which I will address in the 
next chapter.   
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Chapter 6  Angiogenic potential of neonatal and 
adult CDCs in sub-dermal matrigel plugs 
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 Introduction 6.1 
Stem cell transplantation studies following a heart attack aim to establish a way to 
supply adequate blood to the affected myocardium and minimise the infarct size or to 
replace lost myocardial cells. In the former case, transplantation of CDCs and Csphs 
have been shown to be effective either by being involved in direct vascular 
differentiation or by enhancing the host progenitor cells to form new vessels (please see 
section 1.5.7). However, a major dilemma in CDC and any other stem cell 
transplantation studies is the low survival after transplantation into the infarct and peri-
infarct regions. Therefore, improving cell retention after transplantation is critical to 
enhance the efficiency of stem cell therapy. Hypoxia preconditioning has been shown to 
stimulate endogenous mechanisms resulting in multiple responses that protect against 
future lethal hypoxia such as reducing apoptosis and enhancing myocyte protection 
[138]. Studies have shown that hypoxia preconditioning of EDCs and CDCs markedly 
improves cell migration (in vitro) and cell recruitment into the ischemic myocardium 
(please see section 1.7.1). In chapters 3 and 4, I showed that the expression of stem cell 
(Sca-1, Abcg2), endothelial and angiogenic markers (Eng, Flk1, Vegf) increased 
significantly in CDCs preconditioned with 3% O2 for 48 hours. I also observed that 
preconditioning adult CDCs for 48 hours in 3% O2 elevates the level of secreted Vegf 
into the CDC media. It is possible that elevated levels of Sca-1, Abcg2, Eng, Flk1 and 
Vegf in CDCs treated with 3% O2 are critical for their pro-angiogenic potential.  
In order to test the ability of murine CDCs to promote neovascularisation in vivo I first 
established a mouse model of angiogenesis using subcutaneous injection of growth 
factor reduced matrigel combined with neonatal CDCs. CDCs were derived from CAG-
farnesyl-eGFP transgenic mice to enable the tracking of GFP-labelled CDCs in the 
matrigel plugs.  
The matrigel plug assay is an assay that does not require surgical procedures and allows 
for the screening of the potential pro-angiogenic state of different cells. Matrigel is an 
extract of the Engleberth-Holm-Swarm tumour and composed of basement membrane 
proteins that support neo-vessel formation. Microvasculature formation in the matrigel 
plug assay in vivo is a widely used angiogenesis assay. It mimics the formation of 
capillary networks in vivo and has advantages over other assays such as Suitable for 
large-scale screening and rapid quantitative analysis in chambers, reviewed in [176]. In 
this study adult CDCs treated with normoxia and 3% O2 were directly injected 
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subcutaneously with growth factor reduced matrigel and after two weeks the effect of 
CDCs on neovascularisation was assessed by detailed quantification of the vessel 
density in the matrigel using immunofluorescence and histochemistry. The technical 
approach used in this study is based on two papers from the Bischoff laboratory 
[177,178] who showed that the combination of human endothelial and mesenchymal 
cells promotes their angiogenic function more efficiently than using each cell type 
alone. 
 
 Results 6.2 
 Mouse model of angiogenesis using subcutaneous injection of CDCs 6.2.1 
I established a mouse model of angiogenesis using neonatal and adult CDCs to assess 
the vessel density inside the subcutaneous matrigel plug. Briefly, young adult (6 week 
old) C57BL/6 mice were selected as the recipients and CDCs from CAG-farnesyl-eGFP 
mice were passaged twice and mixed with matrigel before injecting the matrigel plug 
(300µl) subdermally in the flank regions. The use of CAG-farnesyl-eGFP mice allowed 
donor CDCs to be tracking using GFP expression as a marker. Two weeks later, the 
mice were humanely killed and the matrigel plugs were removed and processed to 
prepare cryosections to analyse angiogenesis (as described in section 2.12). One group 
of mice was given matrigel seeded with mouse lung endothelial cells (MLECS) as a 
positive control for in-vivo angiogenesis. As Melero-Martin et al. (2008) showed that 
the combination of mesenchymal cells with endothelial cells enhances their angiogenic 
and survival potential, in one of my experimental groups I combined CDCs (which have 
a high mesenchymal cell content) with MLECS (mouse lung endothelial cells) in the 
proportion of 40:60 to test if  CDCs could provide a  pro-angiogenic effect. Figure 6-1 
schematically depicts the experimental design, different stages of CDC preparations and 
injection of subcutaneous matrigel plugs. 
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Figure ‎6-1 Schematic depicting different stages of in-vivo angiogenesis with CAG-farnesyl-
eGFP CDCs derived from neonatal and adult hearts and transplanted sub-dermally with 
matrigel in C57BL/6 recipient mice. The figure depicts different stages of CDC culture and 
the duration of each stage for neonatal and adult CDCs, which were used in two separate 
experiments as summarised below. 
Experiment with neonatal CDCs: Neonatal whole hearts from 3-6 days old neonates were 
used to prepare CDCs at passage 2, which were injected subcutaneously with matrigel. Each 
mouse received 2 matrigel plugs (200 µl matrigel + 100μl PBS). Altogether four different 
groups were compared: 1) Matrigel; 2) Matrigel + CDCs (2x10
6
); 3) Matrigel + MLECS (2x10
6
) 
and 4) Matrigel + CDCs (8x10
5
) + MLECS (1.2x10
6
). Two weeks after the sub-dermal matrigel 
plugs were injected, the mice were humanely killed and plugs were dissected together with the 
surrounding skin and muscle. Tissue was frozen in OCT freezing medium on dry ice. From each 
plug 50 serial slides with 5-6 sections per slide were prepared, with each section of 10-25 µm 
thickness. Every fifth slide was stained with anti-CD31 antibody as an angiogenic marker. For 
quantification, any positive staining for CD31 inside the matrigel section was quantified 
manually and normalized to the matrigel section area. The average values for 8-10 slides from 
each plug were used to derive the microvessel density (MVD= vessels/mm
2
).  
Experiment with adult atrial CDCs: Angiogenesis was compared between the following 
groups: 1) Matrigel; 2) Matrigel + CDCs (2x10
6
) pre-treated with normoxia for 48 hours; 3) 
Matrigel + CDCs (2x10
6
) pre-treated with 3% O2 for 48 hours; 4) MLECS (2x10
6
); and 5) 
Matrigel + CDCs (8x10
5
) + MLECS (1.2x10
6
). In each group, cells were re-suspended in 
matrigel on ice and then transferred into the syringes. All syringes were kept on ice till they 
were injected. Plugs were injected in three sites per mouse – 2 in the flanks and 1 in the scruff. 
All plugs were dissected after 2 weeks and were fixed in 0.2% PFA overnight at 4°C and 
transferred to 30% sucrose, overnight at 4°C, and finally all plugs were frozen on dry ice in 
OCT freezing medium. Serial sections were made and MVD
 
assessed using image J software.  
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 Investigating the role of neonatal CDCs on in-vivo angiogenesis in 6.2.2 
subcutaneous matrigel plugs 
To test the ability of neonatal CDCs to contribute to angiogenesis, 2x10
6
 P2 CDCs were 
injected combined with growth factor reduced matrigel into the flank regions of 
recipient C57BL/6 mice. CDCs were re-suspended in 200 µl of matrigel; however, due 
to the technical difficulties with pipetting the matrigel, I further added 100 µl of PBS in 
order to dilute the matrigel. All syringes were kept on ice till the injection time and cells 
were in matrigel + PBS on ice for approximately 15-20 minutes prior to injection. 
Successful subcutaneous injections were obvious as no cell backwash was observed and 
the matrigel plugs were visible as slightly raised tissue in the flank following the 
injection, which indicated that the matrigel had solidified quickly following the 
injection.  
To ensure that CDC viability was not affected following the injection with insulin 
syringes, I used the ViCell automated cell viability analyser. This system uses standard 
trypan blue assay to measure viability. CDCs were incubated for 20 minutes in matrigel 
+ PBS mix and then passed once through the syringe, then the viability was assessed by 
ViCell. The analyser showed there was no significant difference between the viability of 
cells that passed through the syringe once and those that were not.  
 
Figure ‎6-2 Assessing the viability of neonatal CDCs after passing through an insulin 
syringe once. 2 x10
6 
P2 CDCs derived from neonates, re-suspended in 200µl of matrigel and 
100µl of PBS. Then the matrigel + PBS + CDC mixture passed once through an insulin syringe 
and the viability was measured with the ViCell analyser. As shown in the figure no significant 
difference was observed in the viability of CDCs passed through an insulin syringe once in 
comparison to those which were not. 
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 In-vitro expression analysis of GFP in P2 neonatal and adult-derived CDCs  6.2.3 
In order to confirm the expression of GFP in the candidate P2 CDC cultures derived 
from CAG-farnesyl-eGFP mice, I stained samples from one representative cell culture 
of P2 neonatal and adult CDCs and observed that eGFP was expressed significantly in 
the majority of CDCs (Figure 6-3). The validity of GFP expression in neonatal CDCs 
has also been shown by an independent researcher, Dr. Redgrave, who used FACS to 
quantify GFP-expressing CDCs at passage 2 and showed that 92.5±1.7% of CDCs from  
CAG-farnesyl-eGFP mice express eGFP. 
 
Figure ‎6-3 In-vitro expression of eGFP in passage 2 CDCs derived from CAG-farnesyl-
eGFP mice. Representative fluorescent microscopy image of passage 2 neonatal (A) and adult 
(B) CDCs showing eGFP expression from CAG-farnesyl-eGFP mice following immunostaining 
with a specific anti-GFP antibody conjugated to Alexa-488. This experiment was performed 
once for neonatal CDCs and once for adult CDCs. Scale bar = 100 μm. The inset image B is no 
anti-GFP control.     
 
 Neonatal CDC transplantation with matrigel-increased microvessel density 6.2.4 
(MVD) in recipient C57BL/6 mice 
10 slides (5-6 sections per slide) were prepared from matrigel plugs from 4 different 
groups (Matrigel, Matrigel + CDC, Matrigel + MLECS, Matrigel + CDC+ MLECS) and 
were stained with anti-CD31. The expression of CD31 was measured manually by 
quantifying CD31-expressing cells (any cell or cell-cluster showing CD31 expression 
within the matrigel was quantified as 1, without considering the size of the vessel) in all 
sections and normalized to the surface area of the matrigel to derive the mean of CD31 
expression per matrigel area. The CD31-expression difference was analysed by one-way 
ANOVA (<0.001) then the subsequent post-hoc Tukey test showed the significant 
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difference between the individual groups (table 6-1). Comparison of the vascularity 
between four groups showed that matrigel plugs with CDCs had significantly higher 
microvascular density compared to matrigel plugs alone (7.3-10 versus 1.6-2.7 
vessels/mm
2
). Also the MLECs group showed a higher vascularity level in comparison 
with CDCs alone (18.5-28.3 versus 7.3-10 vessels/mm
2
). Interestingly, mixing CDCs 
with MLECs resulted in the highest level of vascularity (34.3-45.2 vessels/mm
2
). Figure 
6-4 depicts a representative matrigel plug from each group showing CD31 
immunostaining, while table 6-1 summarizes MVD quantification per matrigel plug in 
each group.   
This experiment showed that sub-dermal injection of neonatal CDCs with matrigel 
results in an angiogenic response; however, the combination of CDCs with MLECs 
enhances the microvessel density, suggesting that CDCs may have a paracrine pro-
angiogenic effect. 
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Figure ‎6-4 Angiogenesis in subdermal matrigel plugs seeded with neonatal CDCs. Representative images showing CD31 expression in matrigel 
alone (A), CDCs + matrigel (B), MLECS + matrigel (C) and CDCs + MLECS + matrigel (D). The matrigel boundaries are indicated by dashed lines. 
CD31 expression in matrigel plugs is highest in the CDC + MLECS + matrigel group. The inset images of the region are indicated by the red arrow. As 
shown in (A) and (C) positive expression for CD31 is mostly in single cells but in (B) and (D) the staining revealed a neo-vasculature like structure. To 
quantify the number of vessels formed in the matrigel any positive staining was quantified inside the matrigel manually. The quantification was done 
twice and blindly on several slides with the microscope; random slides were analysed by an independent researcher and similar results were obtained. 
10-12 images (x5) were merged to generate each mosaic image. These data are representative of one experiment with 3 recipient mice per group. Scale 
bar = 1000µm. 
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Table ‎6-1 Summary of MVD assessment in Matrigel, Matrigel/CDC, Matrigel/MLECS 
and Matrigel/MLECS/CDC in subcutaneous plugs 2 weeks after neonatal CDC injection. 
Matrigel plugs were dissected following two weeks of injection and 50 slides made from each 
plug and every fifth slide was stained with CD31 antibody to identify endothelial cells. The 
figures in table (A) are mean MVD calculations which are a manual quantification of any 
positive expression for CD31 inside the matrigel and then normalised against the area of each 
matrigel. Table (B) is the post-hoc Tukey test for all 4 groups and table (C) shows the initial 
CD31 manual counts from several slides for each plug. MVD is the number of CD31 expressing 
cells/mm2 of matrigel. 
 
 Tracking eGFP+ neonatal CDCs in the neovasculature of the matrigel 6.2.5 
In order to allow donor cell tracking in matrigel plugs, CDCs were genetically labelled 
with eGFP using the CAG-farnesyl-eGFP line. In this line eGFP expression is 
controlled by the CAG promoter and the farnesyl group stabilises eGFP protein at the 
cell membrane. As the endogenous expression of eGFP was very difficult to detect, 
immunostaining using anti-GFP antibody was performed to test the expression of GFP 
in P2 CDCs in matrigel plug sections. Several cryosections from all four groups 
(Matrigel n=3. CDC+Matrigel n=3, MLECS+Matrigel n=3, CDC+MLECS+Matrigel 
n=3), approximately 8-10 sections per plug, were stained with anti-GFP antibody, 
directly conjugated with Alexa 488. No eGFP expression was observed in matrigel only 
(figure 6-6 C) or the MLECS+Matrigel group. In CDC+Matrigel and 
CDC+MLECS+Matrigel plugs, I observed very few GFP-expressing cells. To 
investigate whether any of these surviving CDCs had differentiated into vascular cells I 
performed double immunofluorescent staining for CD31 and GFP. Detailed analysis of 
different plugs (Matrigel+CDC, n=3 and Matrigel+CDC+MLECS, n=3) showed that 
very few GFP-expressing cells co-localised with CD31, suggesting a limited 
differentiation to endothelial cells. However, within one of the plugs (CDC+MLECS), I 
observed that some GFP-expressing cells were adjacent to a microvessel close to the 
border of the matrigel and occasionally some eGFP positive cells were co-stained with 
CD31 (figure 6-5). However, immunophenotyping experiments with neonatal CDCs 
showed that 4-16% of CDCs expressed CD31 and therefore it is possible these CDCs 
had been CD31 positive prior to the addition of these cells to the matrigel. I concluded 
that the vascular response achieved following neonatal CDC injection into sub-dermal 
matrigel plugs is likely due to paracrine mechanisms and that MLECs supports their 
angiogenic potential.  
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Figure ‎6-5 Fluorescent staining of GFP and CD31 in matrigel plugs injected with neonatal 
CDCs+MLECs. P2 CDCs were prepared from CAG-farnesyl-eGFP neonates (3-6 days) and 
together with MLECswere used to seed matrigel  in C57BL/6 recipient adult mice (6 weeks 
old). After 2 weeks the plugs were dissected and stained with anti-GFP and CD31 to test if any 
GFP expressing cells also expressed CD31. The majority of eGFP positive cells were not co-
expressing CD31. (A) Rare eGFP expressing cells ajacent to endothelial cells in the matrigel 
plug and (B) depicting co-localisation of eGFP and CD31 in a microvessel (highlighted with 
white arrows). Scale bars =50µm. 
 
 Investigating the effect of adult-derived CDCs CAG-farnesyl-eGFP 6.2.6 
preconditioned with normoxia and 3% O2 on in-vivo angiogenesis using matrigel 
plug assay 
My pilot studies with neonatal CDCs showed that neonatal CDCs enhanced 
vasculogenesis in matrigel plugs (n=3) compared to the group that received matrigel 
alone (n=3). As severe (0.1%) and physiologic (5%) hypoxic preconditioning of mouse- 
and human-derived CDCs has been reported to show some improvements in angiogenic, 
cell survival and cardiogenic potential [73,103], I assessed the angiogenic potential of 
CDCs that had been preconditioned with 3% O2 in the sub-dermal matrigel plug 
angiogenesis assay. Also because of the increased clinical relevance of adult (as 
opposed to neonatal) CDCs in heart repair, adult-derived CDCs were used for this part 
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of the study. As CDCs/MLECs combination enhanced the angiogenic response, I 
included the adult CDC+ MLECs group as before. 
To do this experiment, three plugs were injected into three sites of each C57BL/6 
recipient (two plugs were injected in the flanks and one in the scruff). Each study group 
was injected into one recipient mouse. Each plug contained 2x10
6
 cells (CDCs at P2 
stage or MLECs or CDC+MLECs) that had been re-suspended in 300µl of growth 
factor reduced matrigel (table 6-2). As I observed from the neonatal CDC study above, 
using PBS to dilute the matrigel led to a poor structure of the matrigel plug, I did not 
dilute matrigel with PBS in this experiment. Furthermore, in my previous experiments I 
noticed that matrigel plugs needed light fixation with 0.2% PFA and processing through 
30% sucrose to maintain good structure. Fixing the matrigel plugs with 0.2% PFA 
maintained the structure of the plug during the sectioning process and tissue 
destructions were avoided. This modification provided better slides and the empty areas 
within the matrigel which were evident in the neonatal CDC matrigel plug assay were 
resolved (freezing the plugs without fixation had resulted in a breakdown of the 
structure of the matrigel -compare matrigel structure in Figure 6-4 with 6-8). In 
addition, I assessed CDC survival by examining GFP expression in two protocols which 
have been used to prepare matrigel+cell suspension and tissue processing in adult and 
neonatal plugs (Figure 6-6).   
        
Figure ‎6-6 eGFP expression in matrigel plugs harvested immediately after sub-dermal 
implantation of CDC-seeded matrigel plugs in recipient mice. (A) adult CDC+ 300µl 
matrigel plugs (harvested 30 minutes after sub-dermal injection) fixed in 0.2% PFA, (B) 
neonatal CDC+ 200µl Matrigel + 100µl PBS (harvested 30 minutes after sub-dermal injection)  
fast frozen without fixation, (C) Matrigel only, (harvested 2 weeks after sub-dermal 
injection)(A) shows more efficient detection of CDCs in matrigel probably due to technical 
modifications applied to the sub-dermal matrigel plug implantation protocol in which the 
matrigel dilution step with PBS has been omitted and tissues were fixed with 0.2% PFA and 
30% sucrose and slow-frozen with OCT on dry ice. (B) Low numbers of eGFP
+ 
cells were 
detected in neonatal CDC seeded plugs, possibly due to the fragile texture of the plugs which 
had been fast-frozen without fixation. The inset image (C) is no primary control. Scale bar= 50 
µm. 
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Table ‎6-2 Number and type of cells injected with matrigel plugs in adult CDC 
angiogenesis study. 
  
 Adult CDCs led to increased microvessel density (MVD) in sub-dermal 6.2.7 
matrigel plugs in recipient C57BL/6 mice and preconditioning CDCs with 3% O2 
enhanced this process 
To compare the effect of normoxia and 3% O2 on adult CDCs pro-angiogenic potential, 
CDCs (at P2) were cultured in normoxia and 3% O2 for 48 hours. Initially, in chapter 4, 
I validated the hypoxic cell culture condition, by Hif-1α protein stabilisation and the 
level of secreted Vegf, which was compared in normoxia and 3% O2 preconditioned 
CDCs (shown in chapter 4: see Figure 4-2). However, in this chapter the level of Vegf 
in the supernatant of adult CDCs was also measured by Elisa assay. The results 
confirmed the data from chapter 4 and showed that 3% O2 treatment led to an increase 
in the level of secreted Vegf in the supernatant of P2 CDCs compared with normoxic 
CDCs (367±27 vs. 187±30 pg/ml of supernatant, p<0.005). 
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Figure ‎6-7 The level of Vegf protein supernatant of adult P2 CDCs cultured in normoxia 
and 3% O2. Adult P2 CDCs cultured in normoxia and 3% O2 with the same cell seeding density 
and same total volume of cell culture media. At 48 hours of CDC culture time point the same 
aliquot (250 µl) was used to measure the Vegf level using a commercial Elisa assay. The data 
clearly show that Vegf secretion from P2 CDCs cultured in 3% O2 is appreciably higher than 
CDCs cultured in normoxia. This experiment was repeated three times independently 
(*P<0.005). 
 
To assess the in-vivo angiogenic effect of 3% O2 and normoxia on adult CDCs, 2 x 10
6
 
P2 CDCs were injected sub-dermally in matrigel plugs and after 2 weeks, the MVD was 
assessed, based on the expression of CD31 in the matrigel plugs. Plugs were 
cryosectioned and every fifth slide stained with CD31 antibody. Ten sagittal 
cryosections for each plug were used to make mosaic images (one mosaic image made 
from one section, created by merging 6-10, x5 images) and then the MVD was assessed, 
based on the percentage area of the matrigel that was positive for CD31 staining, using 
Image J software and normalised to the surface area of the matrigel to derive the mean 
percentage area of CD31 expression in each plug. CD31 expression was initially 
assessed using one-way ANOVA and found to be significantly different between the 
groups (p<0.001) and the subsequent post-hoc (Tukey) test was used to show the 
significant difference between any two groups.    
Detailed analysis of CD31 expression in matrigel plugs showed that injection of adult-
derived CDCs pre-treated with 3% O2 resulted in enhanced CD31 expression compared 
to CDCs pre-treated with normoxia (5.1-6.5 versus 10.3-13.7, p<0.001). Furthermore, 
CDCs pre-treated with 3% O2 showed higher levels of CD31 expression in the plugs 
than MLECs alone (10.3-13.7 versus 6.3-7.5, p<0.001). All groups showed higher 
levels of CD31 expression in comparison to the matrigel-only group (p<0.001), showing 
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this was a donor cell mediated effect. However the highest MVD was observed in 
MLECS+CDCs with 14.7-16.8 MVD. 
These data suggest that although sub-dermal injection of adult-derived CDCs with 
matrigel enhanced the vascularity of the plugs, pre-treating adult CDCs with 3% O2 
resulted in significantly higher MVD. However, the combination of adult CDCs with 
MLECs showed the highest level of vascularity in the recipient plugs. The data show 
the potential angiogenesis of adult CDCs, but it is likely that pre-treating with 3% O2 or 
a combination with another group of endothelial cells may increase their pro-angiogenic 
potential. 
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Figure ‎6-8 Angiogenesis in matrigel plugs seeded with adult atrial CDCs, with and without pre-exposure to 3% O2. Representative 
immunohistochemical staining (brown) of three independent experiments (one animal was injected with three plugs) on matrigel plugs, showing the 
expression of CD31 in matrigel alone (A), CDC
N
O2/matrigel (B), CDC
3%
O2/matrigel (C), MLECS/matrigel (D) and CDC
N
O2 /MLECS/matrigel (E). 
The matrigel boundaries are indicated by dashed white lines. CD31 expression was assessed using image J software and normalised to the surface area 
of each plug. The matrigel plugs containing CDCs that were pre-treated with exposure to 3% O2 show higher levels of CD31 compared with normoxic 
CDC and matrigel controls. The strongest expression of CD31 was observed in the CDC
N
O2 /MLECS/matrigel group. The areas highlighted by arrows 
are magnified in the corresponding images below. 
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Table ‎6-3 Summary of MVD assessment in 1) Matrigel, 2) CDCNO2/matrigel, 3) 
CDC
3%
O2/matrigel, 4) Matrigel/MLECs and 5) Matrigel/CDC
N
O2/MLECs in 
subcutaneous plugs 2 weeks following sub-dermal implantation. In each group, each mouse 
received three plugs. MLECS also used as the positive control for the in-vivo angiogenic model. 
One mouse received three plugs of a combination of CDC and MLECS with matrigel in the 
proportion of 40:60 respectively. Matrigel plugs were dissected following two weeks, 50 slides 
made from each plug and every fifth slide was stained with anti-CD31 antibody to identify 
endothelial cells. MVDs were analysed using Image J software and MVD calculated after CD31 
staining was normalised against the matrigel area in each section. Results are presented as MVD 
from analysis of five sections from each slide one-way ANOVA (p=0.001) and the subsequent 
post-hoc (Tukey) test was used to show the significant difference between the pairs. 
 
 Tracking GFP positive adult CDCs two weeks following sub-dermal 6.2.8 
transplantation in matrigel plugs 
Transplanted adult CDCs were genetically tagged with GFP in order to allow tracking 
in vivo, in matrigel plugs. Several cryosections from all of the groups were stained with 
anti-GFP antibody. GFP-expressing cells were observed in all the plugs that were 
originally seeded with CDCs. No difference was observed in the pattern of GFP 
expression between these three groups. GFP-expressing cells within the plug were oval-
shaped (figure 6.9 D) and not associated with CD31-expressing cells. However, I 
observed some GFP/CD31 co-expressing cells in MLECS/CDC and 3% O2 pre-treated 
CDCs expressing cells very close to the vessels (figures 6-9 and 6-11). 
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Figure ‎6-9 Majority of eGFP positive adult CDCs do not express the vascular marker 
CD31. Cryosections of matrigel plugs seeded with 2x10
6 
adult atria-derived CDCs and were 
stained with anti-GFP-Alexa488 antibody (green) and CD31 antibody detected by a secondary 
antibody conjugated to Alexa 594 (red). The image shows the survival of eGFP positive adult 
CDCs 2 weeks following the injection of matrigel plugs. It is also clear that the majority of 
CDCs do not co-express CD31. Here in this image, from 62 eGFP-expressing cells only 5 cells 
(8%) were co-expressing CD31. Inset image D is no GFP and no CD31 primary negative 
control. 
 
To assess further whether transplanted adult CDCs co-express with endothelial and 
smooth muscle markers (CD31 and α-SMA), I stained 3 slides (4-5 sections) from 
CDC
N
O2, CDC
3%
O2 and CDC/MLECS plugs with anti-GFP antibody and CD31 
(conjugated with Alexa 594) and α-SMA (directly conjugated with Cy.3). 
Immunofluorescent analysis of the plugs showed that the majority of the GFP positive 
cells within the matrigel do not co-express CD31 or SMA (figures 6-10 & 6-11), 
although a limited number of GFP positive cells were also CD31 positive (figure 6.9 & 
6.11). These data suggest that the pro-angiogenic effect generated in matrigel plugs is 
likely to be due to paracrine mechanisms. Within one CDC
3%
O2 plug of three, I 
observed a number of eGFP positive cells that were accumulated around one big vessel 
(figure 6-11 A-D).  
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Figure ‎6-10 GFP positive adult CDCs do not co-express α-SMA within the vessels formed 
inside the matrigel. The cryo-section of a matrigel plug received GFP-tagged adult CDCs with 
MLECS, stained with anti-α-SMA antibody (directly conjugated to Cy3) and anti-GFP antibody 
(directly conjugated to Alexa 488). As shown in the figure CDCs do not express α-SMA and do 
not directly contribute to the neo-vessel formation. 
 
   
154 
 
 
Figure ‎6-11 eGFP and CD31 co-expression analysis in a CDC3%O2 plug (A-D) and 
CDC
N
O2 + MLECS plug (E-H) showing limited direct contribution of adult CDCs on 
neovascularisation in matrigel plugs 2 weeks after cell injection. Cryosections from 
CDC
3%
O2 and CDC
N
O2+MLECS plugs stained with GFP antibody (green) and CD31 antibody 
(red). Images A-D show that GFP positive cells co-stained with CD31 and the highlighted 
region with a white box in A is magnified in B-D. Images in E-H show co-localization of GFP 
with CD31 in single cells from a plug seeded with CDC
N
O2+MLECS. The inset H is no primary 
CD31 and No GFP negative control, Scale bar = 20 µm.  
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 CDC3%O2 matrigel implants showed more cytoplasmic protrusions than the 6.2.9 
other groups 
Skovseth et al. (2002) showed that after 10 days of harvesting human umbilical vein 
endothelial cells (HUVECs) with sub-dermal matrigel plugs, some cells showed 
cytoplasmic protrusions resembling pseudopods and then made cellular arrays, which 
then formed tubular structures and contained erythrocytes [179]. I also observed such 
structures, especially in CDC
3%
O2 plugs; interestingly, these cytoplasmic protrusions 
were not that obvious in CDC
N
O2 and CDC
N
O2+MLECS. In this respect it is known 
that ICAM-1 modulates endothelial cell migration and modifies the organization of the 
actin cytoskeleton. Furthermore, they showed that by adding ICAM-1 to ICAM-1-
deficient endothelium enhanced pseudopod formation [180]. It is also shown that 
hypoxia stimulates the expression of ICAM-1 in cultured human proximal tubular cells 
(HPTC) [181]. As shown in the figure 6-12 the elongated eGFP positive cells line up in 
cellular arrays and form cell-to-cell networks in which, occasionally, CD31 co-localised 
with eGFP. Figure 6-12 shows two representative images from CDC
N
O2 and CDC
3%
O2 
plugs forming pseudopods. 
To characterise and identify further the cellular component of the sub-dermal matrigel 
plugs and assess the immune response of the recipient mice to CDC transplantation 
(donor cells: CAG-farnesyl-eGFP and the recipients C57BL/6), I co-stained matrigel 
sections with GFP and CD11b (a marker which is expressed by monocytes, 
macrophages and natural killer cells). Results showed that CD11b shows two patterns of 
co-expression or ingestion of eGFP cells: (i) the majority of eGFP positive cells within 
the border of the matrigel express CD11b; but (ii) GFP positive cells within the middle 
of the matrigel were not positive for CD11b (figure 6-13). This possibly could be due to 
easier accessibility of eGFP cells for the immune system in the borders of matrigel than 
in the middle. 
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Figure ‎6-12 Cytoplasmic protrusions formed more efficiently in matrigel plugs which 
received CDC
3%
O2 than CDC
N
O2. Several cryosections from three different experimental 
groups (CDC
3%
O2, CDC
N
O2 and CDC
N
O2+MLECS) were analysed and stained with anti-GFP 
and CD31. As shown in (A) elongated cytoplasmic features known as cytoplasmic protrusions 
formed in CDC
3% 
O2 plugs are more obvious than in (B) CDC
N
O2 counterpart. (C) High power 
image from the red box highlighted in image A. (D) In some regions of CDC
3%
O2 plug close to 
the edges of matrigel, cytoplasmic protrusions co-express CD31 with eGFP. Scale bar = 50 µm. 
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Figure ‎6-13 The assessment of immune response within the matrigel plugs of the recipient 
mice using CD11b (macrophage marker) expression. Serial matrigel sections from 5 
experimental groups (CDC
N
O2, CDC
3%
O2, CDC
N
O2+MLECs, MLECs and matrigel only) were 
co-stained for GFP (green) and CD11b (red). The representative image (A) shows that the 
majority of eGFP-expressing cells within the border of matrigel plugs (in this case CDC
N
O2 + 
MLECs) are positive for CD11b. (B) However, in B, three GFP positive cells are in the middle 
of the matrigel which do not express CD11b. The immune response of the matrigel plugs was 
assessed using multiple CD11b immunostained sections -examples are shown in (C-G) of plugs 
harvested 2 weeks post-injection. Images (5-8 images from 3-5 sections per plug) taken from 
different regions: middle and close to border of the matrigel were analysed using image J 
software (red colour stained area, normalised to the matrigel region) and CD11b expression is 
shown per microscopic field (x20). Although subcutaneous cell injection with matrigel led to an 
increase in CD11b cells in the plug, no significant differences were observed between the 
CDC
N
O2, (E) CDC
3%
O2, (F) CDC
N
O2+MLECs and (G) MLECs alone groups. However, all cell 
innoculated plugs showed a very significant increase in the CD11b expression level compared 
to the matrigel-only group. Data were analysed using one-way ANOVA (<0.001) and the post-
hoc (Tukey) test was performed to identify significant differences between pairs of groups. 
Representative images of the plugs, (C) matrigel (n=3), (D) CDC
N
O2 (n=3), (E) CDC
3%
O2 (n=3) 
(F) CDC
N
O2+MLECS (n=3), (G) MLECS (n=3) and (H) no primary control. Scale bar = 50µm. 
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Table ‎6-4 The summary of immune response assessment with CD11b expression in CDCN O2, CDC
3%
 O2, CDC
N
O2+MLECS, MLECS and 
matrigel only after 2 weeks of cell transplantation. (A) All parameters are expressed as mean ± SEM, the table shows the mean CD11b expression 
derived for each group. (B) Data were analysed using one-way ANOVA (<0.001) and post-hoc (Tukey) test was performed to identify significant 
differences between pairs of groups.(n=3). As shown in (B) the matrigel-only group had the lowest level of CD11b expression among the others and the 
entire cell-receiving groups did not show any significant difference in CD11b expression.  
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 Perfusion analysis of microvasculature formed by adult CDCs cultured in 6.2.10 
normoxia and 3% O2 within sub-dermal matrigel plugs 
To analyse whether the new vessels formed by CDC are functionally perfused and 
whether there is any difference between the potential perfusion of the vessels formed by 
normoxia or 3% O2 pre-treated CDCs, a perfusion test with directly labelled isolectin 
(isolectin-Alexa 594) was performed. Three experimental groups were analysed for 
perfusion analysis: 1) matrigel alone; 2) CDC
N
O2; and 3) CDC
3%
O2. Each mouse 
received three plugs, two of the plugs injected into the left and right flanks and one in 
the scruff. On day 14 post-sub-dermal delivery of the matrigel plug, 50µg (prepared in 
100 µl of PBS) of isolectin directly conjugated with Alexa 594 was injected via the tail 
vein and the mice were humanely culled after 15 minutes. To assess whether adult 
CDCs are participating in the structure of functionally perfusioned vessels, several 
cryosections (8-10 per plug) were stained with anti-GFP antibody directly conjugated 
with Alexa 488. After fluorescent microscopy I observed perfused microvessels only in 
one plug, which contained CDCs pre-treated with 3% O2. This suggests the 
microvessels in the plug are immature and not connected to the main vascular network 
of the mouse. As expected there was almost no co–expression of GFP with isolectin 
within the matrigel plugs, although GFP positive cells were easily distinguished in 
neighbouring regions of the perfused vessels.   
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Figure ‎6-14 Pre-treatment of adult CDCs with 3% O2 has a limited effect on the in-vivo perfusion potential of adult CDCs. Adult-derived CDCs 
at passage 2 pre-treated with 3% O2 and normoxia for 48 hours. 2 x 10
6
 cells from both groups were combined with matrigel and injected sub-dermally 
(n=3). Plugs were harvested after 2 weeks, but immediately prior to this(at day 14) 50 µg of isolectin - Alexa 594 was injected into the mice via the tail 
vein and the mice were culled humanly after 15 minutes. Serial cryosections were stained with anti-GFP antibody (green) and the co-expression of 
isolectin and eGFP was assessed. Among 3 matrigel plugs which received adult CDC
3% 
O2, I was able to observe in only one plug the positive perfused 
vessels within the matrigel. No positive perfusion response was observed from the CDC
N
 O2 and matrigel alone. As shown in (A) the majority of eGFP-
expressing cells do not co-localise with isolectin-expressing cells. The inset image is a digital zoom of the region of interest highlighted with a red box. 
However, in one specific region I noticed 2-3 eGFP-expressing cells (highlighted with a white arrow) which were co-localising with isolectin within the 
matrigel (F). (D) is the no primary control and (G) is a positive control showing perfused vessels in the same mouse left ear labelled with isolectin. 
Scale bars = 50µm. 
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 Discussion 6.3 
The aims of this chapter were to: (i) establish an in-vivo mouse model of angiogenesis 
using neonatally derived P2 CDCs; (ii) assess the angiogenic potential of adult-derived 
P2 CDCs; and (iii) determine whether pre-treating adult-derived CDCs with 3% O2 
could enhance their in-vivo pro-angiogenic potential. 
 
 MVD analysis of P2 neonatal CDCs in the matrigel plug angiogenesis assay 6.3.1 
Using a sub-dermal matrigel plug assay I have successfully shown that seeding with 
neonatal P2 CDCs leads to significantly increased CD31 expression after 2 weeks, 
indicating an increased angiogenesis response. Using neonatal CDCs, I observed a 3.6 
times increase in MVD compared with matrigel alone, indicating that matrigel itself is 
not the only agent responsible for vessel formation. However, the highest level of MVD 
was observed when neonatal CDCs were mixed with MLECS and MVD was 17.4 times 
higher than the matrigel-alone group (see table 6-1). This finding is similar to previous  
work showing that the combination of endothelial progenitor cells with mesenchymal 
progenitor cells increases their angiogenic potential compared with either cell type 
alone [177]. Although this is a small pilot study, this work showed the beneficial effect 
of neonatal CDCs on in-vivo angiogenesis and shows for the first time that the 
combination of neonatal CDCs with MLECs increases the efficiency of neo-vessel 
formation. The common finding among all of the groups with neonatal CDCs were that 
the highest level of angiogenesis was observed in the border of the matrigel compared 
with the centre which could be due to the host endothelial cell infiltration. It would be 
interesting to assess CDC-mediated angiogenesis in matrigel plugs after a longer time 
period. Indeed, it is possible that more incubating time could allow the endothelial cell 
fraction of CDCs, to make for more functional cell anastomosis with the recipient 
endothelial cells. 
As standard matrigel preparations contains some growth factors such as epidermal 
growth factor, transforming growth factor (TGF-B) and bFGF, I used growth factor 
reduced matrigel in order to minimise the pro-angiogenic effect of matrigel alone. The 
results confirmed that very limited microvasculature formed within the matrigel after 2 
weeks of plug injection (figures 6-4 and 6-8). 
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By using growth factor reduced matrigel, however, I observed variable MVD with 
neonatal CDCs between the plugs, which could be due to the following reasons: (i) 
matrigel implantation assay has been considered a technically challenging method of in-
vivo angiogenesis study due to the difficulty of generating exactly the same three-
dimensional plug even with the same matrigel volume, reviewed in [176]. (ii) I injected 
one plug per recipient mouse, which were all of the same age (6 weeks), it is possible 
that different animals exhibit different angiogenic responses. (iii) It is also possible the 
variability within the experimental groups is due to the heterogeneous nature of CDCs. 
In this respect in chapter 3 I showed variable levels of stem cell and endothelial cell 
marker expression from neonatal CDCs which was fluctuating in three independent 
experiments (please see table 3-5). Therefore, it is possible that CDCs within the 
matrigel are at different stages of differentiation and the microenvironment within the 
matrigel could all affect the angiogenic response. 
I further analysed the eGFP-expressing cells within the matrigel and assessed their co-
expression with CD31. Detailed analysis of cryosections from the CDC and 
CDC+MLECs groups revealed that majority of eGFP-expressing cells do not co-
localise with CD31-expressing cells. In one plug of CDC+MLECs I observed a very 
small number of GFP cells co-stained with CD31 in the wall of new vasculature and 
some were located adjacent to CD31-expressing cells. This suggests that the neonatal 
CDCs’ pro-angiogenic effect is most likely to be paracrine.  
Doing in-vivo neonatal CDC angiogenesis helped me to improve the technical aspects 
of the assay. Initially, I diluted matrigel with PBS at 1:3 ratio in order to ease pipetting; 
although it helped, GFP cell survival was low and locating GFP positive cells within the 
plug was difficult. Therefore, in the subsequent angiogenesis study I used pure matrigel 
to mix with cells. I also found that matrigel plugs need a light fixation with 0.2% PFA 
and 30% sucrose in advance to cryosectioning; this improved tissue sectioning and 
staining significantly.   
 
 In-vivo angiogenesis with adult CDCs 6.3.2 
Due to the increased clinical relevance of using adult human CDCs rather than neonatal 
CDCs I investigated if adult CDCs are capable of promoting neo-vessel formation in 
vivo and whether pre-treating them with 3% O2 could enhance their pro-angiogenic 
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potential. In chapter 4 my studies showed that preconditioning adult CDCs for 48 hours 
in 3% O2 increased their stem cell (Sca-1, Abcg2) and endothelial (Vegf, Eng) at 
mRNA level. Sca-1 expression is already shown to be involved in neo-angiogenesis and 
its co-expression is shown with platelet/endothelial cell adhesion molecule-1 (PECAM-
1) in the lung endothelium [182]. Vegf expression from endothelial precursors is an 
early response of angiogenesis and direct regulation of Vegf has been shown following 
hypoxia due to the stabilisation of the Hif-1α protein, reviewed in [183]. As shown in 
figures 4-7 and 6-7, adult CDCs pre-treated with 3% O2 showed higher levels of Vegf 
protein in comparison with their normoxia counterparts. On the other hand, Flk1 which 
is known to be one of three Vegf tyrosine kinase receptors (reviewed in [183]), was 
slightly increased in CDC
3%
O2 compared with normoxia group (table 4-5). Therefore, 
the pro-angiogenic potential of CDC
3%
O2 could have been primed prior to their delivery 
in the matrigel plug angiogenesis assay. 
In this chapter I utilised a novel preconditioning strategy that related to the hypoxic 
environment of the infarct border zone to enhance CDC pro-angiogenic potential and I 
showed that sub-dermal delivery of adult CDC combined with matrigel leads to a 
significantly enhanced angiogenic response within the matrigel. I also showed that 
preconditioning adult CDCs for 48 hours with 3% O2 increases their pro-angiogenic 
response almost two fold higher that the normoxia counterparts (5.1-6.5 vs. 10.3-13.7 
MVD, p<0.001). However, combination of CDCs with MLECS increased their pro-
angiogenic potential to 2.7 fold higher than CDCs treated with normoxia (5.1-6.5 vs. 
14.7-16.8 MVD, p<0.001). Although I observed significant number of CD31 expressing 
cells within the matrigel plugs of all CDC recipient groups, further investigations with 
isolectin perfusion assay showed that only one of the three matrigel plugs showed inter-
connection of the CD31-positive vessels with the main vasculature. However the 
limitation of the quantifications and angiogenesis assessment could have possibly 
affected the results. For instance as I only assessed 10/50 of slides for each matrigel 
plug, it is still possible that I have missed the true angiogenesis in those slides that I 
have not assessed. It is also possible that a proportion of the CD31
+ 
cells within the 
matrigel are circulating endothelial cells derived from bone marrow of the recipient 
mice which have infiltrated into the matrigel plugs. This could be more relevant in the 
plugs which received CDCs pre-treated with 3%
 
O2. This is because co-relation of 
hypoxia pre-treatment and SDF1 expression has been shown in CDCs [73], therefore it 
is possible that 3% O2 pre-treated CDCs has enhanced SDF1 production which has 
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attracted bone marrow CD31
+
 cells into the plugs. However my findings are in 
agreement with previous reports showing the benefit of hypoxia preconditioning of 
adult CDCs and their increased angiogenic and cardioprotection potential [72,73,103]. 
However, there is an important difference between these studies and my own. In Yan 
[72] and Tang’s [73] work CDCs were treated with severe hypoxic conditions (0.1%), 
equivalent to the injured region but in Li’s study [103] CDCs were treated with 5% O2 
which is found in remote myocardium (away from  the infarct) and healthy heart. I used 
3% O2 (the level approximately equivalent to the infarct border zone) [89]. This is an 
important distinction because the anatomical region of interest for cell delivery in 
preclinical and clinical studies is the border zone. If CDCs are pre-treated with severe 
hypoxic conditions and then delivered into the border zone, the new condition would be 
hyperoxic and if they are preconditioned with physiological O2, the pre-infarct border 
zone may be hypoxic for donor cells. In this way, either hyperoxic or hypoxic 
environments could produce unfavourable circumstances for donor cells and could alter 
their survival and cardioprotection potential. However, culturing CDCs with 3% O2 
could mimic similar conditions of their host region and could give better readouts of 
their in-vitro and in-vivo phenotypes.  
 
 eGFP and CD31 co-expression in matrigel plugs implanted with adult CDCs. 6.3.3 
The endothelial marker CD31 has a reliable epitope for immunostaining. Therefore, I 
used CD31 as the angiogenic marker in my study. I also analysed the proportion of 
eGFP cells which also co-localise with CD31. Although there was increased adult CDC 
survival in comparison to neonatal CDCs (likely due to the technical improvements of 
the matrigel angiogenesis model that I incorporated) the majority of CDCs did not co-
localise with CD31 or with α-SMA (figures 6-9 & 6-10). However, a small number of 
eGFP positive CDCs co-localized with CD31 in few regions of the neo-
microvasculature and in single isolated cells (figure 6-11). However, there is a 
possibility that the limited number of eGFP
+
/CD31
+
-expressing cells which have been 
identified in the matrigel plugs were initially CD31 positive before sub-dermal 
injection, as my studies from FACS data showed that 1-2% of adult CDCs express 
CD31. This is also consistent with Davis et al. (2010) who showed that 3% of human 
cardiac progenitors express CD31 [70]. It is also possible that a fraction of the 
eGFP
+
/CD31
+
 injected CDC sub-population has been removed by the recipient immune 
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system prior to our experiments. According to Li et al. (2009), less than 5% of 
transplanted CDCs are retained in the heart at three weeks following cell delivery [184]. 
Furthermore, it has been reported that 90% of delivered progenitor cells die due to 
apoptosis [87]. However, in one plug which received CDCs preconditioned in 3% O2 
some eGFP cells co-stained with CD31 and located within tubular structures that could 
be neo-vessels (figure 6-11). Angiogenesis is a complex process which involves four 
stages: 1) basement membrane degradation; 2) endothelial cell proliferation; 3) cell 
migration; and, finally, 4) tube or cellular array formation. After detailed analysis of 
several cryosections from five experimental groups I observed cytoplasmic protrusions 
and cellular array formations are common signatures of the plugs that contained 
CDC
3%
O2. In this respect Skovseth et al. (2002) showed the cytoplasmic protrusion 
formation and cellular accumulation (cell migration) to form cellar arrays are 
considered as positive angiogenic responses [179]. SDF1 is shown to induce endothelial 
cell migration and proliferation [185]; on the other hand the induction of SDF1 
expression in murine adult CDCs with severe hypoxic preconditioning has been shown 
by two independent studies [72,73]. Therefore, it would be interesting to assess SDF1 
expression in matrigel plugs which received CDC
3%
O2 and compare it with CDC
N
O2 
counterparts. Ki-67, expressed in the nucleus, is also shown to be very specific in 
identifying proliferating cells [186]. Staining cryosections with Ki-67 and its co-
expression analysis with eGFP and CD31 could give us valuable information about the 
proliferation rate of the endothelial sub-population of CDC
3%
O2 and CDC
N
O2. 
 
 Assessing eGFP and CD11b co-expression in matrigel plugs 6.3.4 
. I further quantified the level of CD11b expression in the matrigel plugs and noticed 
that in all of the plugs which received cells, either with CDC, MLECS or both, had the 
same level of CD11b expression, and all showed a significant increase of CD11b 
expression in comparison with the matrigel-only group, which suggests that the host’s 
immune system has the same angiogenic impact on all four study groups which received 
cells. It is important to know the role of the endogenous immune response in CDC-
mediated angiogenesis. One mechanism has been shown to be by secretion of the pro-
angiogenic factors, such as Vegf and bFGF, by macrophages in ischemic wound healing 
repair [187]. Therefore, it is possible that CDCs stimulate the host’s immune system to 
induce angiogenesis. Investigating the immune response at different time points with 
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matrigel plug assay will enable us to design experiments with the highest level of 
vascularity and the lowest level of CD11b response. Furthermore, to elucidate the 
angiogenesis pathway mediated by CDCs, the in-vivo angiogenesis would be tested on 
SCID mice. This would help us to understand better CDCs’ role in angiogenesis, as 
SCID mice will not activate angiogenesis mediated by their immune response. Further 
analysis of cryosections showed that the location of CDCs in matrigel plugs affects the 
efficiency of CDC ingestion into the CD11b expressing cells. This is probably due to 
easier host animal macrophage infiltration into the border of matrigel plugs than into the 
middle of the plugs. As shown in figure 6-13 the majority of CDCs located in the border 
of the matrigel have been ingested by CD11b positive cells but the majority of CDCs in 
the middle of the gel have not. As it has been shown that the majority of CDCs are 
negative for inflammatory cell markers such as CD11b[71], therefore eGFP
+
/CD11b
+ 
cells within the matrigel plugs are probably the inflammatory cells which have engulfed 
GFP expressing CDCs as foreign bodies. 
 
 CDCs pre-treated with 3% O2 may enhance connection of new vessels within 6.3.5 
the matrigel plugs to the host vasculature 
Perfusion analysis of the plugs made from CDC
N
O2 and CDC
3%
O2 showed that 1 out of 
3 of the plugs with CDC
3%
O2 showed positive isolectin-expressing cells within the 
middle and the borders of the matrigel, even though none of the plugs with CDC
N
O2 
and matrigel alone showed isolectin expression. This could be due to the fact that 
preconditioning CDCs with 3% O2 has enhanced their pro-angiogenic potential. Due to 
the technical difficulties in adult CDC culture and preparation in this final experiment, I 
was only able to assess perfusion analysis in CDC
N
O2 and CDC
3%
O2. Therefore, it 
would also be important to assess the perfusion of the vessels formed in CDC+MLECs 
plugs in a similar way to a previous study using mesenchymal cells and endothelial cells 
in a matrigel plug assay [177]. This work showed the combination of mesenchymal 
cells with endothelial cells enhances their angiogenesis potential. It would be also be 
useful to assess the perfusion analysis of the formed vessels following a longer period. 
My study was limited to matrigel angiogenesis assay of two weeks, but Skovseth et al. 
(2002) showed all of the vessels formed after 40 days within the matrigel plug 
contained erythrocytes [179]. In tumour angiogenesis studies, Das et al. (2005) showed 
the positive effect of hypoxia on the perfusion of the vessels formed in matrigel [188]. 
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In my study it is possible that I have not noticed the perfused vessels with CDC
N
O2 and 
CDC
3%
O2 plugs due to the limitations of the technique. Another possibility is that the 
perfused plug with CDC
3%
O2 was the plug which I injected in to the scruff region of the 
recipient, as different regions of the body may show different levels of angiogenic 
response. I divided each plug into three regions (beginning, middle and the end) and 
stained 3-5 slides containing 18-24 sections. Therefore, it is possible that perfused 
vessels were present in the regions that I have not assessed. It would be very accurate to 
assess the perfusion status of the matrigel plugs with imaging techniques such as 
contrast ultrasound imaging in future experiments. Using an ultrasound system Stieger 
et al. (2006) showed the efficacy of this system in detecting the angiogenesis in matrigel 
subdermal plugs of rats [189].  
One of the longer-term aims of my study was to determine the optimal conditions for 
CDC-mediated angiogenesis by using a matrigel subdermal plug and to use the 
optimised conditions to deliver pro-angiogenic cells to promote angiogenesis in a 
surgical mouse model of cardiac infarction. From my data I would utilise adult CDCs 
pre-treated with 3% O2. An alternative would be to utilise human CDCs pre-treated with 
3% O2 and assess their angiogenic response in MI models of SCID mice, which, finally, 
helps us to design clinical trials to decide the desirable CDC pre-conditioning method in 
order to enhance angiogenesis and cardioprotection in humans.    
My preliminary results also showed that the combination of CDC with endothelial cells 
(MLECs) enhanced their angiogenic potential. However this experiment has some 
limitations; (i) as I used different number of CDCs in CDC and CDC+MLECS plugs, 
this makes angiogenesis comparison between these groups difficult. It would be 
interesting to assess same number of CDCs with and without MLECS, this could also 
show the effect of CDC mediated angiogenesis when implanted alone or combined with 
MLECS sub-dermally. (ii) In this experiment I used un-labeled MLECS; therefore it is 
not possible to track MLECS contribution into the new vessels. Thus, to assess MLECS 
mediated angiogenesis, it would be useful to label them prior to implantation with a 
fluorescent reporter such as Ds-Red and combined with eGFP-CDCs, this experiment 
could tell us how these two cell populations contributing to in vivo angiogenesis in sub 
dermal matrigel plugs.    
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 It is important to know if human-derived CDCs combined with autologous endothelial 
cells such as circulating endothelial cells enhance pro-angiogenic potential and survival 
after injection into the in-vivo matrigel model. 
To summarise, the work described in this chapter confirms that CDC transfer can 
activate angiogenesis in sub-dermal matrigel plugs over 2 weeks post-cell-injection and 
3% O2 pre-treatment for 48 hours enhances this process. The mechanism underlying 
angiogenesis is likely to be paracrine with a limited autocrine contribution. However, 
the exact timing and pre-treatment of CDCs to get the optimum angiogenesis response 
remains uncertain and will require further study. 
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Chapter 7  Final discussion and future 
directions 
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Cardiac stem cell therapy has recently brought new hope to coronary heart patients. As 
low cell survival and cell retention is the main barrier for myocardial cell 
transplantation strategies, hypoxia preconditioning of transplanted cells could improve 
their function in the recipient heart tissue. Hypoxic pre-treatment of CDCs has been 
shown to improve their pro-angiogenic and cardiogenic potential in human- [103] and 
mouse-derived [73] CDCs. The level of atmospheric O2 used in conventional cell 
culture is 21% although the level of physiologic O2 within the heart is 5-7% [89]. More 
importantly, the level of O2 in the infarct border zone, the main target region for 
therapeutic cell delivery, is estimated to be 3% [89]. As described in this thesis I tested 
whether preconditioning of CDCs with 3% O2 enhances their pro-angiogenic potential 
in vitro and in vivo. In addition, I characterised CDCs by using lineage tracing to 
estimate their fibroblast content, as this may affect their repair potential. 
In chapter 3, I established culturing of neonatal CDCs in 3% O2 and compared cell 
viability and proliferation with cells cultured in normoxia. While my data showed that 
expanding neonatal mice cardiac explants in 3%O2 resulted in enhanced EDC 
outgrowth, Csph formation was delayed. This is in agreement with Koh et al. (2012), 
who showed that a prolonged hypoxic environment is shown to cause cell spreading 
rather than cell accumulations, so delaying sphere formation [121]. I also observed that 
culturing P2 neonatal CDCs at 3%O2 for 72 hours did not change their viability, 
clonogenicity and cell proliferation. These finding are in agreement with Li et al. (2011) 
who showed that culturing human-derived CDCs in 5% O2 did not change cell growth 
at early passages (from P1 to P3), but increased their proliferation at higher passages 
(P4 to P5) [103]. qRT-PCR and immunophenotyping results showed that pre-
conditioning of neonatal CDCs with 3%O2 for 72 hours significantly enhanced Sca-1 
gene expression at the mRNA level, it also increased Eng and Vegf mRNA. These 
findings suggested that pre-conditioning CDCs could have clinical applications and may 
be used to prepare progenitor and endothelial sub-populations of CDCs. However, as 
the effect of hypoxia is context-specific, future studies should focus on the effect of 3% 
O2 on human CDCs in vitro and assess the effect on stem cell and endothelial sub-
populations. I also found that Hprt is not a trustworthy housekeeping gene for qRT-PCR 
studies with CDCs as it did not have a stable range of Ct values in CDCs cultured for 
different times in 3% O2. Therefore, in all subsequent qRT-PCR experiments only 
Gapdh, B-actin and RPS-19 were used to normalise the data. This shows the importance 
of choosing valid housekeeping genes in quantitative gene experiments in CDCs. 
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Indeed, hypoxia has been shown to alter the level of housekeeping gene expression in 
CDCs [112]. Nevertheless, my findings do suggest that 3%O2 pre-conditioning 
increases the progenitor and endothelial sub-populations of neonatal CDCs and may 
therefore prove to be of therapeutic value. 
 
In chapter 4 I tested whether pre-conditioning adult-derived CDCs with 3% O2 also 
increases the progenitor and endothelial sub-populations in vitro. The importance of 
using CDCs cultured from adult hearts is that it more closely models to the clinical 
situation, where autologous CDCs are used to treat coronary heart disease in adults. 
However, I first had to establish a culture of adult CDCs. Although I modified several 
steps of adult CDC culture, I observed lots of difficulties with CDC cultures from adult 
C57BL/6 mice, which produced a significantly lower cellular yield in all three stages of 
CDC culture and took a significantly longer time. For instance, CDC culture from 
neonatal mice takes 25-30 days, but from adults takes 55-60 days and their cellular yield 
is 1/2-1/3 in comparison to neonatal CDC culture. This is in agreement with a published 
study showing lower CPC yields in adults compared with  neonates and young patients 
who had congenital cardiac surgery [79]. I further compared CDC culture efficiency 
between the atria and ventricles and noticed murine atrial explants generated higher 
yields of EDCs and Csphs in comparison to ventricles. This is in agreement with Chan 
et al. (2012) who showed that atrial samples generated a more sufficient number of 
EDCs than ventricles for Csph culture [140]. Mishra et al. (2011) suggested that the 
minimised stress wall in the atria favours cardiac progenitors and increases their 
proliferation potential [79]. However, it would be interesting to measure the level of 
growth factors and cytokines expressed in supernatant of atrial versus ventricular 
explant and Csph culture. It would be also interesting to assess the expression of the key 
regulators of cell mobility pathways such as Notch and SDF1/CXCR4, and compare 
them in atria and ventricles. Further immunophenotyping analysis of adult CDCs 
showed that Sca-1 positive CDCs are separate from cKit-expressing cells and, 
interestingly, Sca-1
+
 and cKit
+
  were predominantly CD45 negative which suggest that 
stem cell sub-populations of CDCs are not derived from BM. My findings agreed with 
Davis et al. (2009) who showed that CDCs are predominantly CD45 negative [83]. 
Although I showed the benefit of pre-conditioning adult CDCs with 3% O2 in increasing 
the yield of progenitor and endothelial sub-populations, there were some limitations in 
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this study: (i) adult C57BL/6 is not an optimal model to study adult CDCs due to the 
poor yield; (ii) healthy mice are not a good model of coronary heart patients, therefore it 
would be interesting to generate CDCs from mice following MI or mice models of 
atherosclerosis. Among such models are the Apolipoprotein (ApoE) knockout mice. 
These mice show impaired clearing of plasma lipoproteins and develop atherosclerosis, 
reviewed in [190]. CDC culture from MI mice and ApoE-deficient mice and 
characterising them in normoxic and 3% O2 environments could provide valuable 
information about CDC phenotypes in diseased models. 
 
In chapter 5, I studied lineage tracing in a transgenic mouse Col1a2 CreERT; Rosa26-
floxed STOP eYFP to track CFs in CDC culture and in vivo in the healthy hearts of and 
following MI (1 and 2 weeks post-LAD ligation). This part of my thesis had two aims: 
(i) to assess the specificity of the Col1a2 CreERT; Rosa26-floxed STOP eYFP mice in 
detecting CFs in vivo; and (ii) to investigate the CF contribution to CDC culture. The 
results showed that with this transgenic model, I was able to detect YFP expression in 
approximately 37% of Collagen 1 expressing cells. In addition, co-localisation 
experiments with YFP and additional fibroblast markers (FSP1 and vimentin) showed 
partial co-staining of eYFP with either FSP1 or vimentin. Lineage-tracing studies with 
fibroblasts has always been a difficult task as they lack a specific marker and all of the 
available markers have been shown to be expressed in other cell types, reviewed in [15]. 
Additional possible reasons for suboptimal labelling of CFs include incomplete Cre-
activation. Potentially, this could be improved by further optimising the tamoxifen 
treatment, for example, by oral tamoxifen administration or by using 4-hydroxy 
tamoxifen, the active metabolite of tamoxifen. Nevertheless, the in-vivo experiments 
with healthy and MI models showed that, while the expression of eYFP, FSP1 and 
vimentin in the infarct regions significantly increased in comparison with healthy hearts 
and the remote myocardium of infarcted hearts, co-localisation of eYFP with FSP1 and 
vimentin decreased significantly. My results agreed with the findings of Schneider et al. 
(2007) who showed that fibroblasts are actively proliferating in the infarct region and 
border zone [156]. Further in-vitro experiments using confocal microscopy to analyse 
eYFP expression in CDCs derived from Col1a2 CreERT; Rosa26-floxed STOP eYFP 
mice showed that phase bright cells are predominantly negative for eYFP expression. 
This suggests that there is a possibility of CDC enrichment against fibroblasts in the 
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CDC culture by selecting only phase bright cells. In fact, all EDCs were selected for 
culture using our standard culture protocol and FACS analysis showed that 9-11.5% of 
EDCs express YFP. Considering the 37% efficiency of our transgenic model in CF 
tracing, I estimate that the true proportion of CF derived cells in EDCs and CDCs is 
likely to be higher. I also showed that following Cre-activation in Col1a2 CreERT; 
Rosa26-floxed STOP eYFP mice, Csph formed from both YFP
+
 and YFP
-
 EDCs. This 
suggests Csph formation occurs irrespective of fibroblast content, although eYFP
+
 
EDCs made spheroids more efficiently than eYFP
-
 EDCs. It has been suggested that 
mesenchymal cells provide physical and secretory support to the progenitor sub-
populations of CDCs [68]. To validate this hypothesis it would be informative to 
investigate the immunophenotype of the CDCs derived from YFP
-
 or YFP
+
 EDCs and 
measure the growth factors released to the cell culture medium. When CDCs were 
prepared in the standard way, 8.3-12.9% of CDCs express YFP. Moreover, FACS data 
showed that the majority of stem cell sub-populations of CDCs (Sca-1 or cKit-
expressing cells) were YFP
-
 suggesting that the stem cell populations were not derived 
from cardiac fibroblasts. This chapter showed the potential of using lineage tracing to 
interpret the fibroblast content of the different sub-populations of EDCs and CDCs.  
In order to elucidate the effect of fibroblasts on the stem cell sub-populations of CDCs 
(Sca-1
+
 and cKit
+
), it is possible to culture Col1a2 CreERT; Rosa26-floxed STOP 
eYFP-derived CDCs and sort eYFP
-
/Sca-1
+
 or eYFP
-
/cKit
+
 cells and then assess their 
pro-angiogenic and cardiogenic capacity. The results could be compared with non-
sorted CDCs and further valuable data would be achieved when the stem cell fraction of 
CDCs are used alone or with fibroblasts. The importance of this hypothesis is based on 
the fact that, after the infarction, cardiac fibrosis is activated, so CDCs without or 
having a lower CF sub-population is not likely to enhance this process. However, this 
hypothesis might bring an optimised strategy of delivering CDCs accompanied with 
nanoparticles carrying different paracrine factors. 
 
In chapter 6 I assessed the pro-angiogenic potential of neonatal and adult CDCs derived 
from the CAG-farnesyl-eGFP transgenic line in vivo using a subdermal matrigel plug 
angiogenesis assay. The results showed that neonatal P2 CDCs lead to a significantly 
increased CD31 expression in the matrigel after 2 weeks, indicating an increased 
angiogenesis response. There was a significant increase in MVD compared with 
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matrigel alone, which suggests the pro-angiogenic potential of neonatal CDCs in vivo 
(please see table 6-1). Immunofluorescent staining showed that the majority of eGFP-
expressing cells do not co-localise with CD31-expressing cells, which suggests that the 
pro-angiogenic effect of neonatal CDCs is most likely to be paracrine. I also 
investigated whether adult CDCs are capable of promoting neo-vessel formation in vivo 
and whether pre-treating them with 3% O2 could enhance their pro-angiogenic potential. 
Here I showed that adult CDCs led to a significantly enhanced angiogenic response 
within the matrigel. I also showed that preconditioning adult CDCs for 48 hours with 
3% O2 increased the pro-angiogenic response significantly in comparison with their 
normoxia counterparts. In addition, the combination of CDCs with MLECS increased 
their pro-angiogenic potential significantly more than CDCs treated with normoxia or 
3% O2 (please see table 6-3). Further immunofluorescent staining with eGFP and CD31 
or α-SMA showed very limited co-localisation of eGFP CDCs with CD31 (consistent 
with my findings using neonatal CDCs) and confirming the low direct contribution of 
CDCs to new blood vessels. I observed that the majority of eGFP cells from 3% O2 
plugs show elongated cytoplasmic protrusions and form cellular arrays. Cytoplasmic 
protrusion formation and cellular accumulation (by cell migration) to form cellar arrays 
are considered as positive angiogenic responses and in this respect SDF1 has been 
shown to induce endothelial cell migration and proliferation [185]. As SDF1 is elevated 
in CDCs pre-treated with hypoxia [73], it would be interesting to assess SDF1 and 
CXCR4 expression in the matrigel plugs seeded with 3% O2 treated CDCs. 
CD11b analysis showed that matrigel plugs with CDC
N
O2 and CDC
3%
O2 had a similar 
type of immune response, and this was increased compared with the matrigel-only 
plugs. This suggests the enhanced angiogenic response in 3% O2 in comparison with 
normoxia pre-treated CDCs is due to their enhanced pro-angiogenic potential and not 
due to an enhanced immune response. Perfusion analysis of the plugs made from 
CDC
N
O2 and CDC
3%
O2 showed that 1 out of 3 of the plugs with CDC
3%
O2 showed 
positive isolectin-expressing cells in the matrigel. None of the plugs with CDC
N
O2 or 
matrigel alone showed isolectin expression. This work would need to be repeated to 
determine whether CDC
3%
O2 was able to promote increased numbers of perfused 
vessels. However, I showed that CDC transfer can activate angiogenesis in subdermal 
matrigel plugs over 2 weeks post-cell-injection and 3% O2 pre-treatment for 48 hours 
enhances this process. Using eGFP to track the CDCs, it was clear that CDC-mediated 
angiogenesis was due to paracrine effects and there was limited autocrine contribution. 
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However, the exact timing and pre-treatment of CDCs to get the optimum angiogenesis 
response remains uncertain and requires further study. Nevertheless, this work had some 
limitations: (i) the optimal in-vivo model may be to utilise human CDCs pre-treated 
with 3% O2 and assess their angiogenic response in MI models of SCID mice. This 
could also be combined with endothelial cells derived from BM to enhance 
angiogenesis and cardioprotection. It would also be interesting to investigate whether 
supplementing human CDCs with an endothelial cell source (for example human-
circulating EPCs or human endothelial cells derived from induced pluripotent stem cells 
(iPSC)) would enhance CDC-mediated angiogenesis and improve cardiac function. 
Future studies are needed to better understand the mechanisms underlying CDC-
mediated repair as well as optimising neo-vessel formation potential following 
ischaemic heart injury. 
So far, I have shown that preconditioning neonatal and adult CDCs with 3% O2 in vitro, 
increases their progenitor, endothelial sub-populations and enhances their pro-
angiogenic potential in subdermal matrigel plugs. However, to elucidate the exact 
mechanisms it will be important to investigate further the precise role of CDC-mediated 
pro-angiogenesis. Given that my findings suggest that subdermally transplanted CDCs 
act via paracrine mechanisms this suggests that it would be advantageous to assess 
which proteins are synthesised by CDCs treated with 3% O2 compared with normoxia. 
This could be done using a custom qRT-PCR or protein array focusing on angiogenesis 
and cardiomyocyte differentiation pathways.  
In addition, a time course would be helpful in determining the final pro-angiogenic 
effects of CDCs. In the matrigel plug assays only a 2-week time point was used for the 
analysis. It would be informative also to analyse matrigel plugs at 3-4 weeks when 
vascular networks and tubular structures would be more complete and vessel stability 
could be assessed. As the quantification method of the matrigel plugs is very time-
consuming, it may also be easier to assess the vessel size and density with alternative 
methods such as ultrasound. One on-going project in our lab is studying the effect of 
Eng and TGFβ-signalling pathways on CDC-mediated heart repair. TGFβ signalling has 
been shown to be involved in infarct healing by enhancing angiogenesis and 
suppressing the immune response. For instance, the enrichment of Eng-expressing 
CDCs may lead to an enhanced pro-angiogenic response in the recipient MI models. 
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Recent clinical trials with CDC transplantation for MI patients have revealed some 
promising findings [77,107]. However, the exact characterisation of CDCs is still not 
complete. Here in this thesis, the results showed the importance of 3% O2 pre-
conditioning of CDCs on their pro-angiogenic potential. More preclinical studies (such 
as those mentioned above) will be required to validate and extend these findings and 
will help to design future clinical therapies.    
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